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Abstract
A cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus
have become known as the Metabolic Syndrome (MetS). In the United Arab Emirates,
42% of the population was diagnosed with MetS. Previous researchers observed the
anti-diabetic,

hypolipidemic

anti-oxidative,

anti-inflammatory

and

anti-

antitumorigenic properties of spices on body composition, blood parameters and blood
pressure. The aim of the study was to assess the macronutrient, micronutrient, sugar
and caffeine content for seven commonly consumed spices. Moreover, the aim of the
study was to measure the effect of ginger (Zingiber officinale), cinnamon
(Cinnamomum) and black seed (Nigella sativa) consumption on blood glucose, lipid
profile and body composition in participants at risk of cardiovascular diseases.
Seven spices were analyzed to investigate their proximate content, minerals,
vitamins, sugars and caffeine. One hundred and twenty (N=120) participants with risk
of cardiovascular diseases were randomly allocated to three treatment arms (ginger,
cinnamon and black seed) and a control group (placebo) for a period of 12-weeks.
Each participant consumed 3 g/day of powder (spice or placebo). Data related to
different parameters were collected from participants at baseline, midpoint and at
endpoint of the intervention.
Analysis of the chemical composition of spices showed that the spices had
considerable amount of macronutrients (especially oils) and micronutrients. Therefore,
spices’ active compounds could be used in nutritional supplements and for treatments
considering their decent source of valuable nutrients. Furthermore, consumption of
spices powder significantly improved waist circumference, body fat mass, weight,
body mass index, percent body fat, fasting blood glucose and triglycerides when
compared to placebo group (P ≤ 0.05). Ingestion of 3 grams per day for 12 weeks of
spices powder showed significant improvement in body composition, blood glucose
and lipid profile. Overall this study demonstrates that the consumption of ginger,
cinnamon and black seed powder could help in the management of cardiovascular risk
factors.
Keywords: Ginger, cinnamon, black seed, metabolic syndrome, lipid profile, body
composition, proximate analysis, blood glucose.
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)Title and Abstract (in Arabic

تأثير مطحون التوابل على مستوى سكر الدم ودهون الدم ومكونات الجسم في البالغين
المعرضين لإلصابة بأمراض القلب واألوعية الدموية :دراسة خاضعة للسيطرة،
عشوائية ،منفردة وموازية التصميم
الملخص

أصبحت مجموعة عوامل خطر اإلصابة بأمراض القلب واألوعية الدموية وداء السكري
من النوع الثاني معروفة باسم المتالزمة األيضية .في دولة اإلمارات العربية المتحدة ،تم تشخيص
نحو  %24من السكان بالمتالزمة األيضية.
الحظ باحثون أسبقون خصائص متعددة للتوابل منها خاضية مكافحة السكري و خاصية
مضادات األكسدة وخاصية مضادات الاللتهابات وأيضا خاصية مضادات السرطنة ومدى تأثيرها
على تركيبة الجسم ومقاييس الدم وضغطه .تهدف هذه الدراسة البحثية لتحليل سبعة أنواع من
التوابل الشائع استخدامها لمعرفة ما تحتويه من مغذيات كبيرة المقدار و زهيدة المقدار ومن
سكريات و دهون و فيتامينات .كما تهدف أيضا لقياس مدى تأثير استهالك الزنجبيل والقرفة وحبة
البركة (الحبة السوداء) على مستوى السكر في الدم ومستوى الدهون وتركيبة الجسم لمشاركين
معرضين لخطر اإلصابة بأمراض القلب واألوعية الدموية.
تم تحليل سبع أنواع من البهارات الشائع استخدامها للتحري عن محتوياتها التقريبية من
المعادن والسكريات و الدهون و الفيتامينات .إضافة إلى ذلك ،تم تقسيم  041مشترك معرضين
لخطر اإلصابة بأمراض القلب واألوعية الدموية بشكل عشوائي على أربع مجموعات عالجية.
تم توزيع المشتركين عشوائيا على ثالث مجموعات عالجية (مجموعة الزنجبيل ومجموعة القرفة
ومجموعة حبة البركة) و كانت هناك مجموعة أخرى للعالج الوهمي (البالسيبو) لمدة  04أسبوعا.
قام كل مشارك باستهالك ثالثة غرامات في اليوم الواحد من مطحون التوابل أو مطحون البالسيبو.
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تم جمع البيانات المتعلقة بمؤشرات مختلفة من المشاركين في في بداية التجربة وفي منتصفها
وعند نهايتها .تم جمع البيانات المتعلقة بمؤشرات مختلفة من المشاركين في في بداية التجربة وفي
منتصفها وعند نهايتها .و لوحظ أن تناول مطحون التوابل بأنواعها قد حسن من قياس محيط
الخصر و كتلة الدهون في الجسم و الوزن و نسبة كتلة الجسم ونسبة الدهون بالدم و تركيز غلوكوز
الدم "على الريق" و الدهون الثالثية بشكل كبير ،مقارنة مع مجموعة العالج الوهمي (.)P≤0.05
أظهرت نتائج تحاليل مكونات التوابل الكيميائي بأنها تحتوي على مغذيات كبيرة المقدار
(الزيوت تحديدا) و زهيدة المقدار .لذلك ،يمكن استخدام المركبات الفعالة في التوابل المكمالت
الغذائية وذلك لما تحتويه من مستوى عل ٍل من المغديات القيمة .و تبين أن تناول ثالثة غرامات
يوميا من التوابل (الزنجبيل و القرفة و حبة البركة) على مدار  04أسبوع يساعد وبشكل ملحوظ
في تحسين تركيبة الجسم ومستوى السكر بالدم ونسبة الدهون .بشكل عام أثبتت هذه الدراسة أن
استهالك مطحون التوابل (الزنجبيل و القرفة و حبة البركة) ساعد على تنظيم و تقليل مخاطر
اإلصابة باألمراض القلبية واألوعية الدموية.
مفاهيم البحث الرئيسية :الزنجبيل ،القرفة ،حبة البركة ،المتالزمة األيضية ،مستوى الدهون،
تركيبة الجسم ،تحليل تقريبي ،مستوى السكر بالدم.
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Chapter 1: Introduction
According to the World Health Organization (WHO), the number of deaths caused by
non-communicable diseases (NCDs) is increasing worldwide. In 2015, 70% of deaths
globally were caused by NCDs, and most of these resulted from complications of four
main NCDs: cardiovascular diseases (CVD), cancers, diabetes, and chronic lung
diseases [1].
Of these four, the most frequent cause of death is CVD. Of 40 million NCD deaths
annually, 17.7 million (45%) are attributed to CVD [1]. Obesity, type 2 diabetes,
hypertension, and high blood lipid levels are the main causes of CVD [2-4].
Metabolic syndrome (MetS) is a combination of medical illnesses that can include high
fasting blood glucose (FBG) levels, elevated blood pressure, central obesity, high
blood triglyceride (TG) levels, insulin resistance, diabetes, elevated blood low density
lipoprotein (LDL) levels, and reduced blood high density lipoprotein (HDL) levels [5].
The characteristics of a MetS diagnosis are controversial, although all definitions
agreed on three common characteristics: reduced HDL, elevated blood pressure, and
insulin resistance [5-7]. MetS management aims to reduce the risk of clinical factors
that could lead to CVD. Changing the lifestyle of a patient with MetS could help to
treat symptoms and improve the quality of life for people at risk of CVD [8, 9].
Dietary factors include improving the nutritional components in an individual’s diet.
For example, reducing the fat content of the diet and managing the carbohydrate
content could improve the regulation of insulin sensitivity, blood glucose and blood
lipid levels [10, 11]. One method used to manage blood parameters that could affect
the risk factors leading to MetS is herbal therapy. Herbal therapy is broadly used in
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many countries as a treatment or as a preventive measure to manage MetS risk factors,
including blood glucose, blood pressure, and blood lipid levels [12-16].
On the other hand, chemical analysis could assist to comprehend the positive effects
of herbs and spices on people at risk for CVD, by breaking down the components of
the individual spice to understand the medical and nutritional value of each item.
Additionally, spices such as ginger (Zingiber officinale), cinnamon (Cinnamomum),
black seed (Nigella sativa), fenugreek (Trigonella foenum graecum), cardamom
(Elettaria cardamomum), cloves (Eugenia aromaticum), and saffron (Crocus sativus)
were tested in previous studies, and a positive effect was noted on blood glucose, body
composition, the lipid profile, inflammation markers, tumor necrosis, and the level of
oxidation in blood and tissues because of the availability of active compounds and
their considerably high content of vitamins and minerals [17-23]. In this study, the
above seven spices will be analyzed to explore with the possibility of their use as
treatments or supplements.
The primary objectives of the study is to chemically analyze seven commonly used
spices: ginger (Zingiber officinale), cinnamon (Cinnamomum), black seed (Nigella
stevia), fenugreek (Trigonella foenum graecum), cardamom (Elettaria cardamomum),
cloves (Eugenia aromaticum), and saffron (Crocus sativus), and to evaluate the effects
of ginger (Zingiber officinale), cinnamon (Cinnamomum), and black seed (Nigella
sativa) powders on FBG, hemoglobin (Hb) levels, glycated hemoglobin (HbA1c)
levels, blood pressure, the blood lipid profile, and waist circumference (WC) among
participants at risk for CVD.

3

Chapter 2: Literature Review
2.1 Introduction to Metabolic Syndrome
2.1.1 History of Metabolic Syndrome
From the early 1920s to the late 1980s, scientists noticed the relationship between the
risk factors (upper body obesity, diabetes, hyperlipidemia) and a higher risk of CVD
[24, 25]. However, in 1977, the term “metabolic syndrome” was utilized to describe
different associations of a cluster of abnormalities. MetS was described by Haller et
al.

when

discussing

the

association

between

diabetes

mellitus,

obesity,

hyperlipoproteinemia, hyperuricemia, and hepatic steatosis, when describing the
cumulative effects of risk factors on atherosclerosis [26]. Additionally, in 1977, MetS
was used to describe the correlation of obesity, gout, diabetes mellitus, and
hypertension with hyperlipoproteinemia [27]. One year later, Philip et al. [28]
developed a concept suggesting that risk factors of myocardial infarction produce a
gathering of abnormalities. These risk factors include: glucose intolerance,
hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, and high blood
pressure and are correlated with heart diseases and with aging and obesity [28].
MetS, or ‘Syndrome X’, was first introduced in 1988 as a group of abnormalities,
including hyperglycemia, dyslipidemia, and high blood pressure that could lead to
CVD. It was suggested that all of these abnormalities were caused by insulin resistance
in one way or another [29]. Different names, such as MetS, American syndrome,
syndrome X, and insulin resistance syndrome, describe the gathering of abnormalities
that could lead to CVD and type 2 diabetes.
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2.1.2 Definition of Metabolic Syndrome
The definition of MetS could differ according to its diagnostic characteristics. The
characteristics of a MetS diagnosis remain controversial, although all definitions
agreed on three common characteristics: reduced HDL levels, elevated blood pressure,
and insulin resistance [5-7]. Unfortunately, there was no universal agreement to
accurately define this syndrome and its specific characteristics. A universal definition
of MetS and suitable treatments for the components of this syndrome are crucial to
provide the best health outcomes and to improve the patient’s quality of life. Table 2.1
explains five different definitions of MetS:

1- The World Health Organization (WHO) definition [30]

2- The National Cholesterol Education Program’s (NCEP) Adult Treatment
Panel III (ATP III) [31]

3- American Heart Association (AHA) definition [8]

4- The International Diabetes Federation (IDF) definition [32]

5- The International Classification of Diseases, ninth revision (ICD-9)
definition, where MetS’s code is (277.7) [33]
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Table 2.1 Definitions of Metabolic Syndrome
WHO
(1998)

ATP III
(2001)

AHA
(2005)

IDF
(2006)

ICD-9
(volume
2015)











Low HDL











Hypertension











High TGs







X









X









X

X

Diabetes



X





X

High HDL*

X

X

X



X

Diagnostic
Characteristics
Insulin
Resistance

Central
Obesity
Glucose
intolerance

WHO: The World Health Organization; ATP III: Adult Treatment Panel III; AHA:
American Heart Association; IDF: International Diabetes Federation; ICD-9:
International Classification of Diseases, ninth revision.
 Diagnostic characteristic included in the definition
X Diagnostic characteristic is not included in the definition
The most commonly used published definitions of MetS are those of the National
Cholesterol Education Program’s (NCEP) Adult Treatment Panel III (ATP III) and the
World Health Organization (WHO) [5].
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2.1.2.1 ATP III Definition
MetS is detected when at least three of the following risk factors are present:
1. High waist circumference:
a. Men: greater than 94 cm
b. Women: greater than 80 cm
2. Increased TGs: greater than or equal to 150 mg/dL (1.7 mmol/L)
3. Reduced HDL (“good”) cholesterol:
a. Men: less than 40 mg/dL (1.03 mmol/L)
b. Women: less than 50 mg/dL (1.29 mmol/L)
4. High blood pressure: greater than or equal to 130/85 mm Hg or receiving
antihypertensive medication
5. Elevated fasting glucose: ≥100 mg/dL (5.6 mmol/L) or receiving a medication of
hyperglycemia
2.1.2.2 WHO Definition
According to the WHO definition [30], MetS is present in individuals with FBG >110
mg/dL and at least two of the following characteristics:
1. Abdominal obesity: ≥ waist-to-hip ratio of 0.90
2. Elevated TG levels: greater than or equal to 150 mg/dL (1.7 mmol/L)
3. Elevated blood pressure: ≥140/90 mm Hg or receiving antihypertensive
medication
2.2 Metabolic Syndrome Diagnostic Criteria
The definitive importance of MetS is due to its assistance to recognize individuals who
are at high risk of type 2 diabetes and CVD [7]. Therefore, numerous studies have tried
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to outline the diagnostic criteria for MetS. In 1999, the WHO focused on insulin
resistance or diabetes or impaired glucose tolerance as crucial components of MetS,
with at least two of the following: hypertriglyceridemia, high blood pressure, low
HDL, obesity, and microalbuminuria [34]. In the same year, the European Group for
the Study of Insulin Resistance (EGIR) altered the WHO criteria eliminating people
with diabetes but still demanding the existence of hyperinsulinemia. Waist
circumference was the measure of obesity, however, different cut-off values were
considered for the other variables such as central obesity, hypertension, dyslipidemia
and impaired fasting glucose. In 2001, The US National Cholesterol Education
Program: Adult Treatment Panel III (NCEP ATP III) excluded the obligatory of insulin
resistance and considered hyperglycemia to be a diagnostic criterion along with the
following: elevated TG, low HDL, central obesity, and elevated blood pressure. On
the other hand, the NCEP concluded that to be diagnosed with MetS, any three of the
five diagnostic criteria that were listed by NCEP ATP III must present [31]. In 2004,
the International Diabetes Federation (IDF) amended the WHO definition by requiring
the central obesity criteria for the definition along with four of the following criteria:
increased TG, high blood pressure, high FBG, and reduced HDL [32].
Other parties also refined the previous MetS diagnostic criteria: the American Heart
Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) proposed
lowering the FBG cutoff point to ≥100 mg/dL instead the ATP III FBG cutoff point
(≥110 mg/dL). They also did not use ethnic-specific values for central obesity and did
not include central obesity as a diagnostic criterion [35]. These differences in
identifying the MetS diagnosis criteria led to confusion among research studies, and
therefore, a meeting was held between the International Diabetes Federation (IDF)
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Task Force on Epidemiology and Prevention, the National Heart, Lung, and Blood
Institute (NHLBI), the American Heart Association (AHA), the World Heart
Federation (WHF), and the International Atherosclerosis Society (IAS) to standardize
the criteria. At this meeting, it was approved that there should not be a mandatory
diagnostic criterion, and that waist circumference (central obesity) should be a main
screening tool. The meeting outcomes also concluded that three abnormal risk factors
out of five would qualify as a diagnosis of MetS, and these five criteria are as follows:
elevated blood pressure, central obesity, elevated TG, elevated FBG, and reduced HDL
[36]. Moreover, WC cut-off point determined were based on ethnicity and gender.
Unfortunately, until now there are no data for Eastern Mediterranean and Middle East
(Arab) population, therefore using European cut-off point was recommended until the
availability of more specific data on WC for Arab population.
2.3 Metabolic Syndrome Risk Factors
Diet, physical inactivity, age, sex, genetics, stress, and ethnicity are factors that could
contribute to MetS risk factors such as abnormalities in blood glucose, blood pressure,
central obesity, lipid levels, and insulin resistance. Many researchers have linked
obesity and high WC to CVD [37-39]. According to the WHO, obesity is a medical
condition recognized when there is high accumulation of body fat which could lead to
serious health issues [40]. This will increase the fat tissue in different parts of the body,
which will cause an increase in some inflammatory markers in the blood. The increase
in adipocytes (fat tissue) will increase tumor necrosis factor (TNF)α levels, which
could affect metabolic pathways and increase the level of cytokines in the blood.
Moreover, TNFα, with the help of the TNFα receptors, will stimulate cell signaling,
which could lead to increased insulin resistance [41]. Another result of increasing the
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adipocyte count is the increase of cytokines that regulate the balance between humoral
and cell-based immune responses. This could lead to imbalances in the immune
response and inflammation and subsequently, atherosclerosis [42]. Figure 2.1
illustrates the relationship between increased adipocytes and insulin sensitivity, and
the relationship between adipocytes and the cytokines.

↑Adipocytes

↑TNFα

↑TNFα + TNFα
receptors
↑Insulin
sensitivity

↑cytokines

atherosclerosis

Figure 2.1: Effects of Increasing Adipocytes on Insulin Sensitivity and
Atherosclerosis
TNF α: Tumor Necrosis Factor α
Increased blood pressure is considered to be one of the distinguishing causes
contributing to CVD [43]. Additionally, increased blood pressure could lead to
impediments that would have a substantial impact on health such as stroke. High blood
pressure could cause strokes, dementia, CVD, and chronic kidney disease [44-46].
Earlier studies showed that decreasing blood pressure by 5 mmHg can decrease the
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possibility of having ischemic heart disease by 21% and stroke by 34%, and reduce
the probability of heart failure, dementia, and mortality from CVD [44].
Dyslipidemia was also shown to be one of the main causes of CVD. A meta-analysis
showed that elevated TG levels in the blood could lead to CVD and other health
complications [47]. Moreover, low HDL and high LDL levels in the blood were shown
to be correlated with an increased risk of CVD [48, 49].
Borg et al. reported a strong relationship between glycated hemoglobin (HbA1c) and
CVD, where there was a correlation between high blood glucose and an increased risk
of CVD in patients with diabetes [50]. Another study of 237, 468 participants showed
that prolonged abnormal high levels of glucose in the blood led to 1, 661 strokes and
816 ischemic heart disease (IHD) events [51]. In conclusion, MetS and CVD are
strongly related, and to manage CVD, management of MetS risk factors is crucial.
MetS is crucial. Many studies have called the effects of MetS risk factors into question
and evidenced the direct effects of these risk factors on CVD, quality of life, and
morbidity rate [52-54].
Being under stress for a long period of time could play a negative role by disturbing
the hormonal system and result in flow, which could result in a serious health
problems. Stress could disturb the hypothalamic–pituitary–adrenal axis (HPA-axis)
[55], which could lead to an increase in cortisol levels in the blood and further
complications such as increased blood pressure [56], blood sugar [57], insulin
resistance [58], dyslipidemia [56, 59], and visceral adiposity [60]. All of these factors
can significantly increase the risk of CVD, type 2 diabetes, and stroke [53, 61], as
displayed in Figure 2.2.
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↑Blood
pressure

↑Blood
glucose

↑Dyslipidemia

↑Cortisol

↑Insulin
resisitance

↑Visceral
adiposity

Figure 2.2: Long-term Effects of Increased Cortisol Levels in the Blood
2.4 Prevalence of Metabolic Syndrome
Accurate estimates of the prevalence of MetS are challenging based on the many
definitions employed in different studies within the same testing group. Accordingly,
the extent of the problem is challenging to quantify [62]. Irrespective of the definition,
MetS affects many adults worldwide with an estimated 22.8% of US adult men and
22.6% of adult women affected among all the diverse ethnic groups [63].
Third National Health and Nutrition Examination Survey III (NHANES III) (a survey
of 8814 adults) using ATP III diagnostic characteristics reported that 38.6% had
abdominal obesity, 30.0% had elevated TG levels, 37.1% had low HDL levels, 34.0%
had elevated blood pressure, and 12.6% had hyperglycemia/diabetes. The data indicate
a high occurrence of MetS. Prevalence among adults aging 20 years or older was 24%
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and among those who were >50 years old, it was 44% [64, 65]. In other studies in the
United States, 24% of participants met the ATP III criteria and almost a same
percentage met the WHO criteria for MetS in the Framingham Offspring Study [66].
However, pooled data from eight studies in Europe among participants 40–55 years of
age show that 7%–36% of men and 5%–22% of women met the WHO diagnostic
criteria of MetS [67].
The prevalence of the MetS in the Gulf Cooperation Council Countries (GCC) is
considered 10%–15% higher than in most developed countries, with an increased
prevalence ratios for women [68]. In the United Arab Emirates (UAE), 42% of the
population was diagnosed with MetS, as shown in an earlier study in 2008 [69].
Moreover, a cross-sectional study that included 555 Emirati females between the ages
of 18 and 55 years indicated that the prevalence of MetS was 6.8%. MetS prevalence
was higher for obese participants (34.5%) compared with non-obese participants
(10.1% overweight and 1.7% normal weight) [70]. In 2017, a meta-analysis of crosssectional studies about the prevalence of MetS performed in the Middle East showed
that the prevalence of MetS was 2.2%–44% in Turkish, 16%–41% in Saudi-Arabian,
22%–50% in Emirati, 14%–63% in Pakistani, 26%–33% in Qatari, 9%–36% in
Kuwaiti, 6%–42% in Iranian, and up to 23% in Yemeni people [71].
2.5 Management and Treatment of Metabolic Syndrome
Multiple studies have recommended that the management of MetS must be
individualized and should start with lifestyle changes [9, 72, 73]. As MetS is
characterized by a group of factors that elevate the risk for CVD and type 2 diabetes,
therefore, MetS should begin with managing of each factor. This can be achieved by a
variety of means, including elevating the level of physical activity, attention to the diet,
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and clinical management. Clinical review and management could include the use of
medications or surgery to reduce the MetS effect by improving blood pressure and
HDL, TG, and glucose to reach normal levels. Factors that helped to enhance the
quality of life for patients with MetS include physical activity management, surgical
and medical intervention, and dietary adjustments (Figure 2.3) [8, 9].

Cardiovascular Diseases
Prevention and Treatment
Physical
Activity
Management
Low
Sodium

Dietary
Management

Surgeries and
Medications

Low
Calorie

Herbal
therapy

Ginger

Cinnamon

Black seed

Figure 2.3: CVD Prevention and Treatment
2.5.1 Physical Activity Management
Obesity and a sedentary lifestyle are important contributors to the development of
MetS [74-76], therefore, treating these two factors should be prioritized. Previous
studies reported the effects of increasing the physical activity level on blood
parameters that could positively affect blood pressure and FBG. This could lead to
better management of the MetS and therefore to a better quality of life [77-83].
However, other studies reported the ineffectiveness of physical activity in reducing
MetS risk factors such as blood pressure [77, 84].
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Physical activity was shown to improve body composition by reducing body fat
accumulated in the abdominal area [85, 86]. Physical activity also improves the blood
parameters that are associated with MetS and CVD risk, including HDL and TGs [85,
87-89]. High C-reactive protein levels have been associated with chronic inflammation
and therefore CVD and physical activity lowers the levels of C-reactive protein [79].
This evidence may clarify the positive effects of physical activity in managing MetS
risk factors and thereby CVD risk factors.
2.5.2 Dietary Management
The main goal of clinical and dietary attention and management in people with MetS
is to decrease the risk of CVD by managing high blood pressure, diabetes, and the lipid
profile. For individuals who have diabetes, managing diabetes alone must be a firstline therapy because of their higher risk of CVD [90].
To manage MetS, primary risk factors should be controlled through managing physical
activity, obesity, and a controlled atherogenic diet. Lifestyle changes have been shown
to reduce all of the CVD factors [8], and dietary management was considered to be
one of the most important tools to manage these risk factors [10, 91-93].
Grundy et al. recommended different types of diets to manage MetS risk factors [8,
72]. Many crash diets (short-term diets that are intensive, aimed to meet a weight loss
goal rapidly) were not effective for long-term weight reduction maintenance because
these diets are based on very low calorie intake or high fat and low carbohydrate intake
[94, 95]. However, to treat obesity/abdominal obesity, Stern et al. [96] and Wing et al.
[97] recommended reduced-energy diets, reducing 500–1000 kcal per day, aiming for
an 8%–10% of the total body weight reduction in 6–12 months. Weight loss on these
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diets is better maintained when combined with exercise. These types of diets were
shown to have a better long-term weight maintenance results compared with crash
diets [96, 97].
General dietary recommendations were made by the ATP III for patients with MetS to
manage the CVD risk factors [98-100] and include a diet that is low in total fat (25%
to 35% of total calories) where saturated fat is <7% of total calories, low in cholesterol
(i.e. <200 mg/dL) and trans fats, and most of the dietary fats must be unsaturated,
reducing the consumption of simple sugars and reducing sodium intake to 1500
mg/day. They also advise increasing the dietary fiber intake that requires an increased
intake of whole grains, fruits, and vegetables [8, 101, 102]. These types of diets have
a positive effect on all blood parameters that are known to be risk factors for MetS [31,
103, 104].
AHA, NHLBI, and the American Diabetes Association (ADA) published an article
that discusses the guidelines for the diagnosis and treatment of MetS, the main goal
being to prevent CVD and type 2 diabetes mellitus in higher-risk patients as presented
in Table 2.2.

16
Table 2.2: AHA/NHLBI Guidelines (2009) for Metabolic Syndrome Management

Metabolic Risk
Factors

Management Guidelines

Abdominal Obesity

7%–10% reduction of body weight through the first year
of treatment, and continue the weight loss to reach the
ideal body weight.

Physical Activity

Minimum of 30 min/day 5 days/week of moderate
intensity exercise, and when possible, 60 min/day or
more every day is preferable.

Atherogenic
Dyslipidemia

Primary goal: lowering LDL
Secondary goal: lowering non-HDL
Tertiary goal: increasing HDL

Pro-thrombotic State

Reduce fibrinolytic and thrombotic risk factors

Pro-inflammatory State

Lifestyle therapies

Atherogenic Diet

Reduce saturated fat intake (<7% of total calories), trans
fat, cholesterol (<200 mg/dL), and total fat (25% to 35%
of total calories)

High Blood Pressure

Lower to <140/90 mmHg or to <130/80 mmHg in the
case of diabetes

High Glucose

Delay type 2 diabetes mellitus in the case of impaired
fasting glucose, and lower HbA1c to <7.0% in the case
of diabetes
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Another approach is the ABCDE approach. This approach uses alphabetical order to
simplify the process of managing MetS, and is summarized in Figure 2.4 [105]

A

B

Assessment /
Aspirin
Expands
interactive group
(5%–20%)

C

D

E

Blood
pressure

Cholesterol

Diet /
Diabetes
prevention

Exercise

Target →
125–135 /80
mmHg

Reduction of
non-HDL

Intensive life
style therapy

Target →
10,000
steps/day

Figure 2.4: Summary of the ABCDE Approach with Recommendations
2.5.3 Surgery and Medications
In some cases of obesity (morbid obesity), a medical intervention other than
medications or dietary modifications is needed. Bariatric surgery is considered to be a
solution that could help to enhance the quality of life for people who are obese by
assisting them to reduce their body weight [106-108]. Bariatric surgery is performed
on patients who are morbidly obese, and it requires decreasing the stomach size using
a gastric band, removing a portion of the stomach, or re-routing the small intestine to
a small stomach pouch.
Previous studies recommended and showed the efficiency of bariatric surgery in
treating the complications and risk factors that could lead to CVD and death (e.g.
central obesity, diabetes, high blood pressure, lipid profile, and sleep apnea) [106, 108110]. Table 2.3 clarifies the classification of bariatric surgeries and provides examples
of each type of surgery [111, 112].
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Table 2.3: Definitions of Bariatric Surgeries

Bariatric surgery

Definitions and examples

Malabsorptive surgeries

Surgery that aims to remove portion of the stomach,
which creates a physiological condition of
malabsorption.
These
surgeries
include:
biliopancreatic diversion, jejunoileal bypass, and
endoluminal sleeve.

Restrictive surgeries

Surgery that aims to decrease the oral intake by
restricting the stomach capacity and therefore,
resulting in early satiety. These types of surgeries
include: vertical banded gastroplasty, adjustable
gastric band, sleeve gastrectomy, intragastric balloon
(gastric balloon), and gastric plication.

Mixed surgeries

Surgery that applies both techniques. Mixture of
malabsorption and restrictive surgeries.
These types include: gastric bypass surgery, sleeve
gastrectomy with duodenal switch and implantable
gastric stimulation

Ikramuddin et al. concluded that gastric bypass surgery in addition to lifestyle and
medical management in participants with type 2 diabetes was associated with an
improved blood glucose and lipid profile [113]. Another study also proved the positive
effect of sleeve laparoscopic gastrectomy on weight loss and CVD risk factors [114].
Treatment of the CVD risk factors should be individualized to match each patient’s
needs. Therefore, some patients will need more invasive medical help using
medications, especially if changes in lifestyle factors have not made a significant
difference in the parameters that contribute to CVD. Each parameter should be treated
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separately when using medications because each medication treats a specific symptom.
Table 2.4 explains the medications taken to treat each MetS risk factor.
Table 2.4: Medications Prescribed to Treat Metabolic Syndrome Risk Factors

MetS Risk Factor

High blood pressure

Medications

-

Thiazide diuretics

-

Beta blockers

-

Angiotensin-converting enzyme
inhibitors

-

Angiotensin II receptor blockers

-

Calcium channel blockers.

-

Renin inhibitors
[115]

Hyperglycemia/diabetes

-

Alpha glucosidase

-

Amylin analogues

-

Biguanides

-

Incretin enhancers

-

Incretin mimetics

-

Insulin secretagogues:
sulfonylureas
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Table 2.4: Medications Prescribed to Treat Metabolic Syndrome Risk Factors
(continued)

Medications

MetS Risk Factor
Hyperglycemia/diabetes

Insulin secretagogues:
nonsulfonylureas

-

Thiazolidinediones
[116]

Hypertriglyceridemia

-

Niacin (Vitamin B3)

-

Fibrates

-

Omega-3-fatty acids

-

Lipoprotein lipase gene therapy
(alipogene tiparvovec)

Additionally,

medications

that

are

prescribed to lower LDL cholesterol
were shown to lower the TG level in the
blood, such as:
-

Ezetimibe

-

PCSK9 inhibitors

-

Lomitapide

-

Statins

-

Mipomersen
[117]
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Table 2.4: Medications Prescribed to Treat Metabolic Syndrome Risk Factors
(continued)

MetS Risk Factor

Lowering HDL

-

Medications

-

Fibrates

-

Niacin (Vitamin B3)

-

Statins
[118]

Abdominal Obesity/Obesity

-

Orlistat

-

Rimonabant

-

Sibutramine

-

Lorcaserin

-

Metformin

-

Exenatide

-

Phentermine

-

Tesofensine
[119, 120]

2.5.4 Herbal Therapy
To manage MetS risk factors that could lead to CVD, the use of herbs and spices as
remedies for lowering FBG, reducing high blood pressure, weight loss, and improving
the lipid profile is common in eastern culture [12, 121]. Herbal therapy or alternative
therapy has been mainly prescribed to relieve and treat symptoms of different diseases
[121]. Hasani-Rnjbar et al. reported that in 41 animal studies, weight loss or a
significant restriction of weight gain was found using herbal therapy [122]. Moreover,
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individuals with a higher income and higher education were more likely to be taking
herbal product with the goal of health improvement as reported by Philips et al. [123],
while Kaye et al. [124] and Cappuccio et al. [125] reported a significant use of herbal
therapy among different ethnic groups.
Several herbs and spices were found to be effective in managing obesity/abdominal
obesity, improving the lipid profile, and lowering FBG by improving insulin
sensitivity [12, 122]. Additionally, in some studies, CVD patients reported an
improvement in blood pressure levels when consuming the right herbal therapy [126].
Furthermore, improvements in the waist-to-hip ratio and waist circumference were
reported in studies that used one or more herbal/spice extract, including the use of
Zingiber officinale as Ignjatovic et al. [127] and Boozer et al. [128] demonstrated. On
the other hand, Hackman et al. [129] and Abidov et al. [130] studies reported decreased
appetite in obese individuals after regular consumption of some herbs. This decreased
appetite resulted in reducing the caloric intake and therefore helped with the weight
reduction process [130]. As an example of the clinical use some herbs and spices,
Table 2.5 contains 13 studies that were conducted on humans to observe the effects of
herbs and spices on MetS risk factors.

Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors

Herbs

Target/ Groups

Dose / Duration

Main outcome

Study Reference

Slimax: extract of several plants:

Healthy participants

6 weeks

Significant decrease in body

[127]

Hordeum vulgare, Polygonatum

weight and body mass index

multiflorum, Dimocarpus longan,

(BMI)

Ligusticum sinense, Lilium
Significant reduction in waist

brownie, and Zingiber officinale

and hip circumference

Herbal supplement: (Ma Huang &

Overweight

72 mg of ephedra

Significant decrease in body

Guarana)

participants -

and 240 mg of

weight and total body fat.

Control group

caffeine for 8 weeks

(n=24) /

Significant reduction in hip

Intervention group

and waist circumference

[128]

(n=24)
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

Main outcome

Study Reference

A compound of Aralia mandshurica Obese non-diabetic 450 mg of Aralia

Decrease in total body weight [131]

(A) and Engelhardtia chrysolepis women, n=32

mandshurica (A)

and fat weight

(E) extracts called ARALOX

and 450 mg of
Engelhardtia
-Control group: Diet chrysolepis (E) per
placebo, n=16

Reduction in plasma TGs

day for 15 weeks

-Intervention group:
Diet compound,
n=16
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

White bean extract (Phaseolus

Obese adults

3000 mg per day of Weight reduction in the

vulgaris)

-Control group:

each for 8 weeks

Main outcome

Study Reference

[132]

intervention group

placebo, n=25
-Intervention group:

Decrease in plasma TGs

white bean extract,
n=25

Turmeric (Curcuma longa L)

Prediabetic adults
-Control group:
placebo, n=25

750 mg per day of 16.4% of subjects in the
each for 9 months

[133]

placebo group were
diagnosed with type 2
diabetes mellitus
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

Main outcome

Turmeric (Curcuma longa L)

-Intervention group:

None of the participants from

Curcuma longa,

the Curcuma longa-treated

n=25

group were diagnosed with

Study Reference

type 2 diabetes mellitus

Korean red ginseng (KRG) (Panax Overweight, n=19,

6 g per day of each No change in HbA1c in both [134]

ginseng)

for 12 weeks

well-controlled type

groups

2 diabetes
Intervention group maintained
-Control group:
placebo, n=9
-Intervention group:

good glycemic control and
improved plasma glucose and
plasma insulin regulation.

KRG, n=10
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Bitter

Target/ Groups

lemon

(Momordica Newly diagnosed

charantia)

Dose / Duration

Main outcome

3 g per day of each There was no significant

with diabetes adults, for 12 weeks

Study Reference

[135]

effect on mean FBG, total
cholesterol, and weight in

-Control group:

both groups

placebo, n=20 /
Intervention group:
Momordica
charantia, n=20

Cinnamon (Cinnamomum)

Participants

3 g per day of each The cinnamon extract has a

diagnosed diabetes

for 16 weeks

[136]

moderate effect in reducing

mellitus type 2
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

Main outcome

Study Reference

-Control group:
Cinnamon (Cinnamomum)

Fasting

placebo, n=39

plasma

concentrations
-Intervention group:

in

glucose
diabetic

patients.

cinnamon powder,
n=40

A combination of Cissus

Overweight and

Intervention group: Significant reduction in

quadrangularis (CQ) and Irvingia

obese participants

300 mg CQ + 500 Cholesterol and LDL of FBG

gabonensis (IG)

[137]

mg IG =800 mg of levels
-Control group:

compound per day

placebo, n=36

Significant decrease in body
Control group: 800 weight, body fat percent and
of placebo per day

waist size in both groups
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

A combination of Cissus

-Intervention group:

Duration: 10 weeks

quadrangularis (CQ) and Irvingia

compound of CQ

gabonensis (IG)

and IG, n=36

Terminalia arjuna tree-bark
powder

Main outcome

Study Reference

[138]

Coronary heart

Group I: placebo

Significant antioxidant action

disease (CHD)

capsules;

in the vitamin E group and T.

patients

arjuna tree group
Group II: vitamin E

Group I: control
group, n=35
Group II: vitamin E

capsules 400 units

Significant hypo-

per day;

cholesterolemic effect in the
T. arjuna tree group

group, n=35
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

Main outcome

Study Reference

3 g of each per day

Reduction in FBS and HbA1c

[139]

for 8 weeks

Improvement in insulin

Terminalia arjuna tree-bark powder Group III: T. arjuna Group III received
tree

bark-powder finely pulverized T.

group, n=35

arjuna

tree

bark-

powder (500 mg) per
day For 30 days

Ginger (Zingiber officinale)

Diabetic adults
-Control group:
placebo, n=44

resistance

-Intervention group:
ginger powder,
n=44
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

Main outcome

Study Reference

Black seed (Nigella stevia) and

Males with MetS

Black seeds (1.5

Black seeds reduced lipids

[140]

turmeric (Curcuma longa L)

N=250 (randomly

g/day)

and FBG, while turmeric

distributed
-Control group:
n=64

reduced LDL-cholesterol and
Turmeric (2.4 g/day) C-reactive protein (CRP).
combination (900
mg Black seeds and

-

Turmeric group,

1.5 g Turmeric/day)

n=62
-

Black seed group,

placebo (2 g)

n=62
-

Combination group,

for 8 weeks

n=62
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Table 2.5: Studies and Clinical Trials on the Effects of Herbs and Spices on Metabolic Syndrome Risk Factors (continued)

Herbs

Target/ Groups

Dose / Duration

Main outcome

Study Reference

Cinnamon, cardamom, saffron

Type 2 diabetes

For 8 weeks

Significant beneficial effects

[141]

(Crocus sativus) and ginger

participants

(Zingiber officinale)

-Control group:
Placebo, n=39

on cholesterol, but not on
3 glasses of black

measures of glycemic control,

tea and either 3
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2.5.4.1 Ginger, Cinnamon, and Black Seed Usage
Ginger (Zingiber officinale), cinnamon (Cinnamomum), and black seed (Nigella
sativa) are annual plants that have been traditionally used internationally, particularly
on the Indian subcontinent, Europe, and Arabian countries such as the UAE [141].
These spices were used for food preparation and medicinal purposes, as a cure for
many diseases and conditions including diabetes, asthma, hypertension, inflammation,
cough, bronchitis, headache, eczema, fever, dizziness, and influenza. Additionally,
black seed is used as a diuretic, lactagogue, and vermifuge, while ginger and cinnamon
are used as an anti-tumor agent, and cinnamon is also used to decrease muscle soreness
in athletes. These spices are also used in food as aromatic spices, carminatives, and
condiments [141-147].
2.5.4.2 Chemical Analysis and Active Components of Ginger, Cinnamon, Black
Seed, and Other Spices
In terms of chemical composition, a study published in 2010 analyzing ginger powder
found that the ginger powder moisture content was 76.86%, while it contained 8.75%
crude protein, 5.62% crude fat, 2.93% crude fiber, and 2.54% total ash. The moisture
content varied significantly from study to study. A previous study of the chemical
composition of ginger reported a moisture content of 6.67% [148]. The differences in
the results from the previous studies in the proximate analysis and mineral analysis of
ginger powder was theorized to be a result of different soil types and geographical
locations of the ginger growth, which has an effect on the nutrient composition [149].
Another study analyzed ginger root and found that it has a moisture content of 15%,
and also 5% protein, 3.72% fat, 38.35% carbohydrates, 25.5% soluble fiber, 23.5%
insoluble fiber, and 3.85% total ash [17]. Various authors reported other values for
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ginger composition as following: protein, 7.2%–8.7%; fat, 5.5%–7.3%; and ash,
2.5%–5.7%. Ginger also contains many different vitamins and minerals such as
vitamin C, calcium, phosphorous, zinc, and iron [148, 150]. And is also a good source
of antioxidants due to its content of total polyphenols, tannin, and flavonoids, as
reported by Prakash et al. in 2010 [17].
Furthermore, 6-paradol and 6-shogaol are chemicals that are presented in ginger that
give the ginger its pungent smell and taste and potential anti-glycemic effect. In 2017,
a study was published by Wei et al. [151] stating that 6-paradol and 6-shogaol are
proved to have an effective activity in stimulating glucose usage by adipocytes and
myotubes in high-fat diet-fed mice. The effects were accredited to the elevation in
adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in
adipocytes [151]. Additionally, Li et al. showed that the activity of (S)-(8)-gingerol
was correlated with an elevation of the surface distribution of the glucose transporter
type 4 (GLUT4) protein, which is responsible for glucose uptake in the plasma
membrane, and it also enhanced glucose and insulin uptake [152]. Figure 2.5 features
the chemical structure of 6-gingerol and 6-shagaol.
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Figure 2.5: Chemical Structure of 6-Gingerol and 6-Shogaol
A study published in 2009 reported that cinnamon (Cinnamomum) contains the
following: crude protein, 3.5%; crude fat, 4%; carbohydrates, 52%; crude fiber, 33%;
and total ash, 2.4%. Cinnamon also contains several different vitamins and minerals
such as potassium, copper, phosphate, zinc, and iron [153]. A systematic review
published in 2015 by Kawatra et al. extensively discussed the active compounds of
cinnamon (cinnamaldehyde and cinnamic acid) [18].
Cinnamaldehyde and some of its derivatives (2′-hydroxycinnamaldehyde) and (2′benzoyl-oxycinnamaldehyde) show a substantial role in increasing the level of reactive
oxygen species and in inducing apoptosis by stopping proteasome activity to make the
carcinogenic cell more prone to oxidative stress [18, 154, 155]. Moreover,
cinnamaldehyde and cinnamic acid together play an important role in preventing CVD
because they both have the ability to produce nitric oxide and both have anti-
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inflammatory effects [156]. The antioxidant property of cinnamon results from activity
of the eugenol component, which stops peroxynitrite-induced nitration and also lipid
peroxidation [157]. Polyphenols that are found in cinnamon are also considered to
improve insulin sensitivity [158]. Figure 2.6 shows the effects of cinnamon on health.

Figure 2.6: Effects of Cinnamon on Health [18]
Moreover, in 2003, Ali et al. demonstrated that black seed contains the following:
protein, 26.7%; fat, 28.5%; carbohydrates, 24.9%; crude fiber, 8.4%; and total ash,
4.8%. Black seed also contains copper, phosphate, zinc, iron, and essential (volatile)
and fixed oil. Black seed essential oil contains a major bioactive component, which is
thymoquinone (TQ; 30%–48%) [142]. TQ is a chemical compound that is known for
its therapeutic potentials, and most black seed positive effects are mainly accredited to
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TQ. TQ therapeutic potentials have been investigated in some studies, which showed
that TQ had an anti-oxidant, anti-inflammatory, immunomodulatory, anti-histaminic,
anti-microbial, and anti-tumor effects as well as gastroprotective, hepatoprotective,
nephroprotective, and neuroprotective activities [19]. Figure 2.7 is a graphic abstract
of TQ’s therapeutic potentials.
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Figure 2.7: Therapeutic Potentials of TQ [19]
In 2016, a review by Amin and Hosseinzadeh stated that black seed and its primary
active component, TQ, have been assigned to many pharmacological activities [159].

Black seed can be added to different types of food such as tea, coffee, casseroles, or
breads, and used in canning. Additionally, its extract is used in wine [160].

Another herb, fenugreek (Trigonella foenum graecum), a legume seed that belongs to
the Fabaceae family is widely cultivated and produced in Mediterranean countries and
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Asia. Fenugreek seed is commonly used as medicine in India and Iran. A study
published in 2007 examined the chemical composition of fenugreek and found that
fenugreek composition was as follows: protein, 28.4%; crude fiber, 9.3%; crude fat,
7.1%; moisture, 6.87%; ash, 3.28%; and carbohydrate, 47.4% [161, 162]. Another
study reported that it had 11.44% moisture, 3.9% ash, 27.57% protein, 6.71% fat,
soluble dietary fiber 30.6%, and 20.6% insoluble dietary fiber [163]. Fenugreek is
known to have pharmacological effects such as hypoglycemic, chemoprotective,
antioxidant and hypolipidemic effects [20, 164-166] plus contains alkaloids,
flavonoids, salicylate, and nicotinic acid as active compounds, and these give
fenugreek its properties [167-169].

Jessie et al. tested the effects of commonly used herbs and spices on health using
human and animal models. Saffron (Crocus sativus) was investigated in Jessie et al.
study due to its hypoglycemic, hypolipidemic, and antioxidant properties. Kang et al.
showed that saffron also increased glucose uptake and insulin sensitivity. Moreover,
saffron was also reported to inhibit platelet aggregation and membrane lipid
peroxidation in a study published by Samarghandian et al. [170-172].

A study by Mohammadi et al. in 2013 discussed the chemical composition of saffron.
The results of the study were as follows: moisture, 12.50%; ash, 9.5%; crude fiber,
7.4%; crude fat, 5.8%; crude protein, 23.6%; and total carbohydrate; 20%. The study
also reported that saffron is a decent minerals source, as it contained potassium (57,
460 ppm), magnesium (3, 357.5 ppm), sodium (1, 100 ppm), calcium (600 ppm), zinc
(100.75 ppm), iron (194 ppm), copper (53.2 ppm), and manganese (48.5 ppm) [21].

39
Cardamom, is another commonly used spice that has been extensively investigation in
the last few years. Cardamom is a recognized spice on the Indian subcontinent and is
used for culinary and medical purposes [22, 141, 173]. In a study on rats, cardamom
was reported to have an anti-hypercholesteremic influence [173] plus significant
beneficial effects on cholesterol, but not on measures of oxidative stress, glycemic
control, and inflammation [141]. A recent study reported that cardamom powder
consumption protects against obesity, improves glucose levels, inflammation, and
oxidative stress in the liver of high carbohydrate-high fat diet-induced obese rats [22]
plus was active in improving the lipid profile in diabetic rats [174].

Furthermore, Pruthi et al. reported the chemical composition of large cardamom as
follows: moisture, 8.49%; protein, 6%; total ash, 4%; crude fiber, 22% [175]. In
comparison, small cardamom contains the following: moisture, 8.3%; protein, 10.3%;
crude fiber, 9.2%; and total ash, 5% [176].

On the other hand, the essential oil of cloves (Eugenia aromaticum), which is isolated
from the clove buds is widely used and well known for its medicinal properties. Cloves
are used in the food industry because of their special aroma and their health benefits
[177, 178]. Cloves can significantly reduce blood sugar and increase lipid peroxidation
in diabetic rats [23] and reported to contain 5.98% protein, 20.04% fat, 61.22%
carbohydrate, and 5.88% ash [179, 180]. Another study reported that cloves contains
12.1% moisture, 7.8% protein, 9.3% fat, 68.6% total carbohydrate, 1.1% crude fiber,
and 1.1% total ash [181].
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2.5.5 Effects of Ginger, Cinnamon and Black Seed on Metabolic Syndrome Risk
Factors
2.5.5.1 Effect on Glycemic Control
A 2-month randomized double-blind placebo-controlled trial was conducted by
Mahluji et al. on participants with type 2 diabetes mellitus to examine the effects of
ginger powder on glycemic parameters, and the results showed that ginger
significantly increased insulin sensitivity, but had no effect on FBG and HbA1c [182].
A meta-analysis concluded that ginger consumption in different forms (tablet,
capsules, powder, or rhizomes) substantially lowered FBG and TG, and elevated HDL
levels [183]. Another clinical trial tested the effects of 2 g of ginger powder on 40
women with obesity and their findings revealed ginger treatment had a non-significant
reducing effect on serum glucose, slight positive effect of ginger powder consumption
on serum glucose and significant effect on TG when compared to the placebo [184].
A study published in 2003 by Khan et al. examined the effects of cinnamon when given
in three different doses for three different groups (group 1, 1 g/day; group 2, 3 g/day;
and group 3, 6 g/day) of diabetic people for 40 days. The study showed that cinnamon
powder decreased FBG levels significantly [144]. However, a 2008 meta-analysis of
randomized controlled trials where cinnamon was administered concluded that the
ingestion of cinnamon had no significant effect on improving HbA1c or FBG [185].
A meta-analysis for 10 randomized controlled trials that included a total of 543
diabetic patients showed that consuming cinnamon at a dose from 120 mg/day to 6
g/day for around 4 months causes a significant reduction in FBG levels [186].
Additionally, a study by Heshmati et al. reported that supplementation with black seed
oil (3 g/day) significantly improved FBG, HbA1c, total cholesterol, TG, HDL, and
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LDL levels in the blood in the treatment group when compared to the placebo group
after 12 weeks of consumption [187]. Another study demonstrated that taking 2 g/day
of black seeds for 3 months in individuals with type 2 diabetes mellitus decreased
FBG, 2-hour post-prandial glucose (2-hPG), HbA1c, and increased insulin sensitivity
without any renal or hepatic side effects [188]. Additionally, many researchers have
reported that black seed has anti-diabetic and hypoglycemic activity because the
components of black seed decreases oxidative stress and thus preserves pancreatic beta
cell integrity [189].
2.5.5.2 Effect on Blood Pressure
A randomized controlled clinical trial was on individuals with type 2 diabetes who
were randomly distributed to four interventional groups. Each intervention group
received 3 g each of cinnamon, cardamom, and ginger powder and 1 g of saffron
powder. The participants were asked to consume the spices with three glasses of black
tea every day. The control group consumed only three glasses of tea without any spice
powder for 8 weeks. The study showed that none of the spice powders had significant
effect on improving blood pressure [141].
Torabi et al. concluded that ginger have no significant effect on blood pressure but also
reported that ginger could be offered as a natural alternative dietary supplementation
to anti-hypertensive factors in animal studies. Unfortunately, there is not enough
evidence to support the same outcome in human studies [190, 191].
Furthermore, in a randomized, placebo-controlled, double-blind clinical trial, 58
individuals with type 2 diabetes were randomly assigned to consume either 2 g/day of
cinnamon or placebo for 12 weeks and a significant decrease in systolic and diastolic
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blood pressure was reported [192]. Similarly, a systematic review discussed the effects
of cinnamon on blood pressure in individuals suffering from diabetes mellitus and
reported that the short term consumption of cinnamon is linked to a significant
decrease in systolic and diastolic blood pressure [193]. A double-blind randomized
controlled trial by Datau et al. in 2010 enrolled 62 patients with MetS. The study stated
that the supplementation with 3 g/day of black seed powder for 3 months significantly
reduced systolic BP [194]. Additional evidence supports the positive effects of black
seed on blood pressure. One hundred fifty-nine participants were assigned into two
groups: 78 participants in the control group and 81 in the black seed group. The former
group received two capsules daily for 6 weeks, each with 250 mg of black seed powder.
Participants also received oral hypoglycemic and antihypertensive drugs with dietary
modification including a low-fat diet and physical activity such as walking (60–90
minutes per day) on an empty stomach for 6 days every week. This intervention
showed a significant decrease in blood pressure when compared to the placebo group
[195]. Another study included patients with mild hypertension who were randomly
assigned into three groups: placebo and two other test groups. One of the test groups
received 100 mg and the other received 200 mg of black seed extract twice per day in
the form of capsules for 8 weeks. Systolic and diastolic blood pressure were lowered
significantly in a dose-dependent manner [196].
2.5.5.3 Effect on the Lipid Profile
In 2013, Mahluji published a randomized double-blind placebo-controlled trial and
showed that ginger had significantly decreased LDL and TG in participants with type
2 diabetes mellitus [182]. A meta-analysis showed that ginger consumption (tablet,
capsules, powder, or rhizomes) had a significant effect on decreasing TG and elevating
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HDL [183]. Moreover, a randomized double-blinded placebo-controlled clinical trial
examined the effects of 2 g/day of ginger powder on 40 women with obesity showed
that ginger treatment significantly reduced TG levels in the blood compared with the
placebo group [184]. Another randomized double blinded study examined the effects
of 3 g of ginger powder for 45 days on patients with CVD in Iran, and concluded that
ginger powder had significant effect of reducing in TG, cholesterol, LDL, and very
low-density lipoprotein (VLDL) levels in the blood [197]. An earlier study that tested
the effects of cinnamon given in three different doses people with diabetes for 40 days
showed that cinnamon powder significantly decreased TG, LDL, and total cholesterol
levels in the blood [144]. Additionally, amore recent meta-analysis established that
cinnamon significantly lowered total cholesterol, LDL, and TG and improved HDL
concentrations significantly while having no significant effect on HbA1c levels in the
blood [186]. Similarly, another meta-analysis of randomized controlled trials of
cinnamon was published by Baker et al. and concluded that cinnamon consumption
did not improve any lipid parameters significantly [185].
Moreover, studies conducted by Heshmati and Namazi in 2015 showed that 1 g/day of
black seed powder for 12 weeks increased HDL levels, and 2 g of black seed powder
decreased total cholesterol, LDL concentrations, and TG levels. Additionally,
increasing the dosage from 2 to 3 g/day did not further improve the lipid profile status.
However, the most effective dose was between 2 g and 3 g per day to improve total
cholesterol, TG, LDL, and HDL concentrations [198]. A randomized controlled trial
by Ibrahim et al. in 2014 studied the effects of black seed consumption on menopausal
women for 2 months. This study showed an improvement in the lipid profile (decrease
in total cholesterol, LDL, and TG and an elevation in HDL) [199].
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Additionally, a double-blind randomized controlled study was performed by Amin et
al. (2015). The intervention group received 2 g/day of black seed for 4 weeks and
showed a significant effect of black seed on lowering total cholesterol, LDL, and TG
levels [140].
2.5.5.4 Effect on Weight and Waist Circumference
Mansour et al. examined the short-term effects of hot ginger beverages on feelings of
satiety, energy expenditure, and metabolic risk factors in thirty men who were
overweight. Ginger consumption in a beverage form had no significant effect on blood
glucose, insulin, lipid profile, or inflammatory markers but improved thermogenesis
and increased feeling of satiety suggesting a potential role of ginger consumption in
managing weight [200]. Additionally, a randomized controlled clinical trial that
examined the effects of each cinnamon, cardamom, saffron, and ginger powder for 8
weeks on diabetic individuals concluded that none of the spices powders had a
significant effect on improving weight or WC [141]. Another study by Nayebifar et al.
[201] tested the influence of ginger combined with high intensity training on
inflammation on thirty healthy women who were overweight. Participants consumed
3 g/day of ginger in the first group; 3 g/d of ginger + high intensity training in the
second, and the third group consumed 3 g/d of placebo + high intensity training for 10
weeks. This study showed that interval exercise, by itself or combined with a ginger
supplement, improved the maximum oxygen consumption but did not significantly
lower the body fat percentage or the waist-to-hip ratio [201]. Similarly, Whitfield et
al. tested the effects of a cinnamon, chromium, and magnesium-formulated honey on
blood glucose, weight, and lipid profile in individuals with diabetes [202]. After 40
days of the intervention, there was no difference in FBG or HbA1c, and no significant
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improvement of the lipid profile or weight was reported, however, there was a
tendency towards elevating HDL and lowering systolic blood pressure in the treatment
group [202]. Additionally, a study in 2012 suggested that cinnamon could be an
effective tool to moderate postprandial glucose in normal weight and obese adults,
which will help in weight management [203]. Moreover, a 2008 study tested the effects
of cinnamon on insulin sensitivity in diabetic adults. Significant improvement was
reported in the FBG level, lipid profile, blood pressure, and body fat percentage and it
elevated lean body mass for participants who consumed cinnamon when compared to
the placebo group [158].
Datau et al. reported that the consumption of 3 g of black seeds in men with central
obesity can significantly decrease waist circumference [194]. In this study, the subjects
were divided into two groups: treatment and control. Both groups were evaluated
weekly for 3 months. The study showed a significant decrease of WC when comparing
to the placebo group [194]. Additionally, a double-blind randomized controlled trial
by Amin et al. found that consuming 1.5 g/day of black seed powder for 4 weeks
significantly reduced WC [140]. Furthermore, Shah et al. found that the consumption
of 250 mg of black seeds for 6 weeks, along with dietary modification (cholesterolfree diet) and 60–90 minutes of walking 6 days per week provided protection against
MetS and significantly lowered waist circumference [195]. A prospective randomized
controlled study was carried out by Najmi et al. in 2008 on 60 participants with MetS
to study the effects of 2.5 mL black seed oil twice per day along with atorvastatin 10
mg once a day for 6 weeks. This study proved that black seed oil was significantly
effective in lowering weight and waist circumference of the participant who consumed
the black seed oil when compared to the control group [16].
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A review study by Qidwai and Ashfaq [204] reported that black seed does not have a
direct effect on reducing body weight. However, it affects food intake via an anorexic
effect that causes a reduction in the food consumption, and thereby a decrease in body
weight [204]. A randomized, double-blind, placebo-controlled study by Heshmati et
al. on patients with diabetes showed that the ingestion of 3 g/day of black seed oil for
12 weeks did not cause a significant change in body weight [187]. Another
interventional prospective randomized controlled study was conducted by Haque et al.
in 2011 on 161 participants. The participants were asked to take 2.5 mL of black seed
twice a day for 6 weeks. The results showed that there was an improvement in some
parameters including body weight and BMI in the treatment group and the placebo
group, and the improvement was greater in the black seed group when compared to
the placebo group [205]. Additionally, the results of the study of Najmi et al. in 2008
on 60 participants studied the effects of black seed oil on body weight, and the results
showed a decrease in the body weight in both groups (the intervention and placebo).
This proposes that the effect of black seed on reducing body weight is not significant
[16].
2.6 Summary
MetS history, different definitions, diagnostic criteria, and methods of management
and treatment were extensively reviewed in this chapter. The use of herbal therapy,
chemical analysis of spices, and the active compounds in spices were also discussed.
In conclusion, the effects of ginger, cinnamon, and black seed on parameters related
to MetS and CVD are promising and controversial. Many studies are needed to confirm
their effect in humans, especially studies related to MetS and CVD risk factors.
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Chapter 3: Materials and Methods
3.1 Introduction
This chapter outlines and discusses the research design, methodology and analyses
followed in the clinical trial presented in this dissertation. The purpose of the current
study was to test the hypothesis that seven locally consumed spices have different
nutrient composition and that consumption of ginger, cinnamon and black seed powder
lowers the risk factors of metabolic syndrome and therefore decreases the risk of
developing CVD. Two primary objectives were formulated for the study, the first
objective is to determine the nutrient composition of seven commonly used spices, and
the second objective is to assess the effects of three selected spices namely ginger,
cinnamon and black seed powders on fasting blood glucose, Hb levels, HbA1c levels,
blood pressure, blood lipid profile levels and waist circumference among participants
at risk of CVD.
3.2 Ethical Approval
This study was carried out according to the Declaration of Helsinki guidelines. United
Arab Emirates University Scientific Research Ethics Committee approved all
procedures concerning human subjects (UAEU, Protocol Number: 15/22; Reference
Number: DT/bb/15-22. Participants who approved to take part in the study were asked
to sign a written informed consent in order to participate in the study.
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3.3 Study Protocol
3.3.1 Nutrient Composition of Spices
3.3.1.1 Sample preparation
Seven locally consumed spices were purchased from the local market (Alyahar
Market) in Al Ain city. The selected spices were: ginger (Zingiber officinale),
cinnamon (Cinnamomum), black seed (Nigella sativa), fenugreek (Trigonella foenum
graecum), cardamom (Elettaria cardamomum), cloves (Eugenia aromaticum) and
saffron (Crocus sativus). Part of the purchased spices was used for the chemical
analysis and the rest was used for the interventional study. Spices used for chemical
analysis were purchased as a whole spice and were ground in the laboratory using a
coffee and spices grinder machine (Moulinex Coffee Grinder, MC300161, France).
Spices were prepared in triplicate for the proximate and micronutrient analyses.
3.3.1.2 Proximate Analysis
The seven spices were analyzed chemically according to the Association Official
Analytical Chemist procedure (AOAC) [206] for their moisture, protein, fat, fiber and
ash content according to the following procedures:
3.3.1.2.1 Moisture Content Determination
Oven drying was used to determine the moisture content of the seven spices. As water
evaporates, it will leave the dry matter. The dry matter was used to calculate the
moisture content. In order to calculate the dry matter, three aluminum dishes for each
spice were dried at 105 °C for two hours and were placed in a desiccator to cool down,
thus, avoiding any moisture from the room. After cooling, the electrical balance
Scaltec® SBA 31 (Scaltec®Instruments, Heiligenstadt, Germany) was used to weigh
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the dishes. 1 gram of each spice powder was weighed and spread uniformly in the
aluminum dishes. By using a forced air drying oven Mommert® (Schutzart DIN 40050-IP20, Schwabach, Germany) samples were dried for a further 16 hours at 105 °C ±
3 °C and then were returned to the desiccator to cool down to room temperature.
Samples were weighed to the nearest 0.01 mg. The equations used to calculate the
percentage of total dry matter and total moisture are in Table 3.1 [207].
Table 3.1: Proximate Analysis Equations
Component

Equation

% Total dry
matter

(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑛𝑑 𝑑𝑖𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑖𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠
× 100
100 − % 𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑦 𝑚𝑎𝑡𝑡𝑒𝑟

% Total
Moisture
% Ash

(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑐𝑖𝑏𝑙𝑒 𝑎𝑛𝑑 𝑎𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑐𝑖𝑏𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠
× 100
% 𝑁𝑖𝑡𝑟𝑜𝑔𝑒𝑛 × 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (6.25)

% Protein
% Crude fat
%
Carbohydrate

(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑢𝑝+𝑓𝑎𝑡 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)−(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑒𝑚𝑝𝑡𝑦 𝑐𝑢𝑝 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠

× 100

100 − (% 𝑡𝑜𝑡𝑎𝑙 𝑚𝑜𝑖𝑠𝑡𝑢𝑟𝑒 + %𝐴𝑠ℎ + %𝑃𝑟𝑜𝑡𝑒𝑖𝑛 + %𝐶𝑟𝑢𝑑𝑒 𝑓𝑎𝑡
+ % 𝑇𝑜𝑡𝑎𝑙 𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝐹𝑖𝑏𝑒𝑟)

3.3.1.2.2 Ash Determination
Labeled ashing crucibles were placed in a forced air drying oven Mommert®
(Schutzart DIN 400-50-IP20, city, country) at 500 °C for four hours, then placed in the
desiccator to cool to room temperature after which they were weighed to the nearest
0.01 mg. Around 1 gram of the sample was weighed in the crucibles and placed in a
muffle furnace oven (Carbolite ELM, 11/6) at 500 °C for four hours. The crucibles
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were then allowed to cool to less than 200 °C and weighed to the nearest 0.01 mg. The
equation used to calculate the percentage of ash is in Table 3.1 [208].
3.3.1.2.3 Protein Content Determination
The Kjeldahl method was applied to decide the nitrogen content in the spice samples.
The protein content was estimated using a factor of 6.25. Using the Foss Tecator 2020
digester (Foss Tecator, Hoganas, Sweden) 0.5 gram of each sample was digested using
27 mL of H2SO4 (96%) and a catalyst (Kjedahl selenium tablets) in a digestion tube
for 45 minutes at 410 °C. At the end of the digestion, nitrogen in the samples was
converted to ammonia. Then, a Foss 2300 Kjeltec Analyzer Foss (Technologies Co.,
Ltd., Höganaös, Sweden) was used to determine ammonia and protein content in the
samples [209-211]. The equation used to calculate the percentage of protein is detailed
in Table 3.1 [212].
3.3.1.2.4 Fat Determination
Fat content was determined using Soxhlet extraction as recommended by AOAC
[206]. The procedure starts by drying the extraction cups at 105 °C for two hours. After
weighing the cups to the nearest 0.01 mg, two grams of each sample were positioned
in a 33 mm × 80 mm extraction thimble and extracted with 50 mL n-hexane/acetone
(1:1, v/v) in boiling solvent for one hour using the Soxhlet extraction in a Sotex system
2050 (Foss, Hillerod, Denemark). Thimbles were left to allow for maximum
evaporation of the solvent, meanwhile the extraction cups were removed from the
extractor to be placed in a fume hood to permit the solvent to evaporate at low
temperature. After evaporation, the extraction cups were placed in an oven to be dried
at 105 °C for 30 minutes, then were let to cool to reach room temperature in the
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desiccator to be weighed afterwards to the nearest 0.01 mg [213]. The equation used
to determine percentage of crude fat is listed in Table 3.1 [206].
3.3.1.2.5 Fiber Content Determination
The ANKOMTDF Dietary Fiber Analyzer (Dietary Fiber Analyzer, ANKOM,
Macedon NY, USA, Figure 3.1) was used to measure the fiber content of each spice,
using the AOAC 991.43 TDF method [206], and following the procedure listed in
previous research [214]. ANKOM filter bags (DF-S, DF-FT, ANKOM Technology)
were used to analyze dietary fiber. The bags were labeled, weighed and then placed in
the ANKOM dietary fiber analyzer to begin the analysis. Filter bags were rinsed with
acetone solution and left to dry thoroughly. Once the filtered bags were dry, they were
sealed with a heat sealer (1915, ANKOM Technology) and placed in an oven at 105
°C for 90 minutes. Afterwards, their weight was recorded to the nearest 0.01 mg. One
filtered sealed bag of each spice sample was sent for the protein content determination
and another one was sent for the ash content determination. The percentage of total
dietary fiber content was decided using the dietary fiber data spreadsheets provided by
the manufacturer on the ANKOM Technology website [215].
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Figure 3.1: ANKOMTDF Dietary Fiber Analyzer (Dietary Fiber Analyzer, ANKOM,
Macedon NY, USA)
3.3.1.2.6 Carbohydrate Content Determination
After the calculation of all other components, the carbohydrate content was calculated
by subtracting the mean percentage values of the sum of moisture, ash, protein, lipids,
and dietary fiber from 100 as shown in Table 3.1.
3.3.1.2.7 Energy Calculation
The energy content of the spice samples were calculated according to Atwater’s plan
[216], as this method was used in literature and considered most suitable for the
calculation of the energy content of the spices [153, 217, 218]. Energy content was
calculated by multiplying the percentage of protein with 4, carbohydrate percentage
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with 4 and fat percentage with 9. Then, values were converted to kilo calories per
100 gm of the sample weight.
Energy content = (protein%*4) + (carbohydrate%*4) + (fat%*9)
3.3.1.3 Mineral Content Determination
The procedure for measuring minerals in plants and spices by Inductively Coupled
Plasma Optical Emission Spectrometer (ICP-OES) was followed for the micronutrient
analysis of the spices [219].
The CEM Mars 5 microwave digestion method (Mars5, CEM, Matthews, USA) was
used for elements extraction from the spice samples. The procedure of digestion was
founded upon the USEPA method 3015A guidelines recommendations [219]. This
microwave digestion method was designed to simulate extraction using conventional
heating with nitric acid and hydrochloric acid. The spice samples were accurately
prepared by placing a weighed 0.50 grams of sample into the microwave digestion
vessels, then 10 mL of concentrated nitric acid and 2 mL hydrochloric acid were added.
The vessels were capped and placed in the microwave digestion system. After the
digestion and cooling the samples to room temperature, de-ionized water was added
to the sample solution to reach 50 mL. It was then aspirated through a nebulizer. The
resulting solution was transported to a plasma torch for excitation [220].
Element specific emission spectra were produced by radio-frequency inductively
coupled plasma. The spectra were detached by a grating spectrometer, and intensities
of the line spectra were monitored at specific wavelengths by a charged coupled
detector.
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A fitted background correction was used to correct the blank signal and matrix effect.
Background correction was not required in case of line broadening where a
background correction measurement would actually degrade the analytical result. The
machine used for the analysis was an Inductively Coupled Plasma - Optical Emission
Spectrometer (ICP-OES) (710-ES, Varian, USA).
3.3.1.4 Sugar Content Determination
High-performance liquid chromatography (HPLC) (Waters, Milford, MA, USA) was
used to determine monosaccharides, disaccharides and trisaccharides. Sample
preparation and the analysis procedure were adopted with slight modification from the
research of J.S Smith et al. and Yuan et al. [221, 222]. HPLC was equipped with Binary
pump 1525, auto injector /auto sampler waters 717 plus and Refractive Index Detector
2414. The chromatographic separation was achieved using column oven model code
LAC and Column µ Bondapak NH2 10 µm, 125 A°, 3.9 *300 mm (Waters Associates,
Milford, MA, USA). The mobile phase consisted of acetonitrile and water (83:17, v/v),
while the flow rate was 1.5 mL/minute and the temperature was kept at 35 °C.
3.3.1.5 Lipid Content Determination
Fatty acid composition analysis was carried out using a Young Lin 6500 gas
chromatograph (YL-6500 GC, Gyeonggi-do, South Korea, Figure 3.2), fitted with a
SP-2380 Fused Silica Capillary Column (30 m × 0.25 mm I.D × 0.20 µ film (2-4110),
Sigma Aldrich, St. Louis, MO). The analytical column was heated at 50 °C for two
minutes. Then it was raised to 250 °C at 4 °C/minute, and held for 15 minutes. Helium
was the carrier gas used for analysis, (20 cm/second) at 150 °C. The Supelco 37
constituent Fatty Acid Methyl Esters (FAME) mix standard was utilized for the
recognition of key fatty acids in the spice samples. The Fatty Acid Methyl Esters
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(FAMEs) were prepared following AOAC Method 969.33 [206]. The analysis
procedure followed was as described in the application notes of the manufacture
(Sigma Aldrich) [223].
HPLC (Waters, Milford, MA, USA) was estimate to calculate the cholesterol content.
The HPLC system is composed of a Waters 2487 Dual λ Absorbance Detector,
operated with Breeze software. Cholesterol was analyzed in to a reversed phase XTerra
C18 column, 4.6 mm inner diameter by 150 mm, 5 µm (Waters Associates, Milford,
MA, USA). The mobile phase consisted of methanol and 2-propanol (70:30, v/v), and
the flow rate was set at 1.0 mL/minutes, while the oven temperature was kept at 25 °C.
An ultra violet (UV) detector was used to detect cholesterol, the UV detector
wavelength was of 212 nm [224, 225].

Figure 3.2: Young Lin 6500 Gas Chromatograph (YL-6500 GC, Gyeonggi-do, South
Korea)
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3.3.1.6 Water Soluble Vitamin Determination
Seven water soluble vitamins were analyzed using HPLC (Walters, Milford, MA,
USA) [226]. The system was equipped with a binary pump 1525, auto injector /auto
sampler Waters 717 plus and Dual λ absorbance Detector 2487. The chromatographic
separation was achieved using Column XTeera C18 (4.6 * 150 mm, 5 µm) from Waters
(Walters Associates, Milford, MA, USA). The mobile phase consisted of 50 mM
K2HPO4 (pH7): methanol, gradient: 1% methanol for five minutes, 1-30% methanol
(liner gradient) over 15 minutes, 30% methanol for five minutes with flow rate of 1.0
mL/minute. The column temperature was kept at 35 °C, and the injected volume was
10 µl. The analytical column effluents were monitored at a wavelength of 220 nm as
recommended by Supelco Application Note 148 [227].
3.3.1.7 Fat Soluble Vitamin Determination
Waters ACQUITY UPLC system (Waters, Milford, MA, USA) was used to analyze
fat soluble vitamins. The system operated by Empower software, is composed of three
main parts: ACQUITY sample manager, ACQUITY binary solnet manager and
ACQUITY PDA eλ detector. The concept of fat soluble analysis was based on a
reversed-phase ACQUITY BEH C18 column (2.1 mm inner diameter by 100 mm, 1.7
µm) from Waters (Waters Associates, Milford, MA, USA).
The temperature was set at 35 °C. The mobile phase consisted of solvent A:Water:
Acetonitrile (90:10), and solvent B: methanol and acetonitrile (50:50, v/v). A flow rate
of 0.7 mL/minute and injection volume of 5 µl was used. For vitamin E, the analytical
column effluents were monitored at a wavelength of 285 nm. For vitamin K1, K2, D2,
D3 it was kept at a wavelength of 265 nm and at 325 nm for vitamin A acetate [228].
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3.3.1.8 Caffeine Content Determination
The analysis of caffeine method was adopted from previous research published by
Erickson et al. with modification to adapt to the equipment available in the laboratory
[229]. HPLC (Waters, Milford, MA, USA) was utilized to estimate the caffeine content
in the spices. HPLC was equipped with a binary pump 1525, auto injector /auto
sampler waters 717 plus and Dual λ absorbance detector 2487. The chromatographic
separation was achieved using the Column XTeera C18 column (4.6 * 150 mm, 5 µm)
from Waters (Waters Associates, Milford, MA, USA) and was operated with Breeze
software. The mobile phase consisted of acetonitrile and water (10:90, v/v), and the
flow rate was 1.0 mL/minute. An UV detector was used to detect caffeine and was set
at a wave length of 265 nm.
3.3.1.9 Shogoals, Gingerols and Curcumin Content Determination in Ginger
Powder
Gingerols are thermally unstable and could form many derivatives at high
temperatures, during gas chromatograph. HPLC is the most favored method for a more
accurate analysis of gingerols. It does not involve high temperature during the analysis
of gingerols.
HPLC was used to determine the 6-gingerol content in the spice powders (Waters,
Milford, MA, USA). The 6-gingerol standard was dried over silica gel for three hours.
Then, sufficient HPLC-grade methanol was added to 5 mg of 6-gingerol standard to
produce a solution of 1000 µg/mL. Serial dilutions of the solution were made to
produce different working standards ranging from 1 to 750 µg/mL. All 6-gingerol
standards were capped and stored at 4 °C. An Inertsil ODS-3 column with a dimension
of 250 x 4.6 mm, 5-μm particles was used (Waters Associates, Milford, MA, USA).
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The mobile phase consisted of methanol: water was run for five minutes at a flow rate
of 1 mL/min, while the PDA detector was set at a wavelength of 282 nm. The method
was adopted from previous research with modifications [230].
Shogoals are derivatives of gengerols and are more thermally stable. Shogoals form
after gengerols undergo changes under heat and they are much more pungent than
gengerols [231, 232]. GC (YL-6500 GC, Gyeonggi-do, South Korea) was used to
determine the shogoals content in the ginger powder. After the extraction of ginger oil,
its analysis was carried out using a Shimadzu GC-2010 gas chromatograph equipped
with QP 2010 mass spectrometer and RTX–5 column (30 m × 0.25 mm, 0.25 μm). At
a flow rate of 1.67 mL/min, helium was used as the carrier gas. The injection port was
250 °C and the detector temperature was 220 °C. Meanwhile, the oven temperature
was 60 °C for 5 min and then the temperature was elevated to 110 °C at the rate of 5
°C /min, then increased to 170 °C at the rate of 3 °C/min and finally to 220 °C at the
rate of 5 °C/min. The split ratio was 1:40 and ionization energy 70 eV. The preparation
of the ginger sample and the determination of shogoals in ginger method, was adopted
with modifications from the research of Kizhakkayil et. al. [233].
Curcumin was determined in ginger using HPLC (Waters, Milford, MA, USA). The
isocratic reversed HPLC method using RP C18 column, was used for the simultaneous
determination of the curcumin in the ginger powder. The mobile phase consisted of
acetonitrile: 0.1% trifluro-acetic acid (50:50). The flow rate was 1.5 mL/min and
elution was monitored at a wave length of 420 nm.
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3.4 Statistical Analysis
Statistical Package for Social Sciences (SPSS) version 23.0 (IBM Corp, Armonk, NY,
USA) for windows was used for the analysis of the nutrient composition data. Kruskal
Wallis test was used to carry out the analysis of the data as it is considered the
nonparametric alternative to the ANOVA test. Kruskal Wallis test was used for
comparison of medians of measurements of macronutrients and micronutrients of the
spices due to the lack of normality assumption of ANOVA. Statistical analysis was set
at P-value of <0.05.
3.5 Intervention Study
3.5.1 Study Population
The study was a controlled, randomized, single blind, parallel-design study conducted
during the academic year 2015/2016 at United Arab Emirates University (UAEU) in
Al Ain, United Arab Emirates. The study population included UAEU students, staff
and faculty members aged between 18 and 50 years, who were at risk of metabolic
syndrome or had metabolic syndrome. Participants were recruited through face-to-face
interviews, printed advertisements and via email to voluntarily participate in the study.
Participants who agreed to participate were asked to read the study information sheet
thoroughly and all their questions that are related to the study were answered before
taking part.
A total of 372 participants who showed interest in the study were initially screened for
eligibility at the Nutrition Clinic of UAEU. 252 out of these were excluded from the
study for the following reasons: 203 did not meet the metabolic syndrome diagnostic
criteria nor were at risk for developing metabolic syndrome, 12 were smokers, 6 were
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pregnant or lactating, 3 had a liver or kidney diseases, 7 were on a strict diet, 1 was
bulimic, 9 did not want to sign the consent form and 11 refused to give blood sample.
Therefore, the final number of participants was 120 between the age of 18 and 50 years
old (Figure 3.3).

n=203 did not meet the
MetS criteria

n=12 were smokers

n=6 were pregnant or
lactating
n=372 Subjects
volunteered to participate
in the study

n=252 subjects were
excluded from the study
n=3 had liver or kidney
diseases
n=120 subjects met the
inclusion criteria
n=7 were on a strict diet

n=1 was bolimic

n=11 refused to give blood
sample

Figure 3.3: Number of Participants who were Excluded from the Study

An identification number was allocated to each participant to preserve anonymity,
which confirmed confidentiality and helped link the participant to their clinical
measurements and blood samples. Only cumulative data was reported to protect the
privacy of all participants.
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3.5.2 Inclusion and Exclusion Criteria
Participants were considered eligible to take part in the study after meeting the
following inclusion criteria: age (18-50 years) and had 2 or more of MetS diagnostic
criteria; high waist circumference (>80 cm for female and >94 cm for males), elevated
blood pressure (equal to or greater than 130/85 mm Hg or use of medication for
hypertension), high fasting blood glucose (equal to or greater than 100 mg/dL {5.6
mmol/L} or use of medication for hyperglycemia), lowered HDL cholesterol (less than
40 mg/dL {1.03 mmol/L} for men and less than 50 mg/dL {1.29 mmol/L} for women)
and increased triglycerides (equal to or greater than 150 mg/dL {1.7 mmol/L}).
Participants who had at least three risk factors out of five, or had two risk factors and
one in the borderline level were included in the study.
Participants were excluded if they did not meet the following inclusion criteria, older
than 50 years old or younger than 17 years old and did not meet the metabolic
syndrome diagnostic criteria. Moreover, participants were excluded if they were
allergic to spices, current smokers, pregnant or lactating women, currently taking
medication or if they refused to provide a blood sample. Also, participants with any
acute illnesses or any chronic diseases such as; kidney, liver, cardiovascular and
gastrointestinal diseases were excluded from the study. During the study period,
participants were asked to bring the remaining spice powder to each visit. The amount
left was calculated to make sure that the participants have consumed 80% of the total
amount or more. Those who consumed less than 80% of the treatment powder were
excluded from the study.
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3.5.3 Screening Measurements
To ensure that the selected study population was eligible to participate in the study,
screening measurements were conducted for the MetS diagnostic criteria including:
blood pressure (BP), waist circumference (WC), fasting blood glucose (FBG), high
density lipoprotein (HDL) and triglycerides (TG). Figure 3.4 illustrate the screening

Screening Measurements

measurement of the study.

Clinical

Blood Pressure

≥130/85 mmHg

Anthropometric

Waist
Circumference

M: >94 cm
F: >80 cm

Fasting blood
glucose

≥100 mg/dL

HDL cholesterol

M: <40 mg/dL
F: <50 mg/dL

Triglycerides

≥150 mg/dL

Biochemical

Figure 3.4: Screening Measurement of the Intervention

In addition, participants were asked to fill a health screening questionnaire which
contains questions about medical conditions and medications that might influence
glucose regulations, appetite and energy expenditure (Appendix 1).
Of the 120 participants, 18 were excluded from the study due to failing to comply with
the study requirements: consuming less than 80% of the allocated powder amount,
dieting, increasing their physical activity levels and 5 dropped out from the study for
personal reasons. A total of 97 participants completed the 12-week intervention.
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Participants were divided into control (n=30), ginger (n=30), cinnamon (n=30) and
black seed (n=30) as shown in Figure 3.5.

n=372 participants volunteered to
participate in the study

n=120 participants met the
inclusion criteria

n=30 ginger group

n=21 completed
the study

n=30 cinnamon
group

n=25 completed
the study

n=30 black seed
group

n=29 completed
the study

n=30 control
group

n=22 completed
the study

18 participants were excluded and 5
dropped out of the study

Figure 3.5: Number of Participants during Screening and Intervention
3.5.4 Intervention Study Protocol
A 12-week clinical randomized intervention was conducted by comparing participants
from three treatment groups (ginger, cinnamon and black seed) with those from the
control group (placebo). Participants were divided randomly into four groups;
participants were asked to consume three grams per day, on separate occasion, of the
allocated spice or corn starch powder for 12 weeks. In a normal day, each participant
was asked to consume one gram in the morning, one gram at the middle of the day and
one gram at the end of the day, preferably with hot water. This was recommended to
eliminate heartburn or any gastrointestinal irritation that may result from the
consumption of high dose of spices. As not all participants liked the pungent taste and
smell of some spices like the ginger, it was recommended to consume the spice powder
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combined with a hot beverage, or to be added to their favorite. Participants were asked
not to change any of their dietary or physical activity habits through the study period.
Data were collected from participants at three points: baseline, at midpoint (sixth
weeks) and at endpoint (twelfth weeks) of the study period. Midpoint collection of
data was considered to ensure participant’s compliance to the study protocol and to
follow up their progress and feedback.
Three spices out of the seven analyzed spices were used for the intervention (ginger,
cinnamon and black seed). The three studied spices were chosen due to the fact that
fenugreek consumption could lead to undesirable body odor, along with the highly
expensive price of saffron. Therefore, fenugreek and saffron were eliminated to
increase the enrollment rate of participant and to meet the study budget. Accordingly,
3 spices were chosen among the remaining spices (5 in total), taking into consideration
the research budget limitation. In contrast, corn starch was used as a placebo for the
control group to eliminate the psychological factor [234].
The spices were purchased from a local spices shop in Al Ain city (Alyahar Market),
with the whole amount purchased at once to minimize any error. Part of the purchased
spices was used for the chemical analysis and the rest was used for the interventional
study. Spices were freshly ground into a powder for the intervention study. Pure corn
starch powder was purchased from a local supermarket in 400 g packages.
In a clean and sanitized area, spices powder and starch powder were weighted into one
gram portions and were packed in small zip lock plastic bags for the convenience of
the participant’s usage. Each participant received 300 grams of each powder (3 g/day
* 7 days/week * 12 weeks of the intervention=252 g and by adding 20% of the amount
(50 g) the total amount was 300 g).
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Once participants met all of the inclusion criteria, they were asked to maintain the
same dietary habits and physical activity levels for 12 weeks. They were asked to
record their dietary intake using a three-day food record (Appendix 2) and to report
their physical activity level by using the International Physical Activity Questionnaire
(IPAQ) (Appendix 3). The mentioned records were submitted by participants at each
visit to ensure that there were no changes on dietary and physical activity habits
introduced through the study period.
3.5.5 Anthropometric Measurements
Anthropometric measurements are a practical to evaluate the development of human
body through various ages, as it provides an evaluation of nutritional and health status
of population groups [235]. Anthropometric indicators may not be as accurate as
clinical and biochemical techniques. However, they provide important participant
information regarding undernutrition and overweight/obesity, and also contribute to
the development of proper food and nutrition policies [236]. Anthropometric
measurements includes the measurement of the physical properties of the human body.
These physical descriptions include body size, shape and body composition [237, 238].
All anthropometric measures in this research were taken in a 30-minute visit at each
of baseline, midpoint and endpoint of the study period. All measures were taken by a
trained and skillful researcher who had a received a training on anthropometric
measurements. Participants were asked to attend each visit in a fasted state for 10-12
hours prior to testing. Readings of measures were recorded in triplicate immediately
and the average of the three readings was calculated and used in the study. Measures
included: height, weight, body composition and waist circumference. Cognizant of
culture norms, anthropometric measurements were taken with participants wearing
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minimal clothes and with no shoes on. Daily calibration of all the devices helped to
insure the precision of data.
At each visit, participants were asked to rest for 15 minutes to relax and to adjust to
climatic changes. During this period, participants were asked to complete a physical
activity questionnaire with a research assistance available to clarify and answer any
questions.
3.5.5.1 Height
The measurement of height considered to be one of the heritable human traits. Fetal
growth, nutrition and infections during childhood and adolescence are essential factors
of height variations during adulthood [239].
Data collected of height and height trends can assist the understanding of health
impacts during human life cycle and its relation to nutrition [240]. Height was
collected in many previous research projects to assist the development of human body
as it provides an evaluation of nutritional and health status of population groups [241,
242].
In this study, height was recorded to the nearest centimeter using a Stadiometer (Seca
Stadiometer, Seca Ltd, Birmingham, UK), with participants standing straight and
without wearing shoes, heavy outer garments, hair cover or hair accessories were
removed. Taking into account that the posture of the participants at the time of
measurement may influence the accuracy of the measurement, each participant stood
erect with their head in the Frankfort plane with ears and cheekbones at the same level,
and the arms at the sides, feet positioned close together, knees straight, heels, buttocks,
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and shoulder blades touching the vertical surface of the stadiometer as recommended
by the WHO STEPS protocol [243].
3.5.5.2 Body Weight and Composition
Body weight and body composition varies between individuals and across population.
Weight measurement and body composition were considered to be a tool for assessing
health risk factors [244]. Since, obesity has appeared as a main public health concern,
weight measurement is needed to assess obesity and to calculate body mass index
(BMI). Previous studies evaluated the connection between body weight and body
composition in relation to cardiovascular diseases and related higher weigh and higher
fat composition to cardiovascular diseases [245-247].
In this study, body weight and body composition were recorded to the nearest 0.1 kg
using the InBody 270 (Body Composition Analyzer) and body composition was
measured using the Hologic Discovery Dual energy X-ray Absorptiometry (DXA)
system, with participants wearing light clothing (due to cultural limits) and with no
shoes or socks on.
The InBody 270 (InBody Ltd., Seoul, South Korea) is a non-invasive body
composition analyzer that delivers a comprehensive breakdown of body weight in
terms of muscle, fat, and water. The device predicts body weight, fat percentages, fat
mass, fat free mass, skeletal muscle mass and body water by measuring the resistance
of a small, water- accompanied electrical signal that is sent through the body. InBody
270 scale considers individual's age, height, weight and gender to estimate body
composition [248].
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Participants were asked to stand unassisted on the weighing platform (with no shoes
or socks on), place their heels on the posterior electrodes, and the front part of the feet
in contact with the anterior electrodes. Participants were asked to hold the grips with
both hands and wait 15-120 seconds until the device competed the measurement.
DXA Hologic Discovery (Hologic Ltd., Toronto Ontario, Canada) is an advanced body
composition assessment device that is considered tehe golden standard in measuring
body composition. DXA produces color images of lean mass, bone and fat mass. This
information is provided in a report for enhanced patient management and counseling.
Moreover, DXA system proposes one of the latest innovations in bone densitometry
technology as it uses the one pass single sweep scanning [249]. DXA system was
calibrated every time before usage to insure maximum precision.
A certified radiology technologist conducted all DXA Hologic Discovery
measurements. Participants were asked to remove all objects from pockets (e.g.,
wallet, cell phones, keys). False teeth, hearing aids, jewelry, and watches did not have
to be removed. Before moving the table control arm (C-Arm), the runner area of the
table and the table scan area were cleared of objects that might interfere with table
movement.
Women that met the inclusion criteria were asked to take a pregnancy test and to selfreport that they were not pregnant. If they were pregnant they were automatically
excluded from the study for the safety of the embryo.
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3.5.5.3 BMI Calculation
Body mass index (BMI) is derived from the individual’s weight and height in attempt
to classify each individual weight to height distribution [250] and used as a tool to
screen populations for relative weight status [251].
BMI was calculated from weight and height using the following formula:
(weight (kg)/height (m2)) [252]. Table 3.2 list the classification of BMI.
Table 3.2: BMI Classification [264]
Category

BMI range – kg/m2

Very severely underweight

less than 15

Severely underweight

from 15.0 to 16.0

Underweight

from 16.0 to 18.5

Normal (healthy weight)

from 18.5 to 25

Overweight

from 25 to 30

Obese Class I (Moderately obese)

from 30 to 35

Obese Class II (Severely obese)

from 35 to 40

Obese Class III (Very severely obese)

over 40

3.5.5.4 Waist Circumference
WC is considered to be the best tool to predict abdominal visceral obesity [253] and a
high waist circumference denotes an increased risk for CVD [254]. A study published
in 2004 concluded that WC is a better tool than BMI to explain obesity-related health
risks [255]. Another research recommended the use of WC in health promotion
programs to recognize individuals who should pursue help in managing their weight
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[256]. Waist circumference cutoff points as reported by IDF, AHA/NHLBI are >80
cm for female and >94 cm for males Caucasian [257].
Measurement of WC was carried out using a stretch resistant tape that provides a
constant 100 g of tension and was recorded to the nearest centimeter. Participants were
asked to stand up right with the arms at the sides, feet positioned close together and
weight equally distributed on the feet. The tape was placed at the approximate
midpoint between the lower margin of the last palpable rib and the top superior border
of the iliac crest or at umbilicus level for participants with obesity. The WHO STEPS
protocol states that the tape should be snug around the body, but not pulled so tight
that it is constricting [243]. Three measurements were obtained and the average of the
two readings were recorded.
3.5.6 Diet and Physical Activity Assessment
3.5.6.1 Dietary Assessment
Participants were asked to maintain their dietary habits during the 12 weeks of the
study. A three-day food record was collected from each participant on each visit
(baseline, midpoint and endpoint), providing nine days of food records for each
participant. At the beginning of the study, the researcher sat with each participant and
demonstrated on how to fill the food record using food models, visual aids and
measurements tools.
Details of the food and drinks consumed were very important. Participants were taught
how to record their three day food record, accurately and in detail (example: brand
name, fat percentage, fortification, etc.). Food records were analyzed carefully using
Food Processor Nutrition Analysis software (ESHA). When traditional Emirati and
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local food were consumed, Emirati and Kuwaiti food composition table were used
[258].
3.5.6.2 Physical Activity Assessment
Participants were asked sustain their physical activity habits through the study. A
physical activity questionnaire was collected from each participant on each visit. The
International Physical Activity Questionnaire (IPAQ) was used to monitor physical
activity habits during the study period. IPAQ was developed to be an international
measure for physical activity. It started in Geneva in 1998, the IPAQ was followed by
a wide reliability and validity testing that took place in 12 countries (14 sites) during
year of 2000 [259]. The instrument evaluates total physical activity where the
recommendations are based on activity (leisure-time or recreational) over and above
typical individual activities. This suggests that IPAQ is the best tool available at
present to measure physical activity level. Total duration and the number of
day/sessions are to be recorded in the IPAQ. Guidelines for data processing and
analysis of the International Physical Activity Questionnaire (IPAQ) were used to
analyze the IPAQ [260]. Three levels of physical activity are proposed for categorizing
population activity as described in Table 3.3.

Table 3.3: Physical Activity Category Classification
Physical activity
category

Inactive (category 1)

Health enhancing physical activity
(HEPA) (category 3)

a) 3 or more days of vigorous

a) vigorous-intensity activity on at

activity of at least 20 minutes

least 3 days achieving a minimum of

per day, OR

at least 1500MET -minutes/week OR

b) Some activity is reported

b) 5 or more days of moderate-

b) 7 or more days of any combination

but not enough to meet

intensity activity or walking of

of walking, moderate-intensity or

category 2 or 3

at least 30 minutes per day, OR

vigorous

a) No activity is reported, OR

Category characteristics

Minimally active (category 2)

c) 5 or more days of any
combination of walking,

intensity activities to achieve a

moderate-intensity or vigorous

minimum of at least 3000 MET-

intensity activities achieving a

minutes/week

minimum of at least
Category characteristics

600 multiples of the resting
metabolic rate (MET) min/week.
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3.5.7 Biochemical Parameters
Nutritional status evaluation is crucial for all dietary and nutritional interventions.
Evaluation of nutritional status constitutes a combination of data which includes
clinical evaluation, dietary history, anthropometric evaluation and biochemical
evaluation [261]. Biochemical measures have the potential of providing the most
neutral and quantitative assessment of the nutritional status [262]. In order to collect
such quality of information about nutritional status, biological fluids (urine or blood)
must be collected [263].
All instruments used in the current research project were calibrated (if needed) and
daily checked for correction before use. Therefore, a higher level of sensitivity,
accuracy and a better reproducibility in analyzing the biochemical parameters was
granted
3.5.7.1 Blood Collection
In this research, two methods of blood collection were followed, and blood collection
was undertaken after 10 - 12 hours of fasting. The first is the finger-prick (capillary
blood) method with fresh capillary blood used immediately after collection to measure
TG and HDL using Reflotron® Plus Dry - chemistry analyzer (Roche® Diagnistics
GmbH, Mannheim, Germany) during the screening measurements. Fresh Ethylene
diamine tetraacetic acid (EDTA) plasma was used immediately after capillary blood
collection and centrifusion was completed to measure the high density lipoprotein
(HDL). Furthermore, capillary blood was used to measure hemoglobin (Hb) and
glycated hemoglobin (HbA1c) during the study period.
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Finger pricks were collected by a registered phlebolomist according to the WHO
guidelines on drawing blood [264]. The hand of the participant was positioned with
the palm-side up and the fingertip of the ring, middle, index finger or thumb was
chosen for the prick: whichever had the least hardened skin. The fingertip was cleaned
with alcohol before pricking and pressure was applied to the finger to assist blood
flow. The registered nurse collecting the blood sample, started in the middle and
worked the finger to the fingertip not to re-contaminate the area. The finger was air
dried. A new sterile lancet (Life scan- Johnson and Johnson®, One touch, Ultra soft,
UK) was used for each person. Each new lancet shown to the participants for
reassurance. The lancet was placed off-center on the fingertip and pressed firmly to
puncture the skin. Each lancet was disposed of in a biohazard sharps container. The
first drop of blood was wiped with a disinfected cotton ball. To assist the blood flow,
sometimes the finger was held lower than the elbow, following this, the blood drop
was collected for analysis.
The second form of blood collection was the vinous blood collection (5 mL). A
registered phlebotomist collected the blood samples in a selected clean area using a
sterile butterfly needle and winged bonded to a flexible tubing with a luer connector
(Vacuette®, 2015, Bangnomko, Thailand) was used each time to withdraw blood. A
blood sample was collected from participants after a 10 - 12 hours of fasting in a
vacutainer yellow tube 5 mL (Vacutainer®, 2014, UK) with clot activator and gel for
serum separation. Two drops of the collected vinous blood (8 µ) was used to analyze
hemoglobin (Hb) and glycated hemoglobin (HbA1c). The used needles were disposed
in a biohazard sharps container. Sterilized nitrile powder free gloves were worn at all
times during venipuncture to minimize exposure hazard and to assure sterilized
environment.
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After blood collection, tubes were placed in a centrifuge (Heraeus®, Biofuge Primo
R, Kendro, Germany) with 1500 round per minute for 15 minutes, the serum was
collected from the blood tubes and placed in triplicates in a 1 mL Eppendorf tube
(eppendorf®, Safe- Lock micro test, 2015, Hamburg, Germany). Eppendorf tubes
were identified using participant identification numbers and then placed in a -80
freezing system. To analyze the samples, they were thawed in ice at room temperature
(25 °C) for 30 minutes before processing.
3.5.7.2 Analytical System
Reflotron® Plus Dry - chemistry analyzer (Roche® Diagnistics GmbH, Mannheim,
Germany) was used to analyze TG and HDL during participant screening, while
HemoCue® Glucose 201+ System (Hemocue, Dongan-gu, Korea) was utilized to
assess FBG.
The Refletron® Plus Dry is an in vitro diagnostic device designed to quantitatively
determine clinical chemical parameters. Reflotron® test reagent strips are used to
assess the chemical measurements. Reflotron® Plus Dry uses whole blood (vinous or
capillary), plasma and serum. As for this study, capillary blood was collected. A 32 µl
capillary tube was inserted to an applicator device and was used to collect blood
sample, then was placed directly over the pad of the desired test strip and the plunger
was pushed down gently to eject the blood sample on the strip. Refletron®’s test strip
was then immediately inserted into the measuring chamber and a measurement appears
on the device monitor screen after three minutes.
Since Refletron® HDL analysis requires EDTA plasma, capillary blood was collected
(0.8 mL) in a 1 mL Eppendorf tube (eppendorf®, Safe- Lock micro test, 2015,
Hamburg, Germany) and centrifuged in a Spectrum® Mini Centrifuge (Spectrum
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Chemical MFG CORP, NY, USA) 6000 round per minute. Whole EDTA plasma was
applied to the reagent strip, LDL fractions were precipitated by means of magnesium
ions and dextram sulphate to conduct the test. Daily maintenance of Refletron® was
done using Clean and Check strips and no calibration was required.
The HemoCue Glucose 201+ System is based on glucose dehydrogenase method. A
small analyzer and a disposable microcuvette are the two constitutes of the system.
HemoCue Glucose 201+ microcuvettes (Hemocue, Dongan-gu, Korea) serves as a
pipette and as a measuring microcuvette capillary blood (5 µL) was collected in the
cavity of HemoCue Glucose 201+ microcuvette for analysis. HemoCue Glucose 201+
is factory calibrated and requires no extra calibration and no coding. Reading of the
measurement appeared on the device monitor screen after 40 seconds to 4 minutes.
Hemoglobin (Hb) was analyzed using the HemoCue® Hb 201+ System (HemoCue®
Ltd, UK,). In order to perform a test, whole blood (4 µL) was loaded into the HemoCue
Hb 201+ microcuvette’s cavity, in one continuous process. All excess blood outside
was wiped with a clean lint-free wipe and no air bubbles were present in the
microcuvette. The filled mirococuvette was placed in the cuvette holder during the first
ten minutes after loading the microcuvette. Measurement reading appeared on the
monitor screen of the device after 15-60 seconds.
Glycated hemoglobin (HbA1c) was analyzed using the HemoCue® HbA1c 501
System (HemoCue® Ltd, UK, Figure 3.6). HemoCue® HbA1c 501 System consists
of the HemoCue device and cartridge HemoCue® HbA1c 501 (HemoCue®,
Ängelholm, Sweden). Daily check cartridge (HemoCue® HbA1c 501 Daily Check
Cartilage). Monthly check cartridge (HemoCue® HbA1c 501 Monthly Check
Cartilage) were used on regular basis for quality control purposes. After blood
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collection, 4 µL of blood sample were loaded into the HemoCue® cartridge reagent
compartment and it was placed into the cartridge in the device (any excess blood was
not wiped as the manufacturer manual instructed).

Figure 3.6: HemoCue® HbA1c 501 System (HemoCue® Ltd, UK)

After screening of the participants and during the study period visits, fasting blood
glucose (FBG), triglycerides (TG), high density lipoprotein (HDL), low density
lipoprotein (LDL) and total cholesterol were measured using the Cobas C111
analyzer® (Roche Diagnostics Ltd, Mannheim, Germany, Figure 3.7). Cobas C111
requires the use of blood serum, where serum samples can be loaded and unloaded
uninterruptedly into eight positions on the device. Serum samples for each participant
from the three phases (baseline, midpoint and endpoint) were measured together, in
the same run, to minimize the chance of error. Reagents, controls and calibrations of
the Cobas C111 were used according to manufacturer guidance manual and training
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protocol. The research attended a training offered by the manufacturer company and
carried out all the blood samples analyses.
After switching on the device, it performs an automatic check to precisely meet all the
preconditions of calibration and system automated running process as displayed on its
monitor. As a second step, reagents of the designated parameters (FBG, TG, HDL,
LDL and total cholesterol) were loaded into the reagent disk and calibrated according
to the manufacturer’s recommendation. Different calibrators were needed for each
parameter. f.a.s Lipids® was used to calibrate HDL and LDL, while f.a.s® was used
to calibrate FBG and TG. Furthermore, Cobas C111 asks for a quality control test
using PreciControl ClinChem Multi 1® and PreciControl ClinChem Multi 2®.
Moreover, a daily maintenance that checks cuvettes, loading reagent desk and external
fluid containers was performed. After calibration, maintenance and checkup of the
device, labeled serum samples were loaded uninterruptedly into eight chambers for
test performance. All labeled serum samples were thawed at room temperature before
the analysis.
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Figure 3.7: Cobas c111 Analyzer® (Roche Diagnostics Ltd, Mannheim, Germany)

3.5.7.3 Lipid assessment
Since metabolic syndrome diagnostic criteria included two important lipids measures
(HDL and TG), it was crucial in this study to test the influence of treatment on lipid
profile. Total cholesterol, LDL, HDL and TG were measured in this study at each visit
(baseline, midpoint and endpoint). Dyslipidemia, a multifactorial disorder of
lipoprotein metabolism is defined as high levels of total cholesterol, low-density
lipoprotein (LDL), and non-high-density lipoprotein cholesterol, decreased levels of
high-density lipoprotein (HDL) and increased triglyceride levels which are correlated
with higher risk of cardiovascular disease [265].
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The National Cholesterol Education Project (NCEP) Adult Treatment Panel III (ATP
III) defined the following levels: [266]:


LDL levels “Ideal” when less than 100 mg/dL and “high” as 160 mg/dL or
more



Total cholesterol (TC) levels “ideal” as less than 200 mg/dL and “high” when
240 mg/dL or more



HDL levels “low” when less than 40 mg/dL



Elevated triglycerides (TG) when greater than 150 mg/dL

Elevation in lipid profile is considerably related to increased risk of coronary heart
diseases, type 2 diabetes, high blood pressure and renal diseases [267-271].
3.5.7.4 Total Cholesterol
Previous research demonstrated the direct relationship between elevated total serum
cholesterol and cardiovascular diseases [272, 273]. In this study, total cholesterol was
measured using Cobas® C111. 2 µ of serum was used to measure total cholesterol
using a measuring range of 9.7-800 mg/dL. 47 µL of the testing reagent was used at
each run. The acceptable value for normal range is <190 mg/dL [274].
3.5.7.5 Low Density Lipoprotein
Elevated levels of LDL cholesterol is one of the characteristics of dyslipidemia [275].
Compared to HDL, LDL particles are smaller, more dense, and have a high atherogenic
effect. Lowering increased LDL cholesterol levels has confirmed a significant
decrease in cardiovascular occasions in patients with cardiovascular diseases and
diabetes [276]. According to NCEP/ATP III, the cut-off point valus is >160 mg/dL
and the normal value is anywhere less than 120 mg/dL [31, 266]. Cobas® C111
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required 2 µL of blood serum for the test to be measured at 3.86-548 mg/dL measuring
range. For each test run, 200 µL of the reagent was used.
3.5.7.6 High Density Lipoprotein
High density lipoprotein is considered to be a predictor of and a protective factor in
detecting coronary heart diseases [277, 278]. HDL cut-off point level is <40 mg/dL for
men and <50 mg/dL for women [7].. Using the Cobas® C111, 2.5 µL of the serum
was required to measure HDL at a range of 3-120 mg/dL [274]. 200 µL of reagent was
used for each test run. The acceptable value for normal range is >40 mg/dL and
≤60 mg/dL for both men and women [31].
3.5.7.7 Triglycerides
Elevated levels of triglycerides are associated with higher risk of heart diseases, and
diabetes [47, 279, 280]. According to American Heart Association (AHA), serum
triglycerides is a reliable assessment of coronary heart diseases [281]. The cut-of value
of triglycerides is ≥150 mg/dL to be considered as the inclusion criteria of metabolic
syndrome, while the normal range value was <115 mg/dL [7]. Triglycerides were
measured in this study using Refletron® during screening tests and Cobas® C111
during the study period. 32 µL of capillary blood was collected and used for the
Refletron® for the TG test as instructed by the manufacturer. For Cobas® C111 2 µL
of serum was used at a measuring range of 8.85-885 mg/dL. 120 µL of triglyceride
reagent was needed for each test run.
3.5.7.8 Blood Glucose Assessment
Hyperglycemia is considered to be a very important diagnostic criteria of the metabolic
syndrome. As one of the study objectives was to assess the influence of spice powder
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on metabolic syndrome, FBG and HbA1c were measured. FBG was assessed during
the screening visits and was considered as an inclusion criterion for the participants.
FBG was measured using HemoCue® Glucose 201+ System (Hemocue, Dongan-gu,
Korea) during the screening visits. Moreover, during baseline, midpoint and endpoint.
FBG and HbA1c were measured using Cobas c111 analyzer® (Roche Diagnostics Ltd,
Mannheim, Germany, Figure 3.7), while HemoCue® HbA1c 501 System was used to
analyze HbA1c.
3.5.7.8.1 Fasting Blood Glucose
Fasting blood glucose (FBG) is the measurement of blood glucose level after fasting
for eight hours [282]. Impaired fasting blood glucose was correlated with type 2
diabetes and cardiovascular diseases [283]. Cut-off value of FBG is equal to or greater
than 100 mg/dL, while the target level of FBG in the blood is 70-100 mg/dL [32].
Cobas® C111 was used to measure FBG at range of 1.98-720 mg/dL. 2 µL of serum
was used with 180 µL of reagent for each test run. Analysis process was done
according to the manufacturer instruction.
3.5.7.8.2 Glycated Hemoglobin
Glycated hemoglobin (HbA1c) differs from FBG in definition, HbA1c is a form of
hemoglobin that measures the cumulative status of plasma glucose for the last three
months (due to the hemoglobin life span (120 days)) [284]. HbA1c is a screening tool
for detecting type 2 diabetes as it provides a better insight to the history of blood
glucose level [285]. High levels of HbA1c >5.7% are connected to type 2 diabetes,
cardiovascular diseases and diabetes complications such as retinopathy [286]. 4-5.6%
is the normal level of HbA1c [287]. 4 µL of whole blood was used to analyze HbA1c
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using HemoCue® HbA1c 501 System (HemoCue® Ltd, UK, Figure 3.4) as
manufacturer manual instructed.
3.5.7.9 Hemoglobin Assessment
Hemoglobin (Hb) is the protein portion of the red blood cell that carries oxygen in the
blood [288]. Hb protein makes up to 35% of the red blood cells [289]. Low levels of
hemoglobin (Hb) in blood (anemia) is an independent risk factor of cardiovascular
consequence in individuals with heart failure and coronary artery disease. Moreover,
in patients with myocardial infraction, reduced levels of Hb is are associated with
higher short-term mortality rate [290]. Hb normal levels in blood varies according to
age, race, pregnancy and gender [291]. According to the Wolrd Health Organization
(WHO), cut-off value of Hb for an adult women and men is <8 g/dL, while normal
values for adult women is 12 g/dL or higher and for adult men 13 g/dL or higher [292].
Hb was measured in this study using HemoCue® Hb 201+ System (HemoCue® Ltd,
UK). 4 µL of whole blood was used to conduct the analysis. Blood was loaded to the
microcuvette cavity and processed for analysis.
3.5.8 Blood Pressure Measurement
High blood pressure (BP) is a leading cause of cardiovascular diseases [293].
Moreover, morbidity rate is higher in people with high blood pressure after a stroke
[294]. 1.13 billion people worldwide are affected by high blood pressure [295].
Normal level of BP is <120/<80 mmHg according to the American Heart Association
(AHA), while cut-off point is >140/85 mmHg (Table 3.4) [7].
BP was measured using Omron professional blood pressure monitor (HEM 907,
Tokyo, Japan). Omron HEM 907 is a validated device for measuring blood pressure
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as it fulfilled the accuracy criteria of the Association for the Advancement of Medical
Instrumentation (AAMI) for non-invasive blood pressure monitoring devices
[296, 297]. Moreover, using an automated blood pressure measuring device such as
Omron HEM 907 have been associated with eliminating the office effect [298].
Participants were given 15 minutes of rest to adjust to the climate changes. At the
beginning of the measurement, the cuff suitable to the size of the participant's arm was
chosen. The participant was asked to remove any heavy clothing surrounding the upper
part of his/her arm. The right hand of the participant was placed with the palm of hand
facing upward and the cuff was wrapped snuggly, using both hands and secured with
Velcro tape. At this time, the lower edge of the cuff was placed 1.2 cm to 2.5 cm above
the inner side of elbow joint. The level of the cuff was kept at the level of the heart
during the measurement of the blood pressure. The measurement was taken twice with
5 minutes break between measures, and the average measurement was recorded.
Table 3.4: Classification of Blood Pressure [32]

Category

SBP mm Hg

DBP mm Hg

Normal

<120

and

<80

Prehypertension

120-139

or

80-89

Hypertension, Stage 1

140-159

or

90-99

Hypertension, Stage 2

≥160

or

≥100

SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure
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3.5.9 Power Analysis
Using the power of 80% and referring to previous articles that studied the effect of
similar spices [197, 299, 300], and considering Alpha=0.05, the sample size required
for the experiment was calculated using the Minitab software. Minitab® 15 software
(Minitab Inc., Pennsylvania, USA) assumes an equal standard deviation (SD) for all
groups of intervention and the control. For that reason, another way to calculate the
sample for greater precision was used using the link below:
http://homepage.stat.uiowa.edu/~rlenth/Power/#Download_to_run_locally
Due to the significant difference in the SD between the intervention and the control
group (specifically in the article [300]) for fasting blood glucose and the HbA1c), and
by using the power of 80% and Alpha=0.05, the highest sample size calculated of the
parameters (FBG and HbA1c, TG, Cholesterol, HDL and LDL) was considered.
By choosing the highest sample size, the sample size required for the experiment was
set at 17. In addition, to account for a 75% attrition, the sample size number required
was 30 participants for each group; with a total of 120 participants.
3.5.10 Statistical Analysis
RAND function from the Microsoft excel was used to randomize participants into four
treatment groups: ginger, cinnamon, black seed and control group.
Data analysis was carried out using the IBM Statistical Package for Social Sciences
SPSS® software (version 23.0) (IBM Corp, Armonk, NY, USA) for windows.
Descriptive statistics were computed and summarized; continuous variables were
summarized using means and standard deviations (SD). Differences of the
measurements were calculated separately using the Microsoft excel 2016 (Windows
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8.1, Jones, Chicago, USA), then transferred to the SPSS software for applying the
normality test on data distribution. After testing the normality of the data distribution,
the significancy of difference was calculated either with comparing means through the
independent t-test when data is normally distributed or using the test of Mann-Whitney
U in case of the abnormality of the data distribution. Data was trimmed in some tests
due to extreme abnormalities in the distribution of the data (minimums or maximums),
which explains the different number of participants in some tests.
Mixed models test of linear equation was applied to find interactions of gender with
intervention group, gender with age and gender with the phase of the research period
for the dependent variables: WC, FBG, HDL, TG and BP. All statistical significances
were assessed at the 5% significance level.
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Chapter 4: Results and Discussion
4.1 Results and Discussion of Spices Chemical Analysis
4.1.1 Proximate Analysis
Seven locally consumed spices were analyzed chemically according to the Association
Official Analytical Chemist procedure (AOAC). The proximate analysis data were
expressed as mean and standard derivations (Table 4.1).
Moisture content ranged from 6.40 g/100 g for black seed to 8.92 g/100 g for saffron.
Protein content was lowest in cinnamon at 3.50 g/100 g and highest in fenugreek at
24.99 g/100 g. Fat content was remarkably highest in black seed powder reaching
36.21 g/100 g, while it was lowest in cinnamon powder 0.05 g/100 g. Ash content
varied from 0.02 g/100 g for fenugreek and saffron powder, to 5.68 g/100 g for clove
powder. Low moisture content of black seed increases its shelf life when compared to
other spices [301].
Fiber analysis showed that cinnamon powder had the highest fiber level at 45.40 g/100
g, whereas ginger powder had the lowest level at 3.01 g/100 g. On the other hand,
carbohydrate content ranged from 13.55 g/100 g for black seed powder to 69.61 g/100
g for ginger powder.
Moisture content results of ginger (8.11 g/100 g) was lower than that reported by
Ereifej et al. (10.9 g/100 g) and Prakash el al (15 g/100 g) and higher than what was
reported by Adeyeye et al. (1.62 g/100 g) [17, 302, 303]. Fat (3.13 g/100 g) and ash
(5.63 g/100 g) content were consistent with the previous studies, while fiber content
(3.01 g/100 g) was remarkably lower than what Ereifej et al. and Prakash et al.
reported. On the other hand, protein and carbohydrate content reported by Ereifej et
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al. (9.4 g/100 g and 21.1 g/100 g, respectively), Prakash el al. (5 g/100 g and 38.3
g/100 g, respectively) and Adeyeye et al. (5 g/100 g and 62.88 g/100 g, respectively)
were lower than the current study findings (0.51 g/100 g and 69.61 g/100 g,
respectively) [17, 302, 303]. Protein content of cinnamon (3.5 g/100 g) was similar to
that reported by Gul et al. (3.5 g/100 g) and Ereifej et al. (4.2 g/100 g) [153, 302],
while fiber, moisture and ash content (45 g/100 g, 8.24 g/100 g and 4.6 g/100 g,
respectively) were higher than the results of Gul et al. (33 g/100 g, 5.1 g/100 g and 2.4
g/100 g, respectively), and lower than the results reported by Ereifej et al. (52 g/100 g
for fiber and 16.2 g/100 g for moisture). While ash content of the current study (4.6
g/100 g) was similar to the ash content that Ereifej et al. reported (4.5 g/100 g). In
contrast, energy result reported by Gul et al. (258 Kcal) was significantly higher than
the energy results of the current study (169.78 Kcal) due to a higher fat content [153,
302]. Moisture, protein, fat and ash content (6.4 g/100 g, 18.97 g/100 g, 36.21 g/100
g, 4.2 g/100 g, respectively) of the black seed in the current study are in consistent
with the findings of Al-Jassir et al. (4.64 g/100 g, 20.85 g/100 g, 38.20 g/100 g and
4.37 g/100 g, respectively), Nergiz et al. (6.4 g/100 g, 20.2 g/100 g, 32 g/100 g and 4
g/100 g, respectively) and Cheikh-Rouhou et al. (8.65 g/100 g, 22.6 g/100 g, 40.35
g/100 g and 4.41 g/100 g, respectively) [304-306]. Fiber content of the current study
for black seed (20.67 g/100 g) was higher than those reported previously, while
carbohydrate content (13.55 g/100 g) was lower than the literature [304-306].
Naidu et al. reported a higher moisture content (11.44 g/100 g) of fenugreek than the
findings of the current study (7.33 g/100 g) [33], while Al Jasass et al. and El Nasri et
el. reported similar moisture content to the current study findings (7.71 g/100 g and
6.87 g/100 g, respectively) [162, 307]. Protein content (24.9 g/100 g) was consistent
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with the study results of El Nasri et al. (28.4 g/100 g) and Naidu et al. (27.57 g/100 g)
and higher than Al Jasass et al. (12.91 g/100 g). Fat, ash and carbohydrate content
(4.36 g/100 g, 0.02 g/100 g and 33.43 g/100 g, respectively) were lower than what the
previous studies, while it was higher for the fiber content [162, 163, 307]. Moreover,
Cardamom moisture and ash content (7.52 g/100 g and 0.04 g/100 g, respectively)
results were lower than what was reported by Ereifej et al. (14.7 g/100 g), Pruthi et al.
(8.49 g/100 g) and Singh et al. (83 g/100 g). While protein content result of this study
(10.67 g/100 g) was consistent with the results of Ereifej et al. (9.9 g/100 g) and Singh
et al. (10.3 g/100 g), and higher than what Pruthi et al. reported (6 g/100 g) [175, 302,
308]. Ereifej et al. reported a higher content of ash and fiber (10.2 g/100 g and 40.9
g/100 g, respectively), while Pruthi et al. and Singh et al. reported lower fiber content
(22 g/100 g and 9.2 g/100 g respectively), and a higher ash content (4 g/100 g and 5
g/100 g respectively). Carbohydrate content (47.23 g/100 g) was higher than what was
reported in literature [162, 163, 302].
Al Jasass et al. Adeyeye et al. and Tainter et al. reported a similar protein content for
cloves (6.9 g/100 g, 5.7 g/100 g and 5.98 g/100 g, respectively) to the current study
findings (6.96 g/100 g) [179, 303, 307]. Moisture content of cloves in previous studies
varied from 7.44 g/100 g for Al-Jasass et al. to 16.4 g/100 g for Ereifej et al.. Our result
was on the lower limit (7.87 g/100 g) and was consistent with Al Jasass et al. findings
[302, 303, 307]. Carbohydrate content of cloves (44.5 g/100 g) was lower than what
previously reported by A-Jasass et al., Tainter et al., Adeyeye et al. and Parthasarathy
et al. (51.3 g/100 g, 61.12 g/100 g, 65.12 g/100 g and 68.6 g/100 g, respectively). In
contrast, Ereifej et al. reported lower carbohydrate findings than the current study (31.3
g/100 g) [179, 180, 303, 307]
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Saffron’s moisture, fat and ash content (8.92 g/100 g, 4.4 g/100 g and 0.02 g/100 g,
respectively) were lower than what Mohamadi et al. Srivastava et al. and Fahim et al.
reported [21, 309, 310]. Protein content (11.33 g/100 g) was in the same range when
compared to the study of Srivatava et al. and Fahim et al. (10.2 g/100 g and 12 g/100
g, respectively) [21, 309, 310]. Fiber and carbohydrate content (12.23 g/100 g, 63.1
g/100 g, respectively) were higher than what Mohamadi et al. (7.4 g/100 g, and 20
g/100 g, respectively), Srivatava et al. (5 g/100 g for fiber) and Fahim et al. (8.8 g/100
g for fiber) reported (Table 4.1) [21, 309, 310].
The differences in nutrient composition of spices reported by scientists is theorized
due to the different soil and geographical locations of the source of planting and
growing plants, and due to the difference in environmental conditions, which has an
effect on the nutrient composition [17, 162, 163, 306, 307, 311]. Moreover, different
grinding and storing techniques were proved to have a major effect on the spices
nutrient composition [312, 313].
As an example, a previous study investigated the nutrient content of five different sizes
of ginger powder particles that were produced using a micronizer machine. They found
that protein content increased significantly when the size of ginger powder particles
decreased [312]. In an attempt to explain the differences in the nutrient composition in
spices between previous studies and the current research findings, it is hypothesized
that the superfine grinding of dried spices produces narrow and uniform particle size
and that will increase the surface area and therefore increase the amount available for
analysis [312]. Hence, previous studies that used different ways of grinding the spices
(micronizer machines [312], all glass mortars [303] and grinders [17]) had a different
nutrient composition findings. In the current study, dried whole spices were grinded
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using a coffee grinding machine, with big particles of spices powder that were
produced and analyzed. Grinders can have different intensity levels, different blades
and different durations. Therefore, different particle sizes could be produced using
different grinders, hence, different nutrient composition findings as well [314, 315].

Table 4.1: Proximate Analysis of the Seven Spices (mean ± SD)
Ginger

Cinnamon

Black seed

Fenugreek

Cardamom

Clove

Saffron

Pvalue*

Moisture (g/100 g)

8.11 ± 0.26

8.24 ± 0.20

6.40 ± 0.13

7.33 ± 0.16

7.52 ± 0.09

7.86 ± 0.04

8.92 ± 0.19

<0.001

Protein (g/100 g)

10.51 ± 0.26

3.50 ± 0.02

18.97 ± 0.13

24.99 ± 0.04

10.67 ± 0.08

6.96 ± 0.04

11.33 ± 0.05

<0.001

Fat (g/100 g)

3.13 ± 0.20

0.55 ± 0.05

36.21 ± 0.11

4.36 ± 0.09

4.40 ± 0.27

5.04 ± 0.12

4.40 ± 0.07

<0.001

Ash (g/100 g)

5.63 ± 0.04

4.60 ± 0.17

4.20 ± 0.05

0.02 ± 0.00

0.04 ± 0.00

5.68 ± 0.23

0.02 ± 0.00

<0.001

Fiber (g/100 g)

3.01 ± 0.05

45.40 ± 0.89

20.67 ± 0.59

29.87 ± 0.78

30.13 ± 1.50

29.97 ± 1.99

12.23 ± 1.31

<0.001

Carbohydrate (g/100 g)

69.61 ± 0.21

37.69 ± 0.49

13.55 ± 0.54

33.43 ± 0.61

47.23 ± 1.12

44.50 ± 1.81

63.10 ± 1.46

<0.001

Energy (Kcal)

348.65 ± 2.00

169.78 ± 2.36

455.98 ± 2.80

272.95 ± 2.99

271.20± 7.11

251.19 ± 7.23

337.32 ± 6.20

<0.001

Data is expressed as g/100 g of spice powder,
*Significant at P-value ≤ 0.05
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4.1.2 Minerals Composition Analysis
4.1.2.1 Major Elements
Results of the chemical analysis of the spices showed that these spices contain major
elements in significant amount. For example, cinnamon had the highest calcium
content (1414.82 mg/100 g), while ginger had the lowest calcium content (125.21
mg/100 g) as shown in Table 4.2. Moreover, potassium content ranged from 460.78
mg/100 g for cinnamon to 1125.91 mg/100 g for saffron. Magnesium content ranged
from 42.42 mg/100 g for cinnamon to 375.71 mg/100 g for cloves. On the other hand,
sodium content was the lowest in cinnamon, clove and saffron 1.74, 2.26 and 8.82
mg/100 g respectively. Phosphorous ranged from 45.81 mg/100 g for cinnamon to
675.52 mg/100 g for ginger. Sulfur content did not exceed 310.58 mg/100 g (black
seed) in any of the analyzed spices.
4.1.2.2 Trace Elements
Cobalt, copper, iron, manganese and zinc are trace minerals that play major role in
metabolism. The seven commonly used spices were assessed for their trace mineral
content in the current research study. Trace minerals were found in smaller amount
when compared to major minerals as shown in Table 4.3. None of the trace minerals
exceeded 640 mg/100 g. Moreover, Cobalt level was the highest in ginger (4.52
mg/100 g) while copper was the highest in black seed (16.52 mg/100 g). Iron levels
ranged from 624.77 mg/100 g for saffron to 90.24 mg/100 g for cinnamon powder.
Manganese content was the highest in clove powder (360.85 mg/100 g) and the lowest
in fenugreek (23.90 mg/100 g), while zinc content did not exceed 56.24 mg/100 g
(black seed powder) in any of the spice powders.
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The results of this study were not in agreement with Abd- Alrahman et al., Okwu et
al. and Ogbuewu et al., who reported different mineral content of ginger powder [301,
316, 317]. Another study conducted by Prakaash et al. in 2010 concluded that ginger
powder contained 9.41 mg/100 g of iron, 104.02 mg/100 g of calcium and 204.02
mg/100 g of phosphorous [17]. Findings from Prakash et al. study are in agreement
with the finding of the current study considering the calcium content only (125.21
mg/100 g) [17].
An earlier study published by Gopalan et al. showed that spices have the following
amounts of calcium, phosphorous and iron (mg/100 g) respectively: Cardamom (229,
130 and 160), dried clove (740, 100 and 11.7), fenugreek (160, 370 and 6.5) and fresh
ginger (20, 60 and 3.5) [318]. Moreover, Al-Numair et al. analyzed Chinese cinnamon
and found that calcium content was the highest among the other identified elements.
(Ca:1157.36 mg/dL, Mg: 74.89 mg/dL, and P: 66.31 mg /100 g, respectively). None
of the minerals results of this study was consistent with the findings of the research
undertaken by Al-Numair et al. [311]. In 2014, Khan et al. concluded that the
manganese content for cinnamon, cardamom and clove was 879.8 μg/g, 758.1 μg/g
and 649.9 μg/g, respectively [319]. Findings of the current study were not in agreement
with the findings of Khan et al. as well. It is of note that cinnamon in most of these
studies, had a high level of calcium content when compared to the other minerals.
Additionally, Maghrabi and his colleagues analyzed the commonly used spices in
Saudi Arabia, including fenugreek and black seed. The study stated that fenugreek
contains 3.36, 0.70, 16.15, 34.45 and 8.23 µg/g and black seed contains 0.525, 0.525,
20, 85, 41.14 and 13.80 µg/g of selenium, chromium, manganese, zinc and copper
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respectively [320]. Manganese, zinc and copper content of the current study is not in
agreement with Maghrabi et al. On the other hand, Al-Jassir et al. indicated that
potassium, phosphorus, sodium and iron were the major elements presented in black
seed powder. While, zinc, calcium, magnesium, manganese and copper were found at
minor amounts. However, lead, cadmium and arsenic were not detected in the seeds
as Al-Jassir et al. reported [304]. Al-Jassir et al. study results are not consistent with
the current study.
Moreover, mineral analysis results of black seed reported by Cheikh and his colleages
matches with the finding of the current study in term of calcium and sodium content
(5.75 mg/100 g and 20.4 mg/100 g, respectively), while the other mineral content
values varies widely [306]. Furthermore, Negriz et al. reported a lower level of all
minerals in black seed when compared to the current study, except for sodium and
potassium (85.3 mg/100 g and 1180 mg/100 g, respectively) as they were at high
content when compared to the findings of the current study (23.62 mg/100 g and 633.3
mg/100 g, respectively) [305].
Al-Jasass et al. and Adeyeye et al. mineral composition analysis of clove were not in
agreement with the findings of this study [303, 307]. Adeyeye et al. reported
remarkably higher levels of phosphorous, calcium and sodium (546 mg/100 g, 400
mg/100 g and 60 mg/100 g, respectively), while Al-Jasass et al. reported lower mineral
content of clove powder in all minerals when compared to this study due to the usage
of different analytical techniques [307].
Based on the findings from Al-Jasass et al., fenugreek had lower levels of all minerals
content when compared to the current study [307], whereas higher levels of minerals
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is shown when compared with Naidu at el. findings. This is continue to be true except
for zinc and copper, as they were at lower levels than the current research study
findings [163].
Additionally, a study published by Mohamadi el al. reported that saffron is a good
source of minerals such as potassium, magnesium, sodium, calcium, zinc, iron, copper
and manganese. [21]. Results of Mohamadi et al. were not in agreement with the results
of the current study due to lower mineral content of saffron when compared to the
current study as demonstrated in Table 4.2 and Table 4.3. In conclusion, mineral levels
fluctuate with species, and the difference in mineral content may increase due to the
different colorimetric or qualitative analytical methods used, as well as this might be
owing to the differences in the spices origins [21, 180, 321].

Table 4.2: Major Elements Composition of the Spices (mean ± SD)
Spice

Ca (mg/100 g)

K (mg/100 g)

Mg (mg/100 g)

Na (mg/100 g)

P (mg/100 g)

S (mg/100 g)

Ginger

125.21 ± 0.12

1071.13 ± 40.05

271.35 ± 2.3.00

69.80 ± 0.15

675.52 ± 4.84

176.40 ± 1.36

Cinnamon

1414.82 ± 8.11

460.78 ± 26.68

42.42 ± 0.15

1.74 ± 0.01

45.81 ± 0.53

76.13 ± 0.16

Black seed

578.24 ± 10.03

633.3 ± 54.60

263.60 ± 2.81

23.62 ± 0.35

649.15 ± 8.61

310.58 ± 4.84

Fenugreek

203.74 ± 2.95

853.95 ± 89.86

139.68 ± 2.95

35.13 ± 0.74

399.26 ± 6.68

237.91 ± 3.80

Cardamom

619.71 ± 20.55

873.30 ± 24.91

266.60 ± 12.41

316.79 ± 14.74

84.83 ± 4.12

130.54 ± 6.61

Clove

354.58 ± 3.50

1485.28 ± 72.12

375.71 ± 3.33

2.26 ± 0.01

125.84 ± 0.81

91.72 ± 0.15

Saffron

175.85 ± 2.85

1125.91 ± 13.62

222.32 ± 3.38

8.82 ± 0.18

391.83 ± 5.97

237.39 ± 3.63

Data is expressed as mg/100 g
Ca: Calcium; K: Potassium; Mg: Magnesium; Na: Sodium; P: Phosphorous; S: Sulfur
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Table 4.3: Trace Elements Composition of the Spices (mean ± SD)
Spice

Co (mg/100 g)

Cu (mg/100 g)

Fe (mg/100 g)

Mn (mg/100 g)

Zn (mg/100 g)

Ginger

4.52 ± 0.09

0.28 ± 0.01

149.05 ± 1.15

230.65 ± 0.05

14.17 ± 0.15

Cinnamon

0.28 ± 0.10

2.70 ± 0.03

90.24 ± 0.36

171.52 ± 2.37

12.36 ± 0.10

Black seed

0.25 ± 0.01

16.52 ± 0.18

110.87 ± 1.11

30.64 ± 0.31

56.24 ± 0.78

Fenugreek

1.03 ± 0.06

9.28 ± 0.12

343.81 ± 2.60

23.90 ± 0.19

34.29 ± 1.00

Cardamom

0.52 ± 0.02

5.20 ± 0.07

421.37 ± 12.63

182.66 ± 5.46

12.98 ± 0.82

Clove

0.25 ± 0.06

7.06 ± 0.08

114.54 ± 0.89

360.85 ± 4.19

46.70 ± 0.62

Saffron

0.76 ± 0.02

9.85 ± 0.09

624.77 ± 7.43

32.05 ± 0.45

43.58 ± 1.33

Data is expressed as mg/100 g
Co: Cobalt; Cu: Copper; Fe: Iron; Mn: Manganese; Zn: Zinc
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4.1.3 Vitamin Composition Analysis
4.1.3.1 Water Soluble Vitamins
Nine water soluble vitamins and all fat soluble vitamins (Vitamin C), Vitamin B1
(Thiamin), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B5 (Pantothenic
acid), Vitamin B-6, Vitamin B7 (Biotin), Vitamin B9 (Folic acid), Vitamin B-12,
Vitamin A, Vitamin K1 (phytonadione), Vitamin K2 (menaquinone), Vitamin D2,
Vitamin D3 and Vitamin E (alphatocopherol)) were consecutively found in the seven
spices using the High-Performance Liquid Chromatography (HPLC) method.
Vitamin C and niacin were found to be the highest water soluble vitamins present in
all seven spices (Table 4.4). Vitamin B1 (thiamin) was detected in all spices, except in
black seed. Vitamin B1 (thiamin) was the highest in saffron (237.63 mg/100 g)
followed by cinnamon (60.21 mg/100 g). Vitamin B2 content ranged from 0.71
mg/100 g for cardamom to 93.27 mg/100 g for clove powder. Low levels of vitamin
B1 and B2 are due to the lack of animal product presented in the spices, sense all the
spices were plant based.
Vitamin B7 (biotin) was only detected in ginger powder (127.09 mg/100 g). However,
vitamin B12 and vitamin B5 (pantothenic acid) were not detected in any of the spice
powders. Vitamin B9 (folic acid) was found in all spices except for the cardamom
powder as demonstrated in Table 4.4.
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4.1.3.2 Fat Soluble Vitamins
Fat soluble vitamins were analyzed in the seven spices using the High-Performance
Liquid Chromatography (HPLC) method and date were presented as mean and
standard deviations in Table 4.5. Vitamin A was found in ginger, cinnamon, fenugreek
and clove (4.38, 0.15, 0.09 and 7.23 mg/100 g, respectively). However, vitamin A was
not detected in black seed, cardamom and saffron.
In contrast, vitamin K1 and K2 were present in all spices in low levels. Vitamin K1
ranged from 0.6 mg/100 g for ginger to 7.08 mg/100 g for black seed. Whereas, vitamin
K2 ranged from 1.54 mg/100 g for cardamom to 3.51 mg/100 g for black seed. Vitamin
D2 and D3 were not detected in any of the spices. Vitamin E was not found in ginger,
however, it was the highest in saffron, followed by clove and black seed (52.97, 24.34
and 21.43 mg/100 g, respectively) as shown in Table 4.5.
The findings of the current study were consistent with the values reported by the
United States Department of Agriculture’s (USDA) food composition data base for
ginger, fenugreek and cinnamon [322]. Additionally, the results reported in the current
research study are supported by Gul et al., Mohamadi et al., Hussain et al., Nwinuka
et al. and Parthasarathy et al. with a slight variation in vitamin C and E levels [21, 148,
150, 153, 179, 180].

Table 4.4: Water Soluble Vitamin Composition of the Seven Spices (mean ± SD)
Vitamin

Ginger

Cinnamon

Black seed

Fenugreek

Cardamom

Clove

Saffron

1715.84 ± 142.95

5268.06± 156.48

83.89 ± 25.83

9501.10 ± 466.90

4623.31 ± 33.98

2365.23 ± 38.71

3267.65 ± 120.39

Thiamin (mg/100 g)

6.96 ± 0.05

60.21 ± 4.18

ND

18.23 ± 0.41

6.04 ± 0.95

7.46 ± 0.59

237.63 ± 5.37

Riboflavin (mg/100 g)

4.62 ± 0.05

67.42 ± 4.20

6.06 ± 1.32

3.57 ± 0.15

0.71 ± 1.22

93.27 ± 1.74

33.56 ± 10.91

2100.73±77.16

435.32 ± 20.05

711.17± 152.93

2960.94 ± 88.56

254.04 ± 14.34

414.71 ± 19.31

4394.98 ± 39.63

ND

ND

ND

ND

ND

ND

ND

2.44 ± 0.16

21.35 ± 0.80

1.66 ± 0.26

0.08 ± 0.02

2.69 ± 0.26

12.33 ± 0.19

3.42 ± 0.17

127.09 ± 10.96

ND

ND

ND

ND

ND

ND

Vitamin C (mg/100 g)

Niacin (mg/100 g)
Pantothenic acid (mg/100 g)
Vitamin B6 (mg/100 g)
Biotin (mg/100 g)
Folic acid (mg/100 g)
Vitamin B12 (mg/100 g)

4.01 ± 0.60

0.65 ± 0.00

31.98 ± 0.96

133.98 ± 19.69

ND

62.00 ± 7.39

298.37 ± 14.05

ND

ND

ND

ND

ND

ND

ND

Data is expressed as mg/100 g of the spice powder
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Table 4.5: Fat Soluble Vitamin Composition of the Seven Spices (mean ± SD)
Sample
Name
Vitamin A
(mg/100 g)

Vitamin K1
(mg/100 g)

Vitamin K2
(mg/100 g)

Vitamin D2
(mg/100 g)

Vitamin D3
(mg/100 g)

Vitamin E
(mg/100 g)

Ginger

Cinnamon

Black seed

Fenugreek

Cardamom

Clove

Saffron

4.38 ± 0.10

0.15 ± 0.00

ND

0.09 ± 0.01

ND

7.23 ± 0.35

ND

0.60 ± 0.46

3.50 ± 0.05

7.08 ± 0.07

5.56 ± 0.14

3.44 ± 0.08

4.99 ± 0.13

1.72 ± 0.22

2.20 ± 0.07

1.85 ± 0.03

3.51 ± 0.03

1.80 ± 0.24

1.54 ± 0.00

1.87 ± 0.07

3.43 ± 0.10

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

3.21 ± 0.03

2.18 ± 0.05

21.43 ± 0.16

5.89 ± 0.03

24.34 ± 0.08

52.97 ± 0.03

Data is expressed as mg/100 g of the spice powders
ND: not detected
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4.1.4 Sugar Composition Analysis
Sugars provided by carbohydrates are found in many foods and are major component
of our diet with sucrose (table sugar) being the main type. Sucrose is added to drinks
and found in many processed foods, including cakes and soft drinks [323]. Glucose
and fructose are found naturally in many fruits, some vegetables and in small amounts
in some spices [324].
In the current study, ribose, fructose, glucose and sucrose were detected in all spices.
Ribose was found to be highest in saffron (1217.55 mg/100 g) and the lowest in
fenugreek (4 mg/100 g). Whereas cinnamon had the highest level of fructose followed
by ginger and cardamom (496.8 mg/100 g, 326.07 and 323.67 mg/100 g, respectively).
On the other hand, glucose level was the highest in saffron and cinnamon (1075.57
and 611.93 mg/100 g, respectively) and the lowest in fenugreek (52 mg/100 g).
Sucrose content varied from 7.33 mg/100 g for ginger to 443.8 mg/100 g for fenugreek.
While, xylose was detected only in ginger, black seed and clove (4.93, 0.53 and 7.33
mg/100 g, respectively). Additionally, maltose was found only in black seed,
fenugreek and in saffron (21.6, 310.2 and 205.74 mg/100 g, respectively) as
demonstrated in Table 4.6. Arabinose was detected only in saffron (87.21 mg/100 g)
and mannose was not detected in any of the spices. Total sugar content was the highest
in saffron (2536.37 mg/100 g) followed by cinnamon (1166.47 mg/100 g) and
cardamom (1122.2 mg/100 g). Saffron, cinnamon and cardamom are capable to deliver
a natural sweet taste, hence, the usage of these spices in many Emirati local sweet
dishes such as: khabisa, batheetha, habba hamra and balaleet [325].
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According to USDA food composition data base, cinnamon contained 2.2 g/100 g of
sugar and ginger root 1.7 g/100 g, and cloves, fenugreek, saffron and cardamom had
no significant amount of sugar [322]. These results are not consistent with the findings
of the current study. Additionally, Khazaei et al. reported lower level of total sugar
content of saffron when compared to the findings of the current study (Table 4.6)
[326]. In contrast, Deepa et al. reported similar content of total sugar of cardamom
(1064 mg/100 g), however, cinnamon content in Deepa et al. study was not in
agreement with the finding of the current study [327]. There is a general paucity of
literature that deals with sugar composition of spices, hence comparison between
similar spices were difficult. Therefore, more studies are needed to examine the
nutrient content of sugar in the spices.

Table 4.6: Sugar Composition Analysis of the Seven Spices (mean ± SD)

Ribose (mg/100 g)

Xylose
(mg/100 g)

Fructose
(mg/100 g)

Glucose
(mg/100 g)

Sucrose
(mg/100 g)

Maltose
(mg/100 g)

Arabinose
(mg/100 g)

Mannose
(mg/100 g)

Total Sugars
(mg/100 g)

9.53 ± 1.5

4.93 ± 0.83

326.07 ± 2.01

137.2 ± 1.2

7.33 ± 1.3

ND

ND

ND

485.07 ± 3.97

Cinnamon

35.53 ± 1.45

ND

496.8 ± 12.51

611.93 ± 17.39

22.2 ± 2.82

ND

ND

ND

1166.47 ±
30.65

Black Seed

1.8 ± 0.53

0.53 ± 0.5

190.47 ± 1.15

238 ± 1.59

195.2 ± 4.85

21.6 ± 1.03

ND

ND

647.6 ± 5.82

Fenugreek

4 ± 1.4

ND

136.93 ± 2.27

52 ± 1.78

443.8 ± 2.46

310.2 ± 17.19

ND

ND

946.93 ± 22.5

Cardamom

8.67 ± 1.72

ND

323.67 ± 1.53

383.6 ± 14.1

406.27 ± 12.72

ND

ND

ND

1122.2 ± 23.85

Clove

11.47 ± 1.4

7.33 ± 1.33

164 ± 0.8

250.2 ± 1.44

40.87 ± 2.27

ND

ND

ND

473.87 ± 4.08

1217.55 ± 4.58

ND

154.93 ± 1.17

1075.57 ± 1.67

156.04 ± 1.45

205.74 ± 1.34

87.21 ± 0.45

ND

2536.37 ± 2.58

Spice

Ginger

Saffron

Data is expressed in mg/100 g of the sample powder
ND: not detected
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4.1.5 Lipids and Caffeine Composition Analysis
Table 4.7 illustrates the lipid and caffeine composition data for the seven commonly
used spices. Total saturated fatty acid was the highest in black seed oil (6.451 g/100
g), followed by clove oil (1.800 g/100 g) and cardamom oil (1.692 g/100 g). Total
monounsaturated fatty acids content ranged from 9.341 g/100 g for black seed oil to
0.138 g/100 g for cinnamon oil. In contrast, among all the spices, black seed oil had
the highest content of total polyunsaturated fatty acids (20.279 g/100 g), while
cinnamon oil had the lowest content of total polyunsaturated fatty acids (0.268 g/100
g). Cholesterol is rarely found in plants: such as green bean leafs and etiolated bean
leaves [328]. No cholesterol was detected in the seven spices analyzed. Moreover,
caffeine was not detected in any of the spices (Table 4.7).
Monounsaturated fatty acid percent was the highest component of lipid in ginger oil
(56.074%) and the lowest in fenugreek oil (7.29%). While the total saturated fatty acid
percent was the highest in cardamom oil (38.45%) followed by saffron oil (36.12%)
and clove oil (35.73%), and the total percentages of polyunsaturated fatty acids was
the highest in fenugreek oil, followed by black seed oil and saffron oil (68.25%, 56%
and 52.69%, respectively) as shown in Table 4.8.
Analysis of fatty acid methyl esters presented in Table 4.9 indicated that the highest
fatty acid percent presented in ginger is palmitoleic acid (29.64%) and γ-linoleic acid
(29.63%), followed by elaidic acid (11.92%) and stearic acid (11.32%). Lower
percentages of myristoleic acid, pentadecanoic acid, oleic acid, linoleic acid, αlinolenic acid and nervonic acid were found in ginger as well. Palmitic oil was
remarkably high in all spices except ginger, since palmitic oil was not detected.
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Linoleic fatty acid was detected in high percentages in cinnamon oil, black seed oil,
fenugreek oil, cardamom oil and saffron oil.
The highest fatty acid percent for cinnamon was linoleic (32.04%) followed by elaidic
acid (22.7%) and palmitic acid (11.83%). Moreover, low traces of acids were presented
in cinnamon oil such as capric acid, undecanoic acid, lauric acid, tridecanoic acid,
myristic acid, pentadecanoic acid, palmitoleic acid, stearic acid, linolelaidic acid,
arachidic acid, cis-11-eicosenenoic acid, α-linolenic acid, cis-8, 11, 14-eicosatrienoic
acid and more as shown in Table 4.9.
Furthermore, black seed’s highest fatty acid content was linoleic acid (53.89%),
followed by oleic acid (25.79%), palmitic acid (15.49%), stearic acid (3.32%) and cis11, 14-eicosadienoic acid (2.11%), while no other fatty acids were found in black seed.
Additionally, among all the fatty acids found in fenugreek oil, linoleic acid (50.4%)
exhibited the highest percentage followed by palmitic acid (19.99%) and γ-linoleic
acid (13.92%). Other fatty acids were found in trace amounts in fenugreek oil as well
(Table 4.9). Oleic acid (52.3%) was the highest fatty acid detected in cardamom,
followed by palmitic acid (30.37%). Other fatty acids found in cardamom oil did not
exceed 5.41% (stearic acid).
Additionally, tricosanoic acid (0.55%) and palmitoleic acid (0.34%) along with a
variety of other fatty acids were presented in trace amounts in clove oil, while linoleic
acid was found in higher percentage (40.54%) followed by palmitic acid (21.22%).
Furthermore, palmitic acid (28.10%), lenoleic acid (25.81%) and cis-11-eicosenoic
acid (19.36%) had the highest fatty acid percentages in saffron. Other fatty acids
presented in saffron did not exceed 8.41% (oleic acid).

Table 4.7: Lipid Profile Composition of the Spice Oils (mean ± SD)

Spices oils

Total Saturated (g/100 g)

Total Monounsaturated
(g/100 g)

Total Polyunsaturated
(g/100 g)

Cholesterol
(mg/100 g)

Caffeine
(mg/100 g)

Ginger oil

0.401 ± 0.05

1.755 ± 0.03

0.939 ± 0.01

ND

ND

Cinnamon oil

0.147 ± 0.12

0.138 ± 0.18

0.268 ± 0.23

ND

ND

Black seed oil

6.451 ± 2.43

9.341 ± 1.36

20.279 ± 1.26

ND

ND

Fenugreek oil

1.055 ± 0.02

0.318 ± 0.31

2.978 ± 0.24

ND

ND

Cardamom oil

1.692 ± 0.01

2.376 ± 0.34

0.332 ± 0.37

ND

ND

Clove oil

1.800 ± 0.3

0.661 ± 0.03

2.562 ± 0.09

ND

ND

Saffron oil

1.589 ± 0.22

0.498 ± 0.06

2.319 ± 0.05

ND

ND

Data is expressed per 100 g of the spice oils
ND: not detected
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Table 4.8: Percentage of Fatty Acids of the Spice Oils (mean ± SD)
Spices oil

Total Saturated %

Total Monounsaturated %

Total Polyunsaturated %

Ginger oil

12.8225 ± 0.75

56.074 ± 0.98

30.0275 ± 1.01

Cinnamon oil

26.645 ± 0.23

24.895 ± 1.02

48.375 ± 2.05

Black seed oil

17.815 ± 0.43

25.795 ± 0.32

56 ± 0.33

Fenugreek oil

24.18 ± 0.33

7.295 ± 0.69

68.25 ± 0.92

Cardamom 0il

38.45 ± 1.34

54 ± 1.22

7.55 ± 0.65

Clove oil

35.73 ± 0.23

13.13 ± 0.43

50.865 ± 0.49

Saffron oil

36.12 ± 0.87

11.33 ± 0.84

52.69 ± 0.71
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Table 4.9: Percentage of Fatty Acid Methyl Esters in Spice Oils

Components (Fatty Acid Methyl
Esters)

Ginger oil
%

Cinnamon oil
%

Black seed
oil %

Fenugreek
oil %

Cardamom
oil %

Clove oil
%

Saffron oil
%

C4:0 (Butryic)

0.00

0.00

0.00

0.00

0.00

0.00

0.00

C6:0 (Caproic)

0.00

0.00

0.00

0.00

0.00

0.41

0.00

C8:0 (Caprylic)

0.00

0.00

0.00

0.00

0.00

0.00

0.00

C10:0 (Capric)

0.00

0.59

0.00

0.00

0.00

0.32

0.00

C11:0 (Undecanoic)

0.00

0.20

0.00

0.00

2.67

0.00

0.00

C12:0 (Lauric)

0.00

0.84

0.00

0.88

0.00

0.67

0.00

C13:0 (Tridecanoic)

0.00

0.45

0.00

0.00

0.00

0.00

0.00
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Table 4.9: Percentage of Fatty Acid Methyl Esters in Spice Oils (continued)

Components (Fatty Acid Methyl
Esters)

Ginger oil
%

Cinnamon oil
%

Black seed
oil %

Fenugreek
oil %

Cardamom
oil %

Clove oil
%

Saffron oil
%

C14:0 (Myristic)

0.00

1.96

0.00

0.85

0.00

3.51

0.00

C14:1 (Myristoleic)

1.69

0.00

0.00

0.00

0.00

0.00

0.00

C15:0 (Pentadecanoic)

1.50

0.45

0.00

0.00

0.00

0.00

0.00

C15:1 (cis-10-Pentadecenoic)

0.00

0.06

0.00

0.97

0.00

0.00

0.00

C16:0 (Palmitic)

0.00

11.83

14.50

20.00

30.37

21.23

28.11

C16:1 (Palmitoleic)

29.64

1.07

0.00

0.34

1.62

0.35

0.00

C17:0 (Heptadecanoic)

0.00

0.00

0.00

0.00

0.00

0.00

0.00
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Table 4.9: Percentage of Fatty Acid Methyl Esters in Spice Oils (continued)

Components (Fatty Acid Methyl
Esters)

Ginger oil
%

Cinnamon oil
%

Black seed
oil %

Fenugreek
oil %

Cardamom
oil %

Clove oil
%

Saffron oil
%

C17:1 (cis-10-Heptadecenoic)

0.00

0.00

0.00

0.00

0.00

0.00

0.00

C18:0 (Stearic)

11.33

8.14

3.32

0.80

5.41

6.69

3.40

C18:1n9c (Oleic)

2.98

0.00

25.80

5.48

52.38

12.79

8.41

C18:1n9t (Elaidic)

11.92

22.75

0.00

0.00

0.00

0.00

2.92

C18:2n6t (Linolelaidic)

0.39

1.76

0.00

0.00

0.00

0.00

0.51

C18:2n6c (Linoleic)

0.00

32.04

53.89

50.40

0.00

40.55

25.81

C18:3n6 (γ-Linolenic)

29.64

0.00

0.00

13.92

0.00

0.00

0.00
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Table 4.9: Percentage of Fatty Acid Methyl Esters in Spice Oils (continued)

Components (Fatty Acid Methyl
Esters)

Ginger oil
%

Cinnamon oil
%

Black seed
oil %

Fenugreek
oil %

Cardamom
oil %

Clove oil
%

Saffron oil
%

C20:0 (Arachidic)

0.00

1.64

0.00

0.00

0.00

2.37

0.93

C18:3n3 (cis-11-Eicosenoic)

0.00

5.65

0.00

0.00

2.12

6.09

19.37

C20:1n9 (α-Linolenic)

8.98

1.03

0.00

0.00

0.00

0.00

0.00

C20:2 (cis-11, 14-Eicosadienoic)

0.00

0.00

2.11

0.00

3.52

0.59

0.61

0.00

2.68

0.00

0.00

0.00

0.00

0.00

C20:3n6 (cis-8, 11, 14Eicosatrienoic)
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Table 4.9: Percentage of Fatty Acid Methyl Esters in Spice Oils (continued)

Components (Fatty Acid Methyl
Esters)

Ginger oil
%

Cinnamon
oil %

Black seed
oil %

Fenugreek
oil %

Cardamom
oil %

Clove oil
%

Saffron oil
%

0.00

2.25

0.00

0.00

0.00

2.44

1.71

0.00

0.00

0.00

2.21

0.00

0.00

1.61

0.00

2.63

0.00

0.00

0.83

0.00

0.00

C21:0 (Henicosanoic)

0.00

0.00

0.00

1.17

0.00

0.00

0.00

C22:0 (Behenic)

0.00

0.22

0.00

0.00

0.00

0.00

0.00

C20:3n3 (cis-11, 14, 17Eicosatrienoic)
C20:4n6 (Arachidonic)
C20:5n3 (cis-5, 8, 11, 14, 17Eicosapentaenoic)
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Table 4.9: Percentage of Fatty Acid Methyl Esters in Spice Oils (continued)

Components (Fatty Acid Methyl
Esters)

Ginger
oil %

Cinnamon
oil %

Black seed
oil %

Fenugreek
oil %

Cardamom
oil %

Clove oil
%

Saffron
oil %

C22:1n9 (Erucic)

0.00

0.00

0.00

0.00

0.00

0.00

0.00

C22:2 (cis-13, 16-Docosadienoic)

0.00

0.31

0.00

1.72

0.00

0.00

3.08

0.00

1.07

0.00

0.00

1.08

1.20

0.00

C23:0 (Tricosanoic)

0.00

0.17

0.00

0.50

0.00

0.56

2.26

C24:0 (Lignoceric)

0.00

0.18

0.00

0.00

0.00

0.00

1.44

C24:1n9 (Nervonic)

0.86

0.00

0.00

0.51

0.00

0.00

0.00

C22:6n3 (cis-4, 7, 10, 13, 16, 19Docosahexaenoic)
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In 1992, Al-Jassir et al. concluded that linoleic and oleic acids were the major
unsaturated fatty acids in black seed, while palmitic acid was the main saturated fatty
acid [304]. Additionally, Cheikh-Rouhou et al. stated that the major unsaturated fatty
acids in black seed were linoleic fatty acid (50.3–49.2%), followed by oleic fatty acid
(25.0–23.7%), while the main saturated fatty acid was palmitic acid (17.2–18.4%)
(17.2–18.4%) [306]. The current research study results were in agreement with the
findings of Al-Jassir et al. [304] and Cheikh-Rouhou et al. [306].
Hamden et al. reported that the total saturated fatty acids percent in fenugreek seeds
was 17.7% of the total lipids and palmitic acid percentage was 11.0%. Additionally,
linoleic acid was the highest (43.2%) in fenugreek followed by linolenic (22%) and
then oleic (16.7%) acids as reported by Hamdan et al. [329]. Hamden et al. findings
varied remarkably from the results of the current study.
The percentage of linolenic acid in fenugreek oil or the current study differ from the
results previously presented by Shahat et al. as it was reported to be 13.8% of the
Egyptian fenugreek oil [330]. Whereas, Zafar et al. reported a linolenic acid percentage
of 7% for Indian fenugreek oil, which is considered significantly lower than the
currents study result [331]. In contrast, Sulaiman et al. compared fenugreek fatty acids
content in previous studies, Sulaiman et al. found that temperature, atmosphere and
the origin of fenugreek seed are the main factors that are responsible of variations in
the reported results, especially in linolenic acid [332].
On the other hand, palmitoleic, oleic, elaidic, linoleic, linolenic, cis-11-eicosenoic and
erucic acids content in ginger and cinnamon varied in previous studies. Sing et al. and
Kim et al. analysis of the fatty acids content of cinnamon and ginger were not
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consistent with the findings of the current study as the values presented in their studies
varies significantly from the outcomes of the current study. These differences are due
to the different storage techniques and the different preparation methods followed for
analysis as Sing et al. and Kim et al. reported [308, 313].
Additionally, cardamom content of oleic acid (49.2%), palmitic acid (26.87%) and
palmitoleic acid (1.6%) as reported by Parry et al. [333], were consistent with results
of this research. In addition, Al-Jasass et al. reported a clove content of linoleic acid
(44.73%) and this result was in agreement with the findings of our study [307].
Moreover, saffron content of ursolic, oleanolic, palmitic, palmitoleic and oleic acids
that were reported by Rios et al., Sampathu et al. and Christodoulou et al. were not in
agreement with the findings from our study (Table 4.9) [334-336].
According to Al-jasass et al. [307] and Parry et al. [333], the differences in the results
attained and that reported in earlier studies are possibly due to environmental factors
that conquer in production areas of spices, different planting fertilizers used and due
to the different methods followed for the preparation of the spices for analysis.
4.1.6 Shogaols, Gingerols and Curcumin Composition Analysis in Ginger Powder
Shogaols, paradols, gingerols and curcumin are chemicals that are presented in ginger
that give the ginger its pungent smell and taste and are believed to give ginger its
hypoglyceamic, hypolipidimic and anti-inflammatory effect [337-340]. In 2017, a
study reported that 6-shogaol showed potent activity in stimulating glucose utilization
by adipocytes and myotubes in a high fat diet fed to mouse. The effects were attributed
to the increased phosphorylation in adipocytes [151]. In addition, a study conducted in
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2012, showed that the activity of (S)-(8)-gingerol was found to be correlated with an
elevation in surface distribution of glucose transporter type 4 (GLUT4) protein.
GLUT4 is responsible for glucose uptake on the plasma membrane that enhances
glucose uptake and insulin sensitivity, therefore, improves levels of glucose on the
blood [152]. Moreover, Kunchandy et al. reported the ability of curcumin to scavenge
reactive oxygen radicals which are associated in inflammation, hence the high antiinflammatory effect of curcumin [338]. Additionally, a study conducted by RamirezTortosa et al. concluded that the consumption curcumin inhibited the LDL oxidation
and improved lipid profile [340]. Therefore curcumin was considered to be a protective
tool against atherosclerosis and cardiovascular diseases [340, 341].
Shogaols, paradols, gingerols and curcumin presence in significant amounts in ginger
were reported by previous studies [337-340, 342], while cinnamon and black seed did
not contain shogaols, paradols, gingerols and curcumin as reported by literature [343,
344].
Therefore, as a step further in analyzing the ginger powder, 6-gingerols, 8-gingerols,
6-shogaols and curcumin were investigated. 6-shogaols had the highest value followed
by 6-gingerols and 8-gingerols 56.10, 30.21, 7.92 mg/100 g respectively. Curcumin
content was very low (0.01 mg/100 g) in ginger powder as shown in Table 4.10.
Heat was applied in the process of drying ginger root before grinding, hence for
chemical analysis. 6-gingerols convert to shogaols under heat and this explains the
high content of shogaols in the powder form of ginger when compared to gingerols
[345]. Chen and his colleagues, analyzed ginger root and found that 6-gingerol had the
highest value (11.8%) of the wet weight among the pungent compounds identified in
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raw ginger such as 8-gingerol (1.67%) and 10-gingerol (2.38%) of the body weight.
Shogaols were found in trace amounts as ginger was analyzed in its raw form and did
not go under heat treatment [345]. Results of previous studies were similar to the
findings of this study [337, 345].
Table 4.10: Ginger powder Composition of Shogaols, Gingerols and Curcumin
(mean ± SD)
Samples mg/100 g

Ginger Powder

6- Gingerol

30.21 ± 0.14

6- Shogaol

56.10 ± 0.30

8- Gingerol

7.92 ± 0.28

Curcumin

0.01 ± 0.00

4.1.7 Conclusion
Ginger, cinnamon, black seen, fenugreek, cardamom, clove and saffron were
extensively analyzed in this study. Findings of this current study proved that these
seven spices have different macronutrient, micronutrient and sugar content. Many
previous studies were in agreement with the findings of this current study [163, 302,
305-307], however, findings of some studies in the literature were not in consistence
with the findings of this study [153, 175, 179, 303].
The differences in macronutrient composition of spices reported by scientists is
theorized due to the different soil and geographical locations of the source of planting
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and growing plants, and due to the difference in environmental conditions, which has
an effect on the nutrient composition [17, 162, 163, 306, 307, 311]. Moreover, different
grinding and storing techniques were proved to have a major effect on the spices
nutrient composition [312, 313].
Moreover, mineral and vitamin levels fluctuate within species, this difference may
increase due to the different colorimetric or qualitative analytical methods used, as
well as this might be owing to the differences in the spices origins [21, 180, 321].
Additionally, Saffron, cinnamon and Cardamom had the highest total sugar content,
and are capable to deliver a natural sweet taste, hence, the usage of these spices in
many Emirati local sweet dishes such as: khabisa, batheetha, habba hamra and balaleet
[325]. However, unfortunately, there is a general scarcity of literature that deals with
sugar composition of spices, hence comparison between similar spices were difficult.
Therefore, more studies are needed to examine the nutrient content of sugar in the
spices.
Furthermore, the differences in the lipid profile results obtained in this current study
and that reported in previous studies are possibly due to environmental factors that
conquer in production areas of spices, different planting fertilizers used and due to the
different methods followed to prepare spices for analysis [307].
Lastly, this current study concludes that these tested seven spices while providing
aroma and improving the taste of food, also have some essential nutrients. Therefore,
the use of these spices’s macronutrients, essential oils and active compounds such as

121
gingerols and shogaols could be applied nutritional supplements and for treatments
considering their decent source of valuable nutrients.
4.2 Intervention Treatment of Spices
4.2.1 Population Characteristics
Clinical and demographic characteristics of the study population are presented as mean
± standard deviation in Table 4.11. The mean age of study population was 26.1 ± 9.56,
27.84 ± 12.04, 26.59 ± 8.06 and 28.82 ± 11.7 years old for the ginger, cinnamon, black
seed and placebo groups, respectively, ranging from 19 to 49 years old. The range of
the population age was (19 – 44), (20 – 42), (21 – 47) and (21 – 45) years old for
ginger, cinnamon, black seed and placebo, respectively. The mean age of population
in the ginger, cinnamon, black seed groups was not significantly different from the
placebo group (P-value > 0.05). The mean body mass index (BMI) of participants was
36.07 ± 6.466, 33.53 ± 9.96, 34.78 ± 9.27 and 33.94 ± 5.84 kg/m² in the ginger,
cinnamon, black seed and placebo groups, respectively. No significant difference in
the mean BMI value was observed between ginger, cinnamon, black seed groups and
the placebo group (P-value > 0.05).
All participants had two or more of the metabolic syndrome risk factors. Waist
circumference (WC) was 105.46 ± 14.93, 96.55 ± 13.76, 98.6 ± 17.64 and 102.07 ±
11.91 cm for the ginger (P-value=0.415), cinnamon (P-value=0.125), black seed (Pvalue=0.43) and placebo groups, respectively. Systolic blood pressure mean values
were 119.04 ± 17.74, 121.68 ± 15.64, 115.48 ± 17.72 and 122.5 ± 16.79 mmHg in
ginger (P-value=0.516), cinnamon (P-value=0.863), black seed (P-value=0.158) and
placebo groups, respectively, and 83.47 ± 13.41, 81.36 ± 11.24, 76.72 ± 13.43 and
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81.86 ± 9.52 mmHg for the Diastolic blood pressure in ginger (P-value=0.651),
cinnamon (P-value=0.871), black seed (P-value=0.134) and placebo groups,
respectively. Fasting blood glucose (FBG) mean value was 89.35 ± 12, 99.1 ± 44.43,
93.7 ± 8.1 and 88.58 ± 26.87 mg/dL for the ginger (P-value=0.515), cinnamon (Pvalue=0.055), black seed (P-value=0.35) and placebo groups, respectively. High
density lipoprotein (HDL) mean values ranged from 34.4 ± 8.52 mg/dL for ginger
group to 41.23 ± 11 mg/dL for cinnamon group, with no significant difference between
ginger, cinnamon and black seed groups and the placebo group (P-value ≥ 0.05).
Triglycerides mean value was the highest in cinnamon group 116.76 ± 80.30 mg/dL
and the lowest in black seed group 100.01 ± 33.4 mg/dL. No significant difference was
found between ginger, cinnamon and black seed groups and the placebo group for
triglycerides (P-value > 0.05).
Participants had no significant difference between each treatment group and the
placebo group in term of their age, height, BMI, WC, BP, FBG, HDL and TG (P-value
> 0.05). On the other hand, weight mean value of the participants ranged from 92.77
± 25.44 kg for the black seed group and 100.6 ± 21.12 kg for the ginger group.
Significant difference was observed in weight mean values between placebo group and
ginger group (P-value=0.04), and between placebo group and cinnamon group (Pvalue=0.048) as demonstrated in Table 4.11. Inclusion of the participants was based
on age, WC, FBG, BP, HDL and Triglycerides. Only these factors were taken into
consideration during the random distribution of the population into four treatment
groups. Therefore, it was impossible to distribute the population randomly without
having some significant differences between the placebo group and treatment groups
in some parameters (non- inclusion criteria parameters).

Table 4.11: Population Characteristics of the Intervention Study
Parameter

Ginger group,
n=21
f=12, m=9
(19-44 years)

P-value of
Independent
sample t- test

Cinnamon group,
n=25
f=16, m=9
(20-42 years)

P-value of
Independent
sample t- test

Black seed
group, n=29
f=20, m=9
(21-47 years)

P-value of
Independent
sample t- test

Placebo group,
n=22
f=11, m=11
(21-45 years)

Age (years)
Weight (kg)

26.1 ± 9.56 (b)
100.6 ±
21.12(a)
166.8 ±
8.74(b)
36.07 ±
6.466(b)
105.46 ±
14.93(b)

0.81

27.84 ± 12.04(b)

0.768

0.59

28.82 ± 11.7

0.04

98.05 ± 20.17(a)

0.048

26.59 ± 8.06(b)
92.77 ±
25.44(b)

0.871

93.77 ± 19.17

0.54

165.2 ± 11.36(b)

0.60

164.2 ± 9.11(b)

0.84

167.5 ± 9.93

0.26

33.53 ± 9.96(b)

0.87

34. 78 ± 9.27(b)

0.713

33.94 ± 5.84

0.41

96.55 ± 13.76(b)

0.15

98.6 ± 17.64(b)

0.431

102.07 ± 11.91

89.35 ± 12(b)

0.51

99.1 ± 44.43(b)

0.06

93.7 ± 8.1(b)

0.35

88.58 ± 26.87

0.51

121.68 ± 15.64(b)

0.86

0.158

122.5 ± 16.79

0.65

81.36 ± 11.24(b)

0.87

0.134

81.86 ± 9.52

34.4 ± 8.52(b)

1.0

41.23 ± 11(b)

0.087

36.62 ± 9.01(b)

0.556

34.68 ± 12.32

115 ± 31.97(b)

0.73

116.76 ± 80.30(b)

0.39

100.01 ±
33.4(b)

0.97

102.34 ±
30.02

Height (cm)
BMI
(kg/m2)
WC (cm)
FBG
(mg/dL)
Systolic BP
(mmHg)
Diastolic BP
(mmHg)
HDL
(mg/dL)
TG (mg/dL)

119.04 ±
17.74(b)
83.47 ±
13.41(b)

115.48 ±
17.72(b)
76.72 ±
13.43(b)
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Data are presented as (mean ± standard deviation)
(a) Mean value differs significantly from placebo group at P-value ≤ 0.05. (b) Mean value does not differ significantly from
placebo group at P-value ≤ 0.05
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4.2.2 Clinical, Anthropometric and Body Composition Assessments
Blood pressure (BP), waist circumference (WC), body fat mass (BFM), weight,
skeletal muscle mass (SMM), body mass index (BMI) and percent body fat (PBF) were
assessed during the study period (baseline, midpoint, and endpoint) to examine the
effect of the spice powders on blood pressure, abdominal obesity and body
composition, and therefore understand how they influence the cardiovascular risk
factors.
4.2.2.1 Baseline Assessments
At baseline, systolic blood pressure was 119.05 ± 17.75, 121.68 ± 15.65, 115.48 ±
17.72 and 122.50 ± 16.79 mmHg and diastolic blood pressure was 83.48 ± 13.42, 81.36
± 11.25, 76.72 ± 13.44 and 81.86 ± 9.53 mmHg for the ginger, cinnamon, black seed
and placebo groups respectively.
Waist circumference (WC) was measured as part of the inclusion criteria. WC mean
values were 105.46 ± 14.93, 96.56 ± 13.77, 98.61± 17.64 and 11.92 ± 102.08 cm for
the ginger, cinnamon, black seed and placebo groups respectively. The average WC of
participants of ginger, cinnamon, black seed groups did not differ significantly from
the average WC of the placebo group (P-value ≥ 0.05).
For the ginger group, the mean value of the participants’ weight was 100.61 ± 4.93 kg
and their body mass index (BMI) was 36.0 ± 6.47 kg/m2. Participants were considered
to be severely obese (obese class II) [252]. The mean value of their skeletal muscle
mass (SMM) was 31.34 ± 7.35 kg, body fat mass (BFM) was 44.65 ± 13 kg while
percent body fat (PBF) was 44.04 ± 7.24%. No significant difference between the
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ginger group and the placebo group was observed among the aforementioned
parameters prior to the investigation (P-value > 0.05), except for the mean value of
weight (P-value=0.027).
On the other hand, cinnamon group participant’s weight mean value was 99.06 ± 20.18
kg and the BMI mean value was 33.53 ± 9.96 kg/m2. Furthermore, Participants had a
BFM mean value of 42.23 ± 14.54 kg, while the PBF mean value was 41.6 ± 8.22%
and the SMM mean value was 27.58 ± 7.56 kg. The difference between the cinnamon
group and the placebo group were not significant for BP, WC, BFM, SMM, BMI and
PBF (P-value ≤ 0.05). Moreover, the difference in the weight mean value between the
cinnamon group and the placebo group was significant (P-value=0.048).
Black seed group participant weight mean value was 92.74 ± 24.44 kg and BMI was
34.78 ± 9.28 kg/m2. Their SMM was 28.82 ± 7.31 kg, BFM 40.96 ± 17.26 kg and their
PBF was 43.21 ± 9.24%. Mean value of the weight of the placebo group was 93.77 ±
19.17 kg, BMI was 33.94 ± 5.84 kg/m2, SMM was 31.23 ± 6.99 kg, BFM was 38.30
± 14.65 kg and PBF was 40.52 ± 10.32% as shown in Table 4.12. No significant
difference between the three treatment groups was found when comparing the mean
values of the clinical, body composition and anthropometric measures (P-value >
0.05).

Table 4.12: Clinical, Anthropometric and Body Composition Assessment of the Treatment Groups with the Placebo Group at Baseline (Mean ±
SD)
Ginger group
n=21

P-value of
Independent
sample t- test

Cinnamon
group n=25

P-value of
Independent
sample t- test

Black seed group
n=29

P-value of
Independent
sample t- test

Placebo group
n=22

Systolic BP (mmHg)

119.05 ± 17.75(b)

0.516

121.68 ± 15.65(b)

0.863

115.48± 17.72(b)

0.158

122.50 ± 16.79

Diastolic BP
(mmHg)

83.48 ± 13.42(b)

0.651

81.36 ± 11.25(b)

0.870

76.72± 13.44(b)

0.134

81.86± 9.53

WC (cm)

105.46 ± 14.93(b)

0.415

96.56 ± 13.77(b)

0.152

98.61± 17.64(b)

0.431

102.08± 11.92

BFM (kg)

44.65 ± 13.00(b)

0.147

42.23 ± 14.54(b)

0.162

40.96± 17.26(b)

0.563

38.30± 14.65

Weight (kg)

100.60 ± 21.12(a)

0.027

92.06 ± 20.18(a)

0.048

92.74± 24.44(b)

0.871

93.77± 19.17

SMM (kg)

31.34 ± 7.35(b)

0.267

27.58 ± 7.56(b)

0.094

28.82± 7.31(b)

0.239

31.23± 6.99

BMI (kg/m2)

36.07 ± 6.47(b)

0.272

33.53 ± 9.96(b)

0.867

34.78± 9.28(b)

0.713

33.94± 5.84

PBF %

44.04 ± 7.24(b)

0.206

41.6 ± 8.22(b)

0.791

43.21± 9.24(b)

0.340

40.52± 10.32

Parameter
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Data are presented as (mean ± standard deviation)
(a)Mean value differs significantly from placebo group at P-value ≤ 0.05. (b) Mean value does not differ significantly from placebo group at
P-value ≤ 0.05
BP: Blood Pressure; WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent
Body Fat.
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4.2.2.2 Midpoint Assessments
Table 4.13 demonstrates all the clinical, anthropometric and body composition values
at midpoint. At the sixth week of the intervention period, systolic blood pressure was
115.86 ± 15.40, 115.80 ± 12.81, 114.66 ± 17.70, 120.05 ± 14.80 mmHg and diastolic
blood pressure was 78.38 ± 11.13, 79.72 ± 8.94, 75.83 ± 13.15 and 75.64 ± 14.58
mmHg for the ginger, cinnamon, black seed and placebo groups respectively. No
significant difference was detected between the treatment groups and the placebo
group for the systolic and diastolic blood pressure as shown in Table 4.14.
WC mean values for the ginger, cinnamon, black seed and placebo were 101.32 ±
15.20, 90.35 ± 13.91, 95.84 ± 16.75 and 101.34 ± 12.49 cm, respectively. WC mean
values reduction varied from -6.21 cm for the cinnamon group and -2.77 cm for the
black seed group. The reduction was significant for the ginger (P-value < 0.001),
cinnamon (P-value < 0.001) and black seed (P-value < 0.001) groups when compared
to the placebo group as shown in Figure 4.1.
Moreover, mean value of weight for the participants was 99.41 ± 21.58, 91.45 ± 13.38,
93.13 ± 24.27 and 95.51 ±19.23 kg for the ginger, cinnamon, black seed and placebo
groups, respectively. There was no significant difference in the mean value of the
weight of the participants in ginger and black seed groups when compared to placebo
group at P-value > 0.05, while the difference of weigh was considered significant for
the cinnamon group when compared to placebo group (P-value=0.001).
BMI and Skeletal muscle mass (SMM) did not change significantly in all groups at
midpoint (P-value > 0.05).
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BFM and PBF mean values did not change significantly (P-value > 0.05) for ginger
and black seed group when compared to placebo group. Changes of note were
identifiable and significant in body fat mass (40.85 ± 10.15 kg) and percent body fat
(41.33 ± 8.25%) in the cinnamon group when compared to placebo group with P-value
< 0.001 and P-value=0.038 respectively (Table 4.13).
Weight mean value was significantly different (P-value=0.048) from the placebo mean
value at baseline, with placebo group having a lower weight mean value than the
cinnamon group at baseline as demonstrated in Table 4.12. Moreover, Weight mean
value of the cinnamon group at midpoint was significantly different (P-value=0.001)
from the placebo weight mean value, as shown in Table 4.14 and Figure 4.1. Therefore,
a regression test was conducted at midpoint of the study to test the relevance of the
significancy of the weight change in the cinnamon group. The regression test took into
consideration the different treatment groups, weight mean values at baseline and the
interaction between the treatment and weight mean values at baseline. For the
cinnamon group, no significant difference was detected (P-value=0.626). This means
that the difference in weight mean value for the cinnamon group is significant at
midpoint when compared to placebo group.
Moreover, ginger weight mean value at baseline was significantly different (Pvalue=0.027) from the placebo weight mean value at baseline as demonstrated in Table
4.12. However, no significant difference was detected in the weight mean values of
the ginger group when compared to the placebo group at midpoint (P-value=0.836) as
shown in Table 4.14. Therefore, no further analysis was required.

Table 4.13: Clinical, Anthropometric and Body Composition Assessment of the Treatment Groups with the Placebo Group at Midpoint (Mean ±
SD)
Intervention group

Ginger group n=21

Cinnamon group n=25

Black seed group n=29

Placebo group n=22

Systolic BP (mmHg)

115.86 ± 15.40

115.80 ± 12.81

114.66 ± 17.70

120.05 ± 14.80

Diastolic BP (mmHg)

78.38 ± 11.13

79.72 ± 8.94

75.83 ± 13.15

75.64 ± 14.58

WC (cm)

101.32 ± 15.20

90.35 ± 13.91

95.84 ± 16.75

101.34 ± 12.49

BFM (kg)

43.88 ± 13.69

40.85 ± 10.15

40.68 ± 17.31

39.54 ± 15.70

Weight (kg)

99.41 ± 21.58

91.45 ± 13.38

93.13 ± 24.27

95.51 ± 19.23

SMM (kg)

33.30 ± 11.17

27.84 ± 7.41

29.29 ± 7.23

32.74 ± 6.55

BMI (kg/m2)

35.86 ± 6.49

33.01 ± 10.40

35.05 ± 9.82

34.19 ± 6.11

PBF %

43.9 ± 7.34

41.33 ± 8.25

43.16 ± 9.09

40.58 ± 10.45

BP: Blood Pressure; WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent Body
Fat.

129

Table 4.14: Clinical, Anthropometric and Body Composition Assessment Comparison of the Treatment Groups with the Placebo Group at
Midpoint (Week 6 – Week 0)

Parameter

Ginger group
n=21

P-value

Cinnamon group
n=25

P-value

Black seed group
n=29

P-value

Placebo group
n=22

Systolic BP (mmHg)

-3.19 ± 10.14

0.452

-5.88 ± 11.79

0.676

-0.83 ± 14.21

0.182

-2.45 ± 11.70

Diastolic BP (mmHg)

-5.10 ± 10.41

0.77

-1.64 ± 7.28

0.212

-0.90 ± 13.27

0.072

-6.23 ± 16.28

WC (cm)

-4.14 ± 3.38

0.000*

-6.21 ± 10.91

0.000*

-2.77 ± 2.96

0.000*

-0.74 ± 2.37

BFM (g)

1.62 ± 6.06

0.610

-0.84 ± 1.14

0.000*

0.38 ± 1.84

0.997

0.15 ± 1.94

Weight (kg)

3.78 ± 16.12

0.836

-0.64 ± 1.19

0.001*

0.86 ± 2.14

0.628

2.05 ± 6.20

SMM (kg)

3.46 ± 15.64

0.670

0.26 ± 0.38

0.856

0.47 ± 0.66

0.219

1.50 ± 1.58

BMI (kg/m2)

1.51 ± 6.42

0.626

-0.52 ± 6.45

0.593

0.27 ± 2.63

0.901

0.25 ± 0.93

PBF %

1.96 ± 7.92

0.932

-0.2 ± 0.90

0.038*

-0.04 ± 9.09

0.356

0.06 ± 1.95

*significant at p-value=0.05
BP: Blood Pressure; WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent Body
Fat.
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Figure 4.1: The Effect of Spice Powders on Clinical, Anthropometric and Body Composition after Six Weeks of the Intervention when
Compared to the Placebo Group
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WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent Body Fat.
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4.2.2.3 Endpoint Assessment
At the twelfth week, participants attended the third and last visit and all the clinical,
anthropometric and body composition assessments were taken for the four treatment
groups. Systolic blood pressure mean values varied from 113.63 ± 16.88 mmHg for
the black seed group to 122.55 ± 16.07 mmHg for the placebo group (Table 4.15).
Diastolic blood pressure mean values ranged from 77.78 ± 13.52 mmHg for the black
seed group to 80.73 ± 11.74 mmHg for the placebo group. Table 4.16 shows the
difference between baseline and the twelfth week for the parameters measured in this
study. For the blood pressure measurements, changes from the baseline for the three
treatment groups were not statistically significant when compared to the placebo
group. Table 4.16 shows the difference between baseline and the twelfth week for all
the clinical, anthropometric and body composition parameters measured in this study.
A significant reduction was observed in ginger, cinnamon, black seed groups in
comparison with the placebo group over the twelfth weeks results for the mean values
of WC (P-value ≤ 0.05). The ginger group WC reduction mean value was -6.17 cm ±
4.10 (P-value=0.000) and the cinnamon group’s reduction mean value was -7.13 ±
4.93 cm (P-value=0.000), while the black seed group had the highest WC reduction
among the interventional groups with a mean value of -10.56 ± 26.47 cm (P-value <
0.001), as shown in Figure 4.2.
BFM, weight, BMI and PBF reductions were only significant for the cinnamon group
when compared to the placebo group (-1.3 ± 1.41, P-value=0.001; -2.01 ± 6.53 kg, Pvalue=0.011; -2.70 ± 9.01 kg/m2, P-value=0.001; and -2.82 ± 1.14, P-value=0.027,
respectively). BFM, weight, BMI and PBF changes mean values of the ginger and the
black seed groups were considered not significant when compared to the placebo group
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(P-value > 0.05). SMM increased in the cinnamon group by 0.12 ± 0.99 kg and in the
ginger group by 2.18 kg ± 5.73. However, the increase was not significant when
compared to the placebo group (P-value > 0.05), while it decreased non-significantly
in the black seed group (-0.52 ±1.33 kg) when compared to the placebo group (P-value
> 0.05) (Table 4.16).
Weight mean value was significantly different (P-value=0.048) from the placebo mean
value at baseline, with placebo group having a lower weight mean value than the
cinnamon group at baseline as demonstrated in Table 4.12. Therefore, a regression test
was conducted at end point of the study to test the relevance of the significancy of the
weight change for the cinnamon group. The regression test took into consideration the
different treatment groups, weight mean values at baseline and the interaction between
the treatment and weight mean values at baseline. For the cinnamon group, no
significant difference was detected (P-value=0.732). This means that the difference in
weight mean value for the cinnamon group is significant at endpoint when compared
to placebo group, though there was a significant difference at baseline in the mean
value of weigh of the cinnamon group when compared to placebo group. Moreover,
ginger weight mean value at baseline was significantly different (P-value=0.027) from
the placebo weight mean value at baseline as demonstrated in Table 4.12. However,
the significant difference was detected in the weight mean values of the ginger group
at endpoint when compared to the placebo group (P-value=0.22), as shown in Table
4.16 and Figure 4.2. Therefore, no further analysis was required.

Table 4.15: Anthropometric and Clinical Assessment of the Treatment Groups with the Placebo Group at Endpoint (Mean ± SD)
Intervention group

Ginger group n=21

Cinnamon group n=25

Black seed group n=29

Placebo group n=22

Systolic BP (mmHg)

116.86 ± 13.65

114.64± 15.12

113.63± 16.88

122.55± 16.07

Diastolic BP (mmHg)

79.38± 9.85

77.80± 10.35

77.78± 13.52

80.73± 11.74

WC (cm)

99.29± 14.73

89.43± 13.10

88.05± 29.45

102.36± 12.25

BFM (kg)

44.14± 13.20

40.83± 9.85

41.34± 17.81

38.44± 15.37

Weight (kg)

99.59± 21.41

90.08± 15.23

93.60± 25.39

95.82± 18.19

SMM (kg)

32.02± 7.26

27.59± 7.56

30.02± 7.28

31.77± 6.82

BMI (kg/m2)

35.65± 6.67

32.12± 9.86

34.94± 9.35

34.60± 6.17

PBF %

43.60± 7.28

17.55± 20.74

42.69± 9.31

40.81± 10.53

BP: Blood Pressure; WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent Body
Fat.

134

Table 4.16: Clinical, Anthropometric and Body Composition Assessment Comparison of the Treatment Groups with the Placebo Group at
Endpoint (Week 12 – Week 0)
Ginger group
Parameter

Cinnamon group
P-value

n=21

Black seed group
P-value

n=25

Placebo group
P-value

n=29

n=22

Systolic BP (mmHg)

-2.19 ± 10.84

0.601

-7.04 ± 11.75

0.186

-9.69 ± 28.98

0.536

0.05 ± 14.38

Diastolic BP (mmHg)

-4.10 ± 9.05

0.991

-3.56 ± 9.32

0.965

-4.31 ± 23.55

0.668

-1.14 ± 9.59

WC (cm)

-6.17 ± 4.10

0.000*

-7.13 ± 4.93

0.000*

-10.56 ± 26.47

0.000*

0.29 ± 4.92

BFM (kg)

1.36 ± 5.82

0.274

-1.3 ± 1.41

0.001*

-0.38 ± 1.36

0.070

1.25 ± 3.65

Weight (kg)

3.60 ± 15.67

0.220

-2.01 ± 6.53

0.011*

0.39 ± 1.38

0.304

1.73 ± 6.45

SMM (kg)

2.18 ± 5.73

0.601

0.12 ± 0.99

0.550

-1.91 ± 6.94

0.753

0.53 ± 1.89

BMI (kg/m2)

1.30 ± 5.67

0.105

-2.70 ± 9.01

0.001*

0.16 ± 0.48

0.107

0.66 ± 1.52

PBF %

1.67 ± 8.00

0.307

-2.82 ± 1.14

0.027*

-0.52 ± 1.33

0.726

0.29 ± 1.08

*Significant at P-value ≤ 0.05
BP: Blood Pressure; WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent Body
Fat.
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Figure 4.2: The Effect of Spice Powders on Body Composition after Twelve Weeks of the Intervention when Compared to the Placebo Group
WC: Waist Circumference; BFM: Body Fat Mass; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; PBF: Percent Body Fat.
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4.2.3 Dietary Assessment
In order to accurately test the effect of the spices, participants were asked to uphold
their regular dietary habits and not to change their food intake. Participants who
changed their eating habits or tried to lose weight by following a certain diet during
the study period were excluded.
Three days of food records were collected from each participant at every visit
(baseline, midpoint and endpoint). The food records were distributed before each visit
and participants were asked to complete the food record with their intake of food and
beverages over two days during the week (working days) and one day of the weekend.
Participants were asked to bring the food record at each visit. Each participant filled a
total of nine days of food records during the 12 weeks of study
4.2.3.1 Baseline Dietary Assessment
At baseline, participants consumed a total energy of 2499.74 ± 1067, 2430.55 ±
1244.16, 2492.20 ± 1136.71 and 2454.21 ± 1255.87 Kcal per day for the ginger,
cinnamon, black seed and placebo groups respectively (Table 4.17). No significant
difference was observed between ginger, cinnamon, black seed groups and the placebo
group (P-value ≤ 0.05). Carbohydrate consumption was 358.05 ± 151.92, 350.39 ±
168.60, 358.43 ± 152.37 and 353.62 ± 150.68 grams per day for the ginger, cinnamon,
black seed and placebo groups respectively. Mean value of carbohydrates consumption
did not differ significantly between ginger, cinnamon and black seed groups and the
placebo group (add P-value). Fat consumption was the highest in placebo group
(102.45 ± 61.87 grams per day) while the other groups did not exceed 96.48 ± 62.95
grams per day. No significant difference was observed between ginger, cinnamon and
black seed groups and the placebo group (P-value > 0.05). Protein consumption was
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103.77 ± 49.57, 103.21 ± 36.19, 102.47 ± 34.41 and 104.16 ± 33.69 grams per day for
the ginger, cinnamon, black seed and placebo groups respectively. No significant
difference was observed between ginger, cinnamon, black seed group and the placebo
group (P-value > 0.05). Differences in macronutrients or calories consumption
between groups was not significant (P-value ≥ 0.5) as shown in Table 4.17.

Table 4.17: Macronutrient Consumption for the Treatment Groups and the Placebo Group at Baseline (Mean ± SD)

Intervention
group

Ginger group
n=21

P-value of
Independent
sample t- test

Cinnamon group
n=25

P-value of
Independent
sample t- test

Black seed group
n=29

P-value of
Independent
sample ttest

Placebo group
n=22

Calories (kcal)

2499.74 ± 1067 (b)

0.762

2430.55 ± 1244.16(b)

0.983

2492.20 ± 1136.71(b)

0.863

2454.21 ± 1255.87

Carbohydrates
(g)

358.05 ± 151.92(b)

0.292

350.39 ± 168.60(b)

0.545

358.43 ± 152.37(b)

0.679

353.62 ± 150.68

Fat (g)

94.25 ± 52.19(b)

0.061

95.14 ± 67.33(b)

0.056

96.48 ± 62.95(b)

0.087

102.45 ± 61.87

Protein (g)

103.77 ± 49.57(b)

0.532

103.21 ± 36.19(b)

0.652

102.47 ± 34.41(b)

0.591

104.16 ± 33.69

*Significant at P-value ≤ 0.05
(a)Mean value differs significantly from placebo group at P-value ≤ 0.05. (b) Mean value does not differ significantly from placebo group at Pvalue ≤ 0.05
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4.2.3.2 Midpoint Dietary Assessment
At midpoint, participants consumed a total energy of 2516.49 ± 979.85, 2454.91 ±
1222.11, 2494.93 ± 1118.69 and 2459.44 ± 1249.48 Kcal per day for the ginger,
cinnamon, black seed and placebo groups respectively (Table 4.18). No significant
difference was detected between the ginger, cinnamon and black seed groups and the
placebo group (P-value > 0.05). Participants consumed 353.9 ± 979.85, 349.86 ±
162.91, 357.01 ± 149.21 and 347.13 ± 143.60 grams of carbohydrate per day for the
ginger, cinnamon, black seed and placebo groups respectively. Carbohydrate
consumption of the three treatment groups did not differ significantly (P-value > 0.05)
at the sixth week when compared with the first week and the placebo group as shown
in Table 4.19.
Moreover, fat consumption was 97.35 ± 48.40, 93.62 ± 59.94, 94.27 ± 56.48 and 99.59
± 59.49 grams per day for the ginger, cinnamon, black seed and placebo groups
respectively. Fat consumption did not change significantly during the first six weeks
of the study (P-values > 0.05) for the three treatment groups when compared to the
placebo group and to the baseline results.
Protein consumption did not exceed 105.83 ± 45.40 grams per day for all groups, as
well as did not differ significantly. The P-values of the ginger (P-value=0.264),
cinnamon (P-value=0.839) and black seed (P-value=0.932) groups when compared to
the placebo group and to the baseline results (Table 4.19). This suggests that
participants maintained the same level of macronutrient consumption until the sixth
week of the study period.

Table 4.18: Macronutrients Consumption for the Treatment Groups and the Placebo Group at Midpoint (Mean ± SD)

Ginger group
n=21

Cinnamon group
n=25

Black seed group
n=29

Placebo group
n=22

Calories (kcal)

2516.49 ± 979.85

2454.91 ± 1222.11

2494.93 ± 1118.69

2459.44 ± 1249.48

Carbohydrates (g)

353.96 ± 137.81

349.86 ± 162.91

357.01 ± 149.21

347.13 ± 143.60

Fat (g)

97.35 ± 48.45

93.62 ± 59.94

94.27 ± 56.48

99.59 ± 59.49

Protein (g)

105.83 ± 45.40

102.85 ± 33.80

101.47 ± 32.94

102.64 ± 30.09

Intervention group
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Table 4.19: Macronutrients Consumption for the Treatment Groups and the Placebo Group at Midpoint (Week 6 – Week 0)

Intervention group

Ginger group
n=21

P-value

Cinnamon group
n=25

P-value

Black seed
group n=29

P-value

Placebo group
n=22

Calories (kcal)

16.75 ± 171.03

0.576

24.36 ± 91.49

0.411

6.18 ± 375.33

0.834

5.23 ± 175.18

-4.08 ± 29.70

0.331

-0.53 ± 15.50

0.564

-1.42 ± 83.17

0.962

-6.50 ± 24.78

Fat (g)

3.10 ± 8.78

0.174

-1.52 ± 9.05

0.286

-2.21 ± 17.17

0.812

-2.86 ± 8.88

Protein (g)

2.07 ± 9.68

0.264

-0.36 ± 7.71

0.839

-1.00 ± 16.35

0.932

-1.52 ± 9.34

Carbohydrates (g)

*Significant at P-value ≤ 0.05

142

143
4.2.3.3 Endpoint Dietary Assessment
At the twelfth week, participants consumed 2563.17 ± 965.13, 2474.45 ± 1231.05,
2525.22 ± 1124.20 and 2476.86 ± 1269.73 Kcal per day of their total energy intake for
the ginger, cinnamon, black seed and placebo groups respectively. Carbohydrate
consumption did not exceed 360.31 ± 144.39 grams per day for all four groups and did
not differ significantly for the ginger, cinnamon, black seed groups when compared to
the placebo group and against the baseline results (P-value > 0.05), as shown in Table
4.20 and Table 4.21
Fat consumption was the highest in placebo group (102.74 ± 61.44 grams per day)
while the remaining groups did not exceed 97.25 ± 48.76 grams per day. No significant
difference was detected between the three treatment groups and the placebo group (Pvalue > 0.05). Protein consumption was 104.67 ± 45.18, 101.81 ± 32.32, 100.77 ±
30.64 and 105.12 ± 31.93 grams per day for the ginger, cinnamon, black seed and
placebo groups respectively with no significant difference between the three treatment
groups and the placebo group.
As shown in Table 4.21, there were no significant differences between the treatment
groups for calories, carbohydrates, fat and protein consumption when compared with
the placebo group and against baseline results (P-value > 0.05).
Maintaining the same level of macronutrient consumption is a crucial key to the
success of the study. At the end of the research period, participant who committed to
the study protocol and did not change their macronutrient consumption, were offered
a nutritional consultation to help them manage their calories intake and to improve
their dietary habits.

Table 4.20: Macronutrients Consumption for the Treatment Groups and the Placebo group at Endpoint (Mean ± SD)
Intervention group

Ginger group n=21

Cinnamon group n=25

Black seed group n=29

Placebo group n=22

Calories (kcal)

2563.17 ± 965.13

2474.45 ± 1231.05

2525.22 ± 1124.20

2476.86 ± 1269.73

Carbohydrates (g)

353.03 ± 137.42

351.09 ± 164.80

360.31 ± 144.39

355.25 ± 155.53

Fat (g)

97.25 ± 48.76

95.24 ± 62.07

96.15 ± 57.87

102.74 ± 61.44

Protein (g)

104.67 ± 45.18

101.81 ± 32.32

100.77 ± 30.64

105.12 ± 31.93

Table 4.21: Macronutrients Consumption for the Treatment Groups and the Placebo Group at Endpoint (Week 12 – Week 0)
Intervention
group

Ginger group
n=21

Pvalue

Cinnamon group
n=25

P-value

Black seed group
n=29

P-value

Placebo group
n=22

Calories (kcal)

63.42 ± 214.32

0.296

43.90 ± 123.46

0.201

-49.46 ± 639.02

0.805

22.65 ± 149.25

Carbohydrates
(g)

-5.01 ± 43.41

0.923

0.69 ± 14.94

0.717

-8.12 ± 96.24

0.909

1.62 ± 17.18

Fat (g)

3.00 ± 10.65

0.152

0.09 ± 7.96

0.616

-0.33 ± 12.18

0.819

0.28 ± 13.14

Protein (g)

0.90 ± 7.46

0.382

-1.41 ± 8.47

0.873

-1.71 ± 11.10

0.819

-3.82 ± 22.28

*Significant at P-value ≤ 0.05
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4.2.4 Physical Activity Assessment
Participants were asked to sustain their normal lifestyle and not to change their current
physical activity level, thus reducing the variable effect. To ensure that the participants
did not change any of their physical activity level, a physical activity questionnaire
was collected from the participants on each visit using the international physical
activity questionnaire (IPAQ) [260]. A total of three physical activity questionnaires
were collected from each participant during the study period.
4.2.4.1 Baseline Physical Activity Assessment
At baseline, participants of the ginger, cinnamon and black seed groups were
considered to be inactive as they did not engage in a vigorous physical activity (30
minutes/three times per week) nor any moderate physical activity (five times/per
week). On the other hand, the placebo group was considered to be moderately active,
as the participants were engaged in a moderate physical activity for more than 30
minutes every day of the week (31.2 ± 13.33 minutes every day). However, no
significant difference for moderate activity was considerable between the three
treatment group and the placebo group at baseline (P-value ≥ 0.05). All groups
performed light physical activity for less than 45 minutes per day and participated in a
sedentary activity for around ten hours every day (9.61 ± 2.35. 9.7 ± 2.7, 9.93 ± 2.87
and 9.56 ± 2.24 hours for ginger, cinnamon, black seed and placebo groups,
respectively). Participants spent their sedentary time using electronic devices such as
computers and smartphones, as well as with friends and family. The three treatment
groups had no significant difference in their light physical activity and their sedentary
activity when compared to placebo group (P-value > 0.05) as demonstrated in Table
4.22.

Table 4.22: Physical Activity Assessment at Baseline (Mean ± SD)

Physical Activity Level

Ginger
group
n=21

P-value of
Independent
sample t- test

Cinnamon
group
n=25

P-value of
Independent
sample t- test

Black seed
group
n=29

P-value of
Independent
sample t- test

Placebo
group
n=21

7.38 ± 13.28(b)

0.629

7.4 13 ±
13.85(b)

0.741

7.58 ±
14.244(b)

0.428

7.72 ± 13.33

28.8 ± 30(b)

0.836

28.2 ± 29.4(b)

0.842

28.8 ± 43.8(b)

0.198

31.2 ± 13.33

41.66 ±
23.73(b)

0.981

43.4 ± 21.73(b)

0.657

40.68 ± 22.5(b)

0.293

42.27 ± 22.87

9.61 ± 2.35(b)

0.757

9.7 ± 2.7(b)

0.761

9.93 ± 2.87(b)

0.119

9.56 ± 2.24

Vigorous Physical Activity
(minutes / day)
Moderate Physical Activity
(minutes / day)
Light Physical Activity
(minutes / day)
Sedentary Physical Activity
(hours / day)

*Significant at P-value ≤ 0.05
(a)Mean value differs significantly from placebo group at P-value ≤ 0.05. (b) Mean value does not differ significantly from placebo group at Pvalue ≤ 0.05
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4.2.4.2 Midpoint Physical Activity
At the midpoint, participants of the following three groups: ginger, cinnamon and
placebo were considered to be inactive as they did not engage in a vigorous physical
activity (30 minutes/three times per week) nor any moderate physical activity (five
times per week). No significant difference was detected when comparing the two
treatment groups with the placebo group (P-value ≤ 0.05). On the other hand, the black
seed group was considered to be moderately active, as the participants were engaged
in a daily moderate physical activity (30 ± 58.2 minutes per day). This difference was
not significant as well when compared with the placebo group (P-value=0.701). All
the treatment groups performed light physical activity for less than 45 minutes per day
and had a sedentary activity for around ten hours every day, which were spent in using
electronic devices and spending leisure time with friends and family as shown in Table
4.23. Although there were some changes in the activity of the groups, this change was
not considered to be significant (P-value=0.05). The changes of physical activity
between the treatment groups and the placebo group (week 6 – week 0) did not show
any significant differences, as all P-values were ≥ 0.05 (Table 4.24). This means that
the activity of each group did not change significantly from the starting point of the
study until week six, and the changes in the physical activity in the three treatment
groups were not significantly different from the placebo group.

Table 4.23: Physical Activity Assessment at Midpoint (Mean ± SD)

Physical Activity Level

Ginger group
n=21

Cinnamon group
n=25

Black seed group
n=29

Placebo group
n=22

7.72 ± 12.62

7 ± 13.69

5.34 ± 12.38

7.5 ± 13.07

28.8 ± 34.8

27.6 ± 38.4

30 ± 58.2

28.2 ± 44.4

40.95 ± 20.40

40.6 ± 19.27

38.96 ± 21.79

40 ± 20.93

9.9 ± 2.53

9.92 ± 2.17

10.41 ± 2.52

9.77 ± 1.99

Vigorous Physical Activity
(minutes / day)
Moderate Physical Activity
(minutes / day)
Light Physical Activity
(minutes / day)
Sedentary Physical
Activity
(hours / day)
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Table 4.24: Physical Activity Assessment Differences between Treatment Groups and Placebo Group at Midpoint (Week 6 – Week 0)
Ginger group
Physical Activity Level

Cinnamon group
p-value

n=21
Vigorous Physical
Activity

Black seed group
p-value

n=25

p-value
n=29

Placebo
group
n=22

0.04 ± 3.39

0.694

-0.4 ± 2.46

0.982

-2.24 ± 10.14

0.953

0.04 ± 3.39

0 ± 0.37

0.758

-0.01 ± 0.48

0.482

0.01 ± 0.81

0.701

-0.4 ± 2.46

-0.71 ± 9.52

0.599

-2.8 ± 7.37

0.809

-1.72 ± 9.28

0.556

-2.24 ±
10.1

0.35 ± 1.54

0.678

0.22 ± 1.76

0.785

0.48 ± 1.99

0.742

-0.22 ±
1.06

(minutes / day)
Moderate Physical
Activity
(minutes / day)
Light Physical Activity
(minutes / day)
Sedentary Physical
Activity
(Minutes / day)

*Significant at P-value ≤ 0.05
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4.2.4.3 Endpoint Physical Activity Assessment
At the endpoint, participants of the ginger, cinnamon, black seed and placebo were
considered to be inactive, as they did not engage in a vigorous physical activity (30
minutes/three times per week) nor any moderate physical activity (five times per
week). Mean values of vigorous physical activity level and moderate physical activity
level had no significant differences in the treatment groups when compared to the
placebo group (P-value > 0.05). All groups performed light physical activity for less
than 45 minutes per day (41.42 ± 22.97, 41.4 ± 19.81, 40.68 ± 22.5 and 40.68 ± 20.60
minutes per day for the ginger group, cinnamon group, black seed group and placebo
group, respectively). Moreover, participants had a sedentary activity for around ten
hours every day using their electronic devices and spending leisure time with friends
and family as demonstrated in Table 4.25.
Although there were some minor changes in the activity of the groups (Table 4.25),
the change was not considered to be significant at P-value=0.05. When analyzing the
results of the physical activity differences (week 12 – week 0) between treatment
groups and the placebo group, all P-values were > 0.05 as indicated in Table 4.26. This
means that the activity of each group did not change significantly from the starting
point of the study till the twelfth week, and the changes in the physical activity in the
treatment groups were not significantly different from the placebo group.
Therefore, it is concluded that physical activity level did not change significantly
during the study period.

Table 4.25: Physical Activity Assessment at Endpoint (Mean ± SD)

Physical Activity Level

Ginger group
n=21

Cinnamon group
n=25

Black seed group
n=29

Placebo group
n=22

7.61 ± 13.38

7.4 ± 13.54

7.75 ± 14.67

7.72 ± 13.33

28.2 ± 1.8

28.8 ± 9.4

28.2 ± 13.8

29.9 ± 10.3

41.42 ± 22.97

41.4 ± 19.81

40.68 ± 22.5

40.68 ± 20.60

9.71 ± 2.49

9.92 ± 2.81

9.93 ± 2.8

9.81 ± 2.59

Vigorous Physical Activity
(minutes / day)
Moderate Physical Activity
(minutes / day)
Light Physical Activity
(minutes / day)
Sedentary Physical Activity
(hours / day)
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Table 4.26: Physical Activity Assessment Differences between Treatment Groups and Placebo Group at Endpoint (Week 12 – Week 0)

Physical Activity Level

Ginger group
n=21

p-value

Cinnamon group
n=25

p-value

Black seed group
n=29

p-value

Placebo
group n=22

0.23 ± 3.34

0.545

0.00 ± 2.88

1.00

0.17 ± 0.92

0.384

-3.33 ± 0.24

-0.012 ± 0.16

0.678

0.01 ± 0.19

0.971

-.008 ± 0.1

1.00

0.002 ± 0.11

-0.23 ± 2.94

0.432

-2.00 ± 6.29

0.496

0.00 ± 0.00

0.101

-1.59 ± 6.43

0.09 ± 0.43

0.981

0.22 ± 1.25

0.948

-0.03 ± 0.18

0.499

0.25 ± 1.19

Vigorous Physical Activity
(minutes / day)
Moderate Physical Activity
(minutes / day)
Light Physical Activity
(minutes / day)
Sedentary Physical Activity
(hours / day)

*Significant at P-value ≤ 0.05
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4.2.5 Biochemical Assessment
Vinous blood sample was collected from the participant of the Treatment groups in all
the three visits. Hemoglobin (Hb), glycated hemoglobin (HbA1c), fasting blood
glucose (FBG), total cholesterol, high density lipoprotein (HDL), low density
lipoprotein (LDL) and triglycerides (TG) were analyzed to examine the effect of the
spices powder on hemoglobin, blood glucose and lipid profile.
4.2.5.1 Baseline Biochemical Assessment
At baseline, the mean values of Hb were 13.93 ± 1.87, 14.04 ± 2.28, 14.72 ± 1.78 and
13.78 ± 2.20 g/dL for the ginger, cinnamon, black seed and placebo groups
respectively (Table 4.27). No significant difference was detected when comparing the
treatment groups Hb mean values with the placebo group Hb mean value (P-value >
0.05). HbA1c mean values were all above the cut-off point 5.7% [7]. HbA1c mean
values ranged from 5.91 ± 0.69% for the ginger group to 6.45 ± 1.83% for the
cinnamon group. HbA1c mean values for ginger and cinnamon groups had no
significant difference when compared to the placebo group (P-values > 0.05).
Whereas, black seed group mean value of HbA1c had a significant difference (Pvalue=0.039) when compared to placebo group.
Total blood cholesterol values varied from 121.51 ± 37.95 mg/dL for the placebo
group to 160.86 ± 33.04 mg/dL for the black seed group. All treatment groups mean
value of total cholesterol were significantly different from the placebo group mean
value with a P-value ≤ 0.05 as shown in Table 4.27.
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FBG mean value level approached 100 mg/dL for the cinnamon group (99.06 ± 42.62
mg/dL) and was 82.63 ± 15.03, 93.69 ± 8.47, 89.30 ± 30 mg/dL for the ginger, black
seed and placebo groups respectively. No significant difference was observed when
comparing the treatment groups mean value of FBG to the placebo group mean value.
P-values were 0.259, 0.34 and 0.33 for ginger, cinnamon and black seed, respectively.
The LDL mean value level was 94.28 ± 33.14, 110.32 ± 33.39, 95.52 ± 22.61 and
70.52 ± 28.25 mg/dL for the ginger, cinnamon, black seed and placebo groups,
respectively. Only the ginger group mean value had no significant difference when
compared to the placebo group (P-value=0.15), whilst cinnamon group and black seed
group mean values were significantly different when compared to the placebo group
mean value (P-values=0.00 and 0.001, cinnamon group and black seed group,
respectively).
Furthermore, the average HDL value ranged from 34.71 ± 12.88 mg/dL for the placebo
group to 41.36 ± 12.76 mg/dL for the cinnamon group. No significant difference was
detected when comparing the mean value of the treatment groups to the mean value of
the placebo group (P-values > 0.05).
Moreover, TG mean values were 113.50 ± 91.97, 116.63 ± 79.37, 101.29 ± 33 and
102.34 ± 34 mg/dL for ginger, cinnamon, black seed and placebo group, respectively.
The average values of TG had no significant difference at P-value ≤ 0.05 as shown in
Table 4.27.
As participants were randomly distributed into four treatment groups considering age
and metabolic syndrome criteria (high blood pressure, large waist circumference,
elevated fasting blood glucose, increased triglycerides and low high density
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lipoprotein), some significant differences between treatment groups in the other
parameters were expected at baseline as observed in Table 4.27. If the parameters of
the significant difference at baseline were significantly different at midpoint or
endpoint, further analysis were be taken into consideration.

Table 4.27: Biochemical Assessment of the Treatment Groups and the Placebo Group at Baseline (Mean ± SD)

Intervention group

Ginger group
n=21

P-value of
Independent
sample t- test

Cinnamon group
n=25

P-value of
Independent
sample t- test

Black seed group
n=29

P-value of
Independent sample
t- test

Placebo group
n=22

Hb (g/dL)

13.93 ± 1.87(b)

0.817

14.04 ± 2.28(b)

0.702

14.72 ± 1.78(b)

0.09

13.78 ± 2.20

HbA1c %

5.91 ± 0.69(b)

0.816

6.45 ± 1.83(b)

0.79

5.92 ± 0.59(a)

0.039*

6.33 ± 1.16

Total Cholesterol
(mg/dL)

153.23 ± 47.38(a)

0.02*

158.15 ± 33.19(a)

0.001*

160.86 ± 33.04(a)

0.00*

121.51 ± 37.95

FBG (mg/dL)

82.63 ± 15.03(b)

0.259

99.06 ± 42.62(b)

0.34

93.69 ± 8.47(b)

0.33

89.30 ± 30.00

HDL (mg/dL)

34.81 ± 10.05(b)

1.00

41.36 ± 12.76(b)

0.08

36.81 ± 10.60(b)

0.545

34.71 ± 12.88

LDL (mg/dL)

94.28 ± 33.14(b)

0.15

110.32 ± 33.39(a)

0.00

95.52 ± 22.61(a)

0.001*

70.52 ± 28.25

TG (mg/dL)

113.50 ± 91.97(b)

0.59

116.63 ± 79.37(b)

0.42

101.29 ± 33.00(b)

0.90

102.34 ± 34

*Significant at P-value ≤ 0.05
(a)Mean value differs significantly from placebo group at P-value ≤ 0.05. (b) Mean value does not differ significantly from placebo group at P-value ≤ 0.05
Hb: Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein
cholesterol; TG: Triglyceride
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4.2.5.2 Midpoint Biochemical Assessment
At the sixth week of the intervention, hemoglobin (Hb) mean values did not change
dramatically. Hb mean values were 13.98 ± 1.81, 14.10 ± 2.26, 14.74 ± 1.77 and 13.66
± 2.14 g/dL for the ginger, cinnamon, black seed and placebo groups respectively,
while HbA1c mean values were above the cutoff point (5.7%) for all treatment groups
[7]. HbA1c mean values were 5.73 ± 0.50, 6.21 ± 2.02, 5.8 ± 0.56 and 6.35 ± 1.24%
for the ginger, cinnamon, black seed and placebo groups, respectively. Only cinnamon
group HbA1c mean value were significant when compared to the placebo group mean
values (P-value=0.04). Fasting blood glucose mean values were below 100 mg/dL for
the ginger, cinnamon, black seed and placebo groups 86.00 ± 12.34, 96.21 ± 48.94,
90.72 ± 8.65 and 94.57 ± 19.33 mg/dL, respectively. Fasting blood glucose reduction
was considered significant for ginger group (P-value=0.012), cinnamon group (Pvalue=0.002) and black seed group (P-value=0.001) in comparison with placebo group
at the sixth week of the study.
Lipid profile did not change significantly either. For instance, cholesterol mean values
ranged from 159.06 ± 45.71 for the ginger group to 145.13 ± 38.03 mg/dL for the
placebo group, as shown in Table 4.28. HDL increased remarkably in the black seed
group with a mean value of 41.84 ± 10.76 mg/dL, however the increase was not
considered significant (P-value=0.63). No remarkable changes were noticed in LDL
mean values as well (P-value > 0.05).
Furthermore, TG mean values were reduced significantly in ginger group (108.89 ±
85.09 mg/dL, P-value=0.05), cinnamon group (112.71 ± 84.59 mg/dL, P-value=0.006)
and black seed group (93.58 ± 34.40 mg/dL, P-value=0.000) when compared to the
placebo group as shown in Table 4.28, Table 4.29 and Figure 4.3.

Table 4.28: Biochemical Assessment of the Treatment Groups and the Placebo Group at Midpoint (Mean ± SD)
Ginger group

Cinnamon group

Black seed group

Placebo group

n=21

n=25

n=29

n=22

Hb (g/dL)

13.98 ± 1.81

14.10 ± 2.26

14.74 ± 1.77

13.66 ± 2.14

HbA1c %

5.73 ± 0.50

6.21 ± 2.02

5.58 ± 0.56

6.35 ± 1.24

Total Cholesterol (mg/dL)

159.06 ± 45.71

148.25 ± 29.81

153.79 ± 28.55

145.13 ± 38.03

FBG (mg/dL)

86.00 ± 12.34

96.21 ± 48.94

90.72 ± 8.65

94.57 ± 19.33

HDL (mg/dL)

36.24 ± 9.04

40.89 ± 12.32

41.84 ± 10.76

35.02 ± 13.16

LDL (mg/dL)

98.30 ± 32.17

113.74 ± 30.27

92.12 ± 21.71

86.66 ± 30.09

TG (mg/dL)

108.89 ± 85.09

112.71 ± 84.59

93.58 ± 34.40

91.08 ± 43.49

Intervention group

Hb: Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein
cholesterol; TG: Triglyceride
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Table 4.29: Biochemical Assessment Comparison of the Treatment Groups with the Placebo Group at Midpoint (Week 6 – Week 0)
Parameter

Ginger group
n=21

P-value

Cinnamon
group n=25

P-value

Black seed
group n=29

P-value

Placebo
group n=22

Hb (g/dL)

0.05 ± 0.45

0.074

0.07 ± 0.23

0.063

0.01 ± 0.24

0.092

-0.12 ± 0.17

HbA1c %

-0.18 ± 0.69

0.632

-0.23 ± 0.71

0.04*

-0.12 ± 0.57

0.000

0.22 ± 0.31

Total Cholesterol (mg/dL)

5.83 ± 22.72

0.120

-9.90 ± 27.69

0.396

-7.07 ± 29.71

0.415

23.62 ±
33.76

FBG (mg/dL)

-0.91 ± 5.27

0.012*

-2.85 ± 12.10

0.000*

-2.97 ± 5.85

0.000*

5.26 ± 9.72

HDL (mg/dL)

1.43 ± 4.49

0.128

-0.46 ± 7.97

0.991

4.26 ± 5.83

0.063

6.14 ± 8.98

LDL (mg/dL)

4.02 ± 18.39

0.444

3.42 ± 26.03

0.296

-3.40 ± 21.62

0.831

16.15 ±
23.06

TG (mg/dL)

-4.61 ± 32.78

0.05*

-3.92 ± 31.78

0.006*

-7.71 ± 13.53

0.000*

19.10 ±
25.46

*Significant at P-value ≤ 0.05
Hb: Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein
cholesterol; TG: Triglyceride
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Figure 4.3: The Effect of Spice Powders on Hb, Blood Sugar and Lipid Profile after Six Weeks of the Intervention when Compared to the Placebo Group
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*Significant at P-value ≤ 0.05
Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein
cholesterol; TG: Triglycerides

161
4.2.5.3 Endpoint Biochemical Assessment
At the end point of the study period, participants with significantly abnormal levels of
blood parameters, which were tested during the study, were informed. They were
advised to visit their physician and were offered appropriate advices to help them
manage their blood glucose and lipid profile.
Through the statistical analysis of the data, some data were trimmed due to their
extremely high values in order to normalize the distribution of the data. One participant
had an extremely high cholesterol value in the placebo group, therefore the participant
cholesterol reading was removed (trimmed).
Hb mean values of all groups were in the normal range with mean values ranging from
13.60 ± 2.16 g/dL for the placebo group to 14.69 ± 2.15 g/dL for the black seed group.
HbA1c level was below the cut-off point (<5.7%) [7] for the ginger group (5.62 ±
0.52%) and black seed group (5.56 ± 0.51%). HbA1c decreased dramatically for the
cinnamon group (-0.6 ± 0.94) to reach 5.85 ± 1.65%. The reduction in the mean value
of HbA1c was significant for the cinnamon (P-value=0.003) and black seed (Pvalue=0.009) groups when compared to the placebo group, as illustrated in Table 4.31.
FBG mean values were 79.23 ± 14.12, 97.79 ± 37.64, 86.27 ± 25.24 and 92.40 ± 13.93
mg/dL for the ginger, cinnamon, black seed and placebo group respectively, as shown
in Table 4.30. The decrease in FBG was significant for the ginger, cinnamon and black
seed groups at P-values 0.012, 0.048 and 0.007 respectively, when compared to the
placebo group.
Blood lipid profile had a remarkably improving results in HDL, LDL and TG levels,
although cholesterol level did not change remarkably in the treatment groups. Total
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cholesterol mean value ranged from 129.37 ± 27.31 mg/dL for the placebo group to
157.84 ± 50.42 mg/dL for the cinnamon group. No significant reduction was observed
in the total cholesterol mean values for the treatment groups when compared to placebo
group (P-value > 0.05). HDL mean values increased in all groups at the twelfth week.
HDL mean values were 35.42 ± 9.51, 49.12 ± 18.87, 41.03 ± 17.23 and 36.51 ± 12.09
mg/dL. The increase was considered significant only in the cinnamon group (7.76 ±
13.88 mg/dL, P-value=0.012) when compared to the placebo group.
Mean values of LDL ranged from 76.92 ± 23.26 mg/dL for the placebo group to 96.25
± 22.89 mg/dL for the cinnamon group. LDL mean values decreased in ginger,
cinnamon and black seed groups as shown in Table 4.30 and Table 4.31. This reduction
was only significant in the cinnamon group when compared to the placebo group with
a P-value of 0.004.
LDL mean value of black seed group was significantly different (P-value < 0.001)
from the placebo group mean value at baseline, and placebo group had a lower LDL
mean value than the cinnamon group at baseline as well (Table 4.27). Therefore, a
regression test was conducted at end point of the study to test the relevance of the
significancy of the LDL change in the cinnamon group. The regression test took into
consideration the different treatment groups, LDL mean values at baseline and the
interaction between the treatment and LDL mean values at baseline. For the cinnamon
group, no significant difference was detected (P-value=0.505). This means that the
difference in LDL mean value for the cinnamon group is significant at end point when
compared to placebo group, though there was a significant difference at baseline in the
mean value of LDL of the cinnamon group when compared to placebo group as shown
in Table 4.31.
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Additionally, black seed mean value of LDL at base line was significantly different
(P-value=0.001) from the placebo LDL mean value at baseline as demonstrated in
Table 4.30, nonetheless, no significant difference was detected in the LDL mean
values of the black seed group when compared to the placebo group at endpoint (Pvalue=0.447) as shown in Table 4.31. Therefore, no further analysis was required.
In contrast, TG was reduced remarkably in the ginger, cinnamon and black seed groups
as shown in Figure 4.4. TG mean values were: 95.87 ± 57.99, 112.32 ± 62.76, 93.20 ±
28.56 and 112.67 ± 40.45 mg/dL for ginger, cinnamon, black seed and placebo groups,
respectively. The reduction was significant for the ginger (P-value=0.029), cinnamon
(P-value=0.046) the black seed (P-value=0.001) group when compared to placebo
group as shown in Table 4.31 and Figure 4.4.

Table 4.30: Biochemical Assessment of the Treatment Groups and the Placebo Group at Endpoint (Mean ± SD)
Intervention group

Ginger group n=21

Cinnamon group n=25

Black seed group n=29

Placebo group n=22

Hb (g/dL)

13.98 ± 2.08

14.16 ± 1.83

14.69 ± 2.15

13.60 ± 2.16

HbA1c %

5.62 ± 0.52

5.85 ± 1.65

5.56 ± 0.51

6.37 ± 0.89

Total Cholesterol (mg/dL)

141.74 ± 40.14

157.84 ± 50.42

147.80 ± 55.02

129.37 ± 27.31

FBG (mg/dL)

79.23 ± 14.12

97.79 ± 37.64

86.27 ± 25.24

92.40 ± 13.93

HDL (mg/dL)

35.42 ± 9.51

49.12 ± 18.87

41.03 ± 17.23

36.51 ± 12.09

LDL (mg/dL)

88.97 ± 33.17

96.25 ± 22.89

93.38 ± 30.06

76.92 ± 23.26

TG (mg/dL)

95.87 ± 57.99

112.32 ± 62.76

93.20 ± 28.56

112.67 ± 40.45

Hb: Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density
lipoprotein cholesterol; TG: Triglycerides
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Table 4.31: Biochemical Assessment Comparison of the Treatment Groups with the Placebo Group at Endpoint (Week 12 – Week 0)

Parameter

Ginger group
n=21

P-value

Cinnamon group
n=25

P-value

Black seed group
n=29

P-value

Placebo group
n=22

Hb (g/dL)

0.05 ± 1.48

0.401

0.13 ± 1.85

0.949

-0.03 ± 1.36

0.834

-0.19 ± 0.15

HbA1c %

-0.29 ± 0.72

0.134

-0.60 ± 0.94

0.003*

-0.21 ± 1.18

0.009*

0.04 ± 0.81

-11.49 ± 34.74

0.099

-0.31 ± 43.94

0.565

-13.05 ± 66.52

0.300

7.86 ± 29.76

FBG (mg/dL)

-3.40 ± 8.97

0.012*

-2.27 ± 11.96

0.048*

-7.43 ± 23.87

0.007*

3.10 ± 15.94

HDL (mg/dL)

0.62 ± 6.19

0.375

7.76 ± 13.88

0.012*

4.22 ± 16.85

0.138

1.71 ± 9.42

LDL (mg/dL)

-5.32 ± 22.89

0.950

-14.07 ± 28.92

0.004*

-2.14 ± 38.18

0.447

6.41 ± 18.36

TG (mg/dL)

-17.63 ± 48.73

0.029*

-9.14 ± 67.59

0.046*

-8.08 ± 12.12

0.001*

10.64 ± 36.07

Total Cholesterol
(mg/dL)

*Significant at P-value ≤ 0.05.
Hb: Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein
cholesterol; TG: Triglyceride

165

Hb (g/dL)

HbA1c %

Cholesterol (mg/dL)

FBG (mg/dL)

HDL (mg/dL)

LDL (mg/dL)

TG (mg/dL)

15

10.64
10

7.86

7.76

5

3.1
0.13
0.05

0.62

0.04

6.41
4.22
1.71

0
-5

-0.03
-0.19

-0.29

-0.21
-0.6

-0.31

-2.14

-2.27
-3.4

-5.32
-7.43

-10

-8.08

-9.14

-11.49
-13.05

-15

-14.07
-17.63

-20
Ginger group

Cinnamon group

Black seed group

Placebo group

Figure 4.4: The Effect of Spice Powders on Hb, Blood Sugar and Lipid Profile after Twelve Weeks of the Intervention when Compared to the
Placebo Group
*Significant at P-value ≤ 0.05.
Hb: Hemoglobin; HbA1c: Glycated hemoglobin; FBG: Fasting blood cholesterol; HDL: High density lipoprotein cholesterol; LDL: Low density
lipoprotein cholesterol; TG: Triglycerides
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4.2.6 Further Analysis
The SPSS® program mixed models test of linear equation was applied to find if there
was any effect of the interactions of gender with treatment group, gender with age and
gender with the phase of the research period. Dependent variables were the metabolic
syndrome risk factors: blood pressure (BP), waist circumference (WC), fasting blood
glucose (FBG), high density lipoprotein (HDL) and triglycerides (TG).
Results proves that there was a significant difference in WC (P-value=0.019), HDL
(P-value=0.003) and TG (P-value=0.05) between males and females response to the
intervention in the treatment groups.
Moreover, there was no difference between males and females mean values with age
on WC, FBG, HDL, TG and BP (P-values > 0.05) as demonstrated in Table 4.32. On
the other hand, the difference between males and females mean values of WC, FBG,
HDL and TG over time is significant (P-value < 0.05). This means that the reaction of
males was different from the reaction of females to the treatment at each phase in the
three phases of the research (baseline, midpoint and endpoint).
Table 4.32: Type III Test For Fixed Effect Model Results for Gender Differences
Interaction

WC pvalue

FBG pvalue

HDL pvalue

TG pvalue

Systolic BP Diastolic
p-value
BP p-value

Gender * Group

0.019*

0.07

0.003*

0.05*

0.902

0.871

Gender * Age

0.082

0.09

0.13

0.06

0.681

0.998

Gender * Phase

0.001*

0.000*

0.09

0.042*

0.212

0.843

WC, FBG, HDL, TG and BP are dependent variables
*Significant at P-value ≤ 0.05
WC: Waist circumference; FBG: Fasting blood glucose; HDL: High density lipo
protein cholesterol; TG: Triglycerides; BP: Blood pressure.
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Table 4.33 illustrates the mean values of the difference between males and females
reaction to treatments over 12 weeks of intervention. Table 4.34, Table 4.35, Table
4.36 and Table 4.37 demonstrates the differences between males and females in
reaction to the four treatment groups through the 3 study phases.
Male participants at the ginger group had significantly more elevated systolic blood
pressure at baseline (P-value=0.02), midpoint (P-value=0.000) and endpoint (Pvalue=0.000) when compared to females, while diastolic blood pressure mean value
for males was significantly higher than females only at endpoint (P-value=0.004). WC
mean values of males had a significant difference when compared to females at
midpoint (P-value=0.005) and endpoint (P-value=0.004), where males had higher
mean values. Moreover, FBG mean values of males were significantly higher than
females at baseline (P-value=0.010), with females having a lower FBG. Furthermore,
no significant difference between males and females for HDL mean values were
observed through the study phases (P-value > 0.05). Instead, TG mean value of males
were significantly higher than females at baseline (P-value=0.0.028), midpoint (Pvalue=0.04) and endpoint (P-value=0.015) (Table 4.34).
For the cinnamon group, male participants had significantly higher systolic blood
pressure at baseline (P-value=0.002) and endpoint (P-value=0.001) when compared to
females, while diastolic blood pressure and FBG mean values did not differ
significantly between males and females through the study phases (P-value > 0.05).
WC mean values of males were significantly higher when compared to females at
midpoint (P-value=0.026) and endpoint (P-value=0.021). Moreover, significant
difference between males and females HDL mean values was observed. Females HDL
mean values were significantly higher at baseline (P-value=0.015) and midpoint (P-
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value=0.11). Furthermore, TG mean value of males were significantly higher from the
mean value of females at midpoint (P-value=0.007) and endpoint (P-value=0.001) as
shown in Table 4.35.
In addition, male participants at the black seed group had significantly higher systolic
blood pressure at baseline (P-value=0.012), midpoint (P-value=0.002) and endpoint
(P-value=0.001) when compared to females. Diastolic blood pressure mean value for
males were significantly higher at midpoint (P-value=0.026) and endpoint (Pvalue=0.010). WC mean values of males were significantly higher when compared to
females at baseline (P-value=0.019), midpoint (P-value=0.008) and endpoint (Pvalue=0.017). Furthermore, FBG and TG did not differ significantly between males
and females through the study phases (P-value > 0.05). Moreover, significant
difference between males and females HDL mean values was detected. Females HDL
mean values were significantly higher than males at baseline (P-value=0.030) and
midpoint (P-value=0.031) as Table 4.36 demonstrates.
Male participants of the placebo group had significantly more elevated systolic blood
pressure at baseline (P-value=0.001), midpoint (P-value=0.000) and endpoint (Pvalue=0.002) when compared to females. Diastolic blood pressure, WC, HDL and TG
mean values did not differ significantly between males and females through the study
phases (P-value > 0.05). FBG mean values of males were significantly higher when
compared to females at midpoint (P-value=0.017) and endpoint (P-value=0.016)
(Table 4.37).
Overall, males tended to have a higher systolic blood pressure, diastolic blood
pressure, WC, FBG, LDL and TG mean value levels than females in all treatment
groups. While females were more likely to have higher HDL mean values than males.

Table 4.33: Difference between Males and Females Reaction to Treatments Over 12 Weeks of Intervention (Mean ± SD)
Ginger group

Cinnamon Group

Black seed Group

Control group

Males

Females

(M-F)

Males

Females

(M-F)

Males

Females

(M-F)

Males

Females

(M-F)

Systolic
BP
(mmHg)

127.55 ±
12.88

108.83 ±
7.37

18.72

126 ±
12.68

107.81
± 11.95

18.19

127.88
± 16.19

106.5 ±
12.28

21.38

132.27
± 9.11

112.81 ±
15.84

19.46

Diastolic
BP
(mmHg)

86 ± 9.11

74.41 ± 7.3

11.59

81.66 ±
10.59

75.62
±9.87

6.04

86.85 ±
15.31

73.22 ±
10.16

13.63

82.90 ±
9.65

78.54 ±
13.62

4.36

WC (cm)

109.22 ±
14.8

91.83 ±
9.67

17.39

97.29 ±
9.78

85 ±
12.85

12.29

107.07
± 20.89

78.48 ±
29.07

28.59

105.48
± 12.44

99.24 ±
11.78

6.24

FBG
(mg/dL)

85.34 ±
17.6

74.64 ±
9.13

10.7

112.52 ±
39.80

89.49 ±
34.89

23.03

94.96 ±
6.80

82.35 ±
29.44

12.61

92.94 ±
17.54

80.68 ±
12.50

12.26

HDL
(mg/dL)

34.07 ±
6.7

36.43 ±
11.35

-2.36

41.46 ±
9.88

53.42 ±
21.51

-11.96

43.61 ±
6.98

39.87 ±
20.30

3.74

33.97 ±
9.20

39.04 ±
14.41

-5.07

TG
(mg/dL)

130.07 ±
69.79

76.21 ±
29.94

53.86

162.48 ±
58.75

84.09 ±
45.84

78.39

92.18 ±
32.23

93.66 ±
27.63

-1.48

94.43 ±
56.37

70.81 ±
42.78

23.62

(M-F): Males - Females
WC: Waist circumference; FBG: Fasting blood glucose; HDL: High density lipoprotein cholesterol; TG: Triglycerides; BP: Blood pressure.
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Table 4.34: Differences between Males and Females Reaction to Ginger Powder Treatment through the Intervention Three Phases.
Baseline

Midpoint

Endpoint

Males

Females

(M-F)

Pvalue

Males

Females

(M-F)

P-value

Males

Females

(M-F)

P-value

Systolic
BP
(mmHg)

131.77 ±
15.74

109.5 ±
12.66

22.27

0.02*

128.88 ±
12.82

106.25 ±
8.76

22.63

0.000*

127.55 ±
12.88

108.83 ±
7.37

18.72

0.000*

Diastolic
BP
(mmHg)

88.77 ±
1231

79.5 ±
13.29

9.27

0.113

84.11 ±
12.82

74.08 ±
7.65

10.03

0.037*

86 ± 9.11

74.41 ±
7.3

11.59

0.004*

WC (cm)

114 .9±
14.16

98.3 ±
11.36

16.7

0.007

111.48 ±
15.06

93.69 ±
10.35

17.79

0.005*

109.22 ±
14.8

91.83 ±
9.67

17.39

0.004*

FBG
(mg/dL)

91.94 ±
16.15

75.65 ±
9.84

16.29

0.010*

92.68 ±
12.77

80.99 ±
9.7

11.69

0.014

85.34 ±
17.6

74.64 ±
9.13

10.7

0.085

HDL
(mg/dL)

35 ±
6.48

34.65 ±
12.37

0.35

0.940

35.1 ±
6.78

34.7 ±
12.37

0.4

0.940

34.07 ±
6.7

36.43 ±
11.35

-2.36

0.585

TG
(mg/dL)

163.24 ±
116.79

76.18 ±
36.89

87.06

0.028*

152.24 ±
111.93

76.37 ±
36.89

75.87

0.040*

130.07 ±
69.79

76.21 ±
29.94

53.86

0.015*

(M-F): Males – Females
*Significant at P-value ≤ 0.05
WC: Waist circumference; FBG: Fasting blood glucose; HDL: High density lipoprotein cholesterol; TG: Triglycerides; BP: Blood pressure
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Table 4.35: Differences between Males and Females Reaction to Cinnamon Powder Treatment through the Intervention Three Phases
Baseline

Midpoint

Endpoint

Males

Females

(M-F)

P-value

Males

Females

(M-F)

P-value

Males

Females

(M-F)

P-value

Systolic
BP
(mmHg)

133.77
± 15.02

114.87 ±
11.58

18.9

0.002*

122.22
± 11.30

112.18 ±
12.98

10.04

0.058

126 ±
12.68

107.81 ±
11.95

18.19

0.001*

Diastolic
BP
(mmHg)

83.33 ±
8.84

80.25 ±
12.52

3.08

0.522

83.88 ±
5.55

77.37 ±
9.74

6.51

0.080

81.66 ±
10.59

75.62
±9.87

6.04

0.166

WC (cm)

101.81
± 10.83

93.60 ±
14.65

8.21

0.156

98.42 ±
10.45

85.81 ±
13.79

12.61

0.026*

97.29 ±
9.78

85 ±
12.85

12.29

0.021*

FBG
(mg/dL)

113.86
± 47.51

90.72 ±
38.69

23.14

0.199

108.08
± 46.27

89.52 ±
50.57

18.65

0.364

112.52 ±
39.80

89.49 ±
34.89

23.03

0.145

HDL
(mg/dL)

33.34 ±
8.25

45.87 ±
12.79

-12.53

0.015*

38.44 ±
7.65

47.9 ±
11.56

-9.46

0.011*

41.46 ±
9.88

53.42 ±
21.51

-11.96

0.131

TG
(mg/dL)

`158.49
± 104.9

93.08 ±
50.66

0.109

170.38
±
106.39

80.27 ±
47.88

90.11

0.007*

162.48 ±
58.75

84.09 ±
45.84

78.39

0.001*

65.41

(M-F)=Males - Females
*Significant at P-value ≤ 0.05
WC: Waist circumference; FBG: Fasting blood glucose; HDL: High density lipoprotein cholesterol; TG: Triglycerides; BP: Blood pressure
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Table 4.36: Differences between Males and Females Reaction to Black Seed Powder Treatment through the Intervention Three Phases
Baseline

Midpoint

Endpoint

Males

Females

(M-F)

P-vale

Males

Females

(M-F)

P-value

Males

Females

(M-F)

P-value

Systolic
BP
(mmHg)

127.44 ±
15.36

110.1 ±
16.28

17.44

0.012*

129.22 ±
14.58

108.1 ±
15.03

21.12

0.002*

127.88
± 16.19

106.5 ±
12.28

21.38

0.001*

Diastolic
BP
(mmHg)

78.88 ±
11.64

75.75 ±
14.34

3.13

0.570

83.77 ±
11.75

72.25 ±
12.37

11.52

0.026*

86.85 ±
15.31

73.22 ±
10.16

13.63

0.010*

WC (cm)

109.77 ±
22.71

93.58 ±
12.47

16.19

0.019*

107.70 ±
21.49

90.5 ±
11.05

17.2

0.008*

107.07
± 20.89

78.48 ±
29.07

28.59

0.017*

FBG
(mg/dL)

95.80 ±
7.81

92.74 ±
8.77

3.06

0.378

93.14 ±
6.79

89.63 ±
9.31

3.51

0.320

94.96 ±
6.80

82.35 ±
29.44

12.61

0.219

HDL
(mg/dL)

30.54 ±
7.72

39.62 ±
10.64

-9.08

0.030*

35.74 ±
5.27

39.72 ±
16.74

-3.98

0.031*

43.61 ±
6.98

39.87 ±
20.30

3.74

0.597

TG
(mg/dL)

`96.14 ±
31.35

103.60 ±
34.24

-7.46

0.572

88.57 ±
34.91

95.83 ±
34.82

-7.26

0.612

92.18 ±
32.23

93.66 ±
27.63

-1.48

0.900

(M-F)=Males - Females
*Significant at P-value ≤ 0.05
WC: Waist circumference; FBG: Fasting blood glucose; HDL: High density lipoprotein cholesterol; TG: Triglycerides; BP: Blood pressure
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Table 4.37: Differences between Males and Females Reaction to Placebo Treatment through the Intervention Three Phases
Baseline

Midpoint

Endpoint

Males

Females

(M-F)

Pvalue

Males

Females

(M-F)

P-value

Males

Females

(M-F)

P-value

Systolic
BP
(mmHg)

133.09 ±
14.11

111.90 ±
12.09

21.19

0.001*

129.9 ±
12.62

110.18
± 71.09

19.72

0.000*

132.27
± 9.11

112.81 ±
15.84

19.46

0.002*

Diastolic
BP
(mmHg)

85.36 ±
9.88

78.36 ±
8.12

7

0.085

80.18 ±
8.63

71.09 ±
18.07

9.09

0.148

82.90 ±
9.65

78.54 ±
13.62

4.36

0.396

WC (cm)

106.03 ±
12.35

98.12 ±
10.54

7.91

0.122

105.46 ±
12.95

97.21 ±
11.07

8.25

0.124

105.48
± 12.44

99.24 ±
11.78

6.24

0.241

FBG
(mg/dL)

85.99 ±
33.37

70.52 ±
16.12

15.47

0.232

104.8 ±
21.9

83.24 ±
12.36

21.56

0.017*

92.94 ±
17.54

80.68 ±
12.50

12.26

0.016*

HDL
(mg/dL)

30.93 ±
8.07

38.67 ±
15.82

-7.74

0.164

31 ± 8.51

38.77 ±
17.2

-7.77

0.189

33.97 ±
9.20

39.04 ±
14.41

-5.07

0.337

TG
(mg/dL)

90.65 ±
21.6

69.87 ±
33.19

20.78

0.872

113.45 ±
36.61

68.70 ±
39.09

44.75

0.509

94.43 ±
56.37

70.81 ±
42.78

23.62

0.688

(M-F)=Males - Females
*Significant at P-value ≤ 0.05
WC: Waist circumference; FBG: Fasting blood glucose; HDL: High density lipoprotein cholesterol; TG: Triglycerides; BP: Blood pressure
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4.2.7 Discussion and Conclusion
This study is the first to examine the effect of ginger, cinnamon and black seed powder
on individuals at high risk of developing cardiovascular disease in the United Arab
Emirates. It is also one of the few studies to have measured the effect of ginger,
cinnamon and black seed powder on people who are at risk of developing heart
diseases and have two or three out of five metabolic syndrome risk factors.
Ginger, cinnamon and black seed powder effect on MetS risk factors and body
compositions was thoroughly investigated in the undertaken study. Among the three
spices, only cinnamon had a significant effect on body composition (PBF, BFM and
weight) and HDL. While all of the three spices had a positive significant effect on
FBG, TG and WC. However, none of the three spices had a significant effect on
systolic and diastolic blood pressure.
The findings from the current study indicate that the consumption of 3 g/day of ginger
powder for 12 weeks in individuals at risk of CVD significantly reduced WC (Pvalue=0.000), FBG (P-value=0.012) and TG levels (P-value=0.046).
Jafarnemjad and colleagues published a meta-analysis and concluded that ginger
supplementation (tablet, capsules, powder or rhizomes) significantly lowered FBG and
TG, and significantly improved HDL [183]. Moreover, a randomized double-blinded
placebo clinical trial explored the effect of two grams of ginger powder on 40 obese
women. Their findings revealed a slight but non-significant positive effect of ginger
powder supplementation on serum blood glucose a significant effect on TG levels
when compared to placebo [184].
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The glyceamic effect of ginger is believed to be due to its high content of gingerols,
paradols and shogaols. 6-Paradol and 6-Shogaol are chemicals present in ginger that
give the ginger its pungent smell and taste. In 2017, Wei et al. published a research
stating that 6-paradol and 6-shogaol stimulated glucose use by adipocytes and
myotubes in a high fat diet fed mouse. The effects were credited to the upsurge in 50
adenosine monophosphate-activated protein kinase (AMPK) phosphorylation that are
found in adipocytes [151]. In addition, Li et al. concluded that the activity of (S)-(8)gingerol was correlated with an incline in surface distribution of glucose transporter
type 4 (GLUT4) protein, a protein which enhances the glucose uptake and insulin
sensitivity [152].
Ginger was believed to lower lipid levels due to its ability to increase pancreatic lipase
and amylase [346]. Furthermore, ginger consumption inhibits lipid hydrolyze in
intestines, which results in a lower lipid absorption and therefore a lower lipid profile
[347]. Moreover, findings of Hashimoto et al. concluded that 6-shogaol, found in
ginger, increases intestinal efficient movement which could contribute to the
improvement of lipid profile levels [348, 349].
Fuhrman et al. reported that the ingestion of 250 mg/day of ginger extract for 10 weeks
reduced the TG levels and that ginger extract lowers total cholesterol levels and
inhibits LDL oxidation, hence improves lipid profile and lowers risk for CVD [350,
351]. In contrast, Bhandari et al. examined the effect of ginger extract on cholesterol
fed rabbits for 10 weeks and reported that ginger reduced total cholesterol and
triglycerides level in blood, while the reduction was only significant for the
triglycerides [352]. Similarly, Verma et al. examined the effect of daily consumption
of four grams of ginger powder on rabbits for three months. Their work showed that

177
ginger powder had no effect on reducing total cholesterol, LDL and triglycerides [353].
Findings of the current study were consistent with the studies of Jafarnemjad et al.,
Attari et al., Fuhrrman et al. and Bhandari et al. [183, 184, 350, 352, 353]. However,
different from Verma et al.
Findings of the current study confirmed that ginger, cinnamon and black seed reduced
WC (-6.17 ± 4.10, -7.13 ± 4.93 and -10.56 ± 26.47 cm, respectively) significantly
without any significant reduction in weight or BFM. Ginger and cinnamon also
increased SMM (2.18 ± 5.73 and 0.12 ± 0.99 kg, respectively), however the difference
was not significant at P-value > 0.05. This slight increase in SMM could explain the
stability in the body weight of the participants in ginger group, regardless the reduction
in WC.
High fat mass in the upper body portion is significantly correlated with higher serum
glucose [354]. While, decreased levels of serum glucose were significantly associated
with lower abdominal fat accumulation [355]. Therefore, the lower level of fasting
blood glucose in our recent findings could be behind the lower waist circumference.
Moreover, Feldman et al. found that diabetics, especially females had a significant
shift toward central accumulation of fat due to male/ female hormonal imbalances,
causing the typical masculine centripetal fat distribution and therefore increasing the
waist circumference [356]. It is suggested that the decrease in FBG in the recent study
findings caused a correction in male/ female hormonal imbalances and consequently
lead to the redistribution of fat from centripetal to peripheral without affecting the total
BFM. To further analyze this observation, it is recommended that further studies
should examine into details the fat distribution after consuming ginger, cinnamon and
black seed powder. Moreover, participants in this study reported a positive feedback
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regarding better bowel movement, less bloating and a relief from distention after
consuming spice powder, consistent with findings of Hashimoto et al., Harada et al.
and Randhawa et al. [348, 357, 358]. This would lead to a lower WC measurements,
as a bloated abdomen can measure more than a flat relieved abdomen [359, 360].
Furthermore, the current research study concluded that the consumption of 3 g/day of
cinnamon powder for 12 weeks resulted in a significant decrease in WC (P-value <
0.001), BFM (P-value=0.001), weight (P-value=0.011), BMI (P-value=0.001), PBF
(P-value=0.027), HbA1c (P-value=0.003), FBG (P-value=0.048), LDL (Pvalue=0.004) and TG (P-value=0.046). Additionally, a significant increase in mean
HDL mean value was observed (P-value=0.012).
In 2006, Ziegenfuss et al. concluded that ingestion of 500 mg/day of cinnamon extract
for 12 weeks led to improvement in FBG and body composition [15]. Another study
by Khan et al. (2003), examined the effect of cinnamon when given in three different
doses for three different groups (group 1 (1 g/day), group 2 (3 g/day) and group 3 (6
g/day)) of diabetic people for 40 days. Their study showed that cinnamon powder
significantly decreased FBG, total cholesterol, triglycerides and LDL levels [144]. On
the other hand, a meta-analysis of randomized controlled trials of cinnamon conducted
by Baker et al. concluded that cinnamon consumption did not significantly improve
HbA1c or FBG [185]. A meta-analysis for 10 randomized controlled trials that
observed the effect of ingesting cinnamon in a dose of 120 mg/day to 6 g/day for 4
months, on a total of 543 diabetic patients has proven that consuming cinnamon led to
a significant reduction in the levels of FBG, total cholesterol, LDL, and triglyceride
and an improvement in HDL levels. However, cinnamon had no significant effect on
HbA1c [186]. On the contrary, a randomized controlled trial conducted by Crawford
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et al. to examine the effect of consuming 1 gram per day for 90 days on diabetics
resulted in a significant lower HbA1c levels [361]. The current study findings are
consistent with Ziegenfuss et al., Khan et al., Allen et al. and Crawford et al. findings.
However, Baker et al. study findings were not in agreement with the findings of the
current study.
Cinnamaldehyde and cinnamic acid, found in cinnamon, play an important role in
preventing CVD as they both have the ability to produce nitric oxide and both have
anti-inflammatory effect [156]. Camacho and his colleagues examined the effect of
cinnamon on obese mice for five weeks with a diet containing cinnamaldehyde.
Camacho et al. found that cinnamaldehyde significantly decreased body weight
increase and enhanced glucose tolerance [362]. Similarly, Saifudin et al. stated that
cinnamaldehyde inhibited protein tyrosine phosphatase-1B (PTP-1B), which helped in
preventing type 2 diabetes and obesity. In addition, a recent study (2016) proved that
cinnamon supplementation reduced only the insulin resistance index. [363].
Furthermore, an earlier study (2012), suggested that cinnamon could have a positive
effect on normalizing postprandial glucose response in normal weight and obese adults
and, in turn assist will help in weight management [203]. Similarly, another study
examined cinnamon’s effect on insulin sensitivity in diabetic adults demonstrated
significant improvement of FBG, lipid profile, blood pressure, body fat percent, with
an elevation in lean body mass [158]. A double blind, randomized, placebo controlled
clinical trial conducted on 44 diabetic patients who consumed three grams per day of
cinnamon supplement for 8 weeks reported that cinnamon supplement significantly
decreased the levels of fasting blood glucose, HbA1c, triglyceride, weight, BMI and
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body fat mass when compared to baseline, however, this finding was not significant
[364].
Cinnamon stimulates glucose uptake by regulating the expression of GLUT4 and by
acting as an insulin mimetic that leads to the stimulation of the translocation of GLUT4
and therefore a reduction in blood glucose levels [365, 366]. Moreover, polyphenols,
found in cinnamon improve insulin sensitivity and this effect could help in controlling
blood glucose level [158]. Jarvill et al. concluded that cinnamon extracts activate
insulin receptor kinase and inhibits dephosphorylation of insulin receptors, causing
maximal phosphorylation of the insulin receptors. This phosphorylation is associated
with improved insulin sensitivity, and linked to improved lipid profile and glyceamic
response [366]. Moreover, cinnamon have the ability to inhibit hepatic reductase
activity, hence lower lipid profile [136].
Additionally, chromium (Cr) and polyphenols found in cinnamon have significant
effects on insulin signaling and glucose control. Cr was shown to improve all
metabolic syndrome risk factors signs in human participants and decreases cortisol
concentration [367], which is important for weight management, as it increases insulin
circulation and fat accumulation [368]. Therefore, consuming cinnamon supplements
may reduce PBF, BFM, WC and body weight. A meta-analysis published in 2003
reported a significant reduction in body weight caused by Cr supplements consumption
[369]. Similarly, Anderson et al. reported that 500 mg of water-extract
supplementation of cinnamon for 6 weeks lowered fasting blood glucose, total
cholesterol and LDL, and enhanced insulin sensitivity of diabetic individuals [370].
Findings of Jarvill et al. and Anderson et al. are in agreement with the findings of the
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current research study [366, 370]. Previous studies findings are in agreement with the
finding of the current study when administrated in similar dosage and duration.
Findings of this current study concluded that ingesting 3 g/day of black seed powder
for 12 weeks significantly reduced WC (P-value=0.000), HbA1c (P-value=0.009),
FBG (P-value=0.007) and TG (P-value=0.001) when compared to placebo group.
Earlier research concluded that black seed oil contains the major bioactive component,
thymoquinone (TQ) at 30% - 48% [142], a chemical compound known for its
therapeutic potential. Most of the positive effects of black seed on health are believed
to be due to TQ as it inhibits the electrogenic intestinal absorption of glucose and
therefore improves glucose levels [371]. The fixed oil of the black seed accompanied
with TQ supplements had anti-eicosanoid and antioxidant activity, which can inhibit
eicosanoid generation and therefore lower lipid profile [372].
A study by Heshmati et al. showed that supplementation of 3 g/day of black seed oil
changed significantly the FBG and HbA1c, total cholesterol, TG, HDL and LDL levels
in the blood in the intervention group after 12 weeks [187]. In addition, multiple
researchers have reported that black seed has anti-diabetic and hypoglycemic activity
as the components of black seed decreases oxidative stress and thus preserve the
pancreatic beta cell integrity [189].
Similarly, other research has confirmed that the black seed improves lipid profiles
significantly [189, 198]. For example, studies by Heshmati and Namazi showed that 1
g/day of black seed powder for 12 weeks increased HDL levels and 2 g of black seed
powder decreased total cholesterol, LDL concentrations and TG levels [198]. A
randomized controlled trial was conducted by Ibrahim et al. (2014), to examine the
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effect of black seed consumption on menopausal women for 2 months. The study
reported an improvement in the lipid profile (decrease in total cholesterol, LDL and
TG and an elevation in HDL levels) [199]. In addition, a double blind randomized
controlled study undertaken by Amin et al. (2015). In this case, intervention group
received two g/day of black seed for the duration of four weeks. The study confirmed
the significant effect of black seed on lowering total cholesterol, LDL and TG levels.
Reduction of TG is a result of the presence of nigellamin that act like a clofibrate
(hypolipidimic agent) [373].
Additionally, this study concluded that there was a decline in total cholesterol and LDL
levels when consuming ginger and black seed powder. While, the reduction was not
significant, it is still could be explained throughout the antioxidative action of
thymoquinone in black seed and gengerols and shogaols in ginger [374, 375]. The
reduction could also be due to the ability of black seed to increase the secretion of
cholesterol in the bile and hence excretion in feces [376] and lowering the total
cholesterol level in the blood.
In contrast, Najmi et al. tested the effect of black seed consumption on body
composition, WC, lipid profile and blood glucose. 60 participants at risk for CVD,
consumed 2.5 mg of black seed oil twice daily for six weeks. This study reported that
only FBG, total cholesterol and LDL levels reduced significantly, while black seed oil
had no significant effect on body composition, nor WC [16]. Another study conducted
by Shah et al. tested the effect of black seed on metabolic syndrome risk factors and
reported a significant improvement on HDL, LDL and FBG, while it had no significant
effect on blood pressure, TG and WC [195]. Previous studies are consistent with the
findings of this current study when administrated in similar dosage and duration.
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The increase in body weight, FBG, cholesterol, LDL and TG measurements in the
placebo group when compared to the spice groups, could be due to the increase in
dietary consumption of fat among the same group. However, the mentioned increase
was not statistically significant. Correspondingly, previous studies reported the
positive correlation between fat consumption and body weight, lipid profile, blood
sugar and WC [377-379].
Moreover, corn starch that was used for the placebo group and administered in small
amounts (3 grams per day), was proved to have no significant effect in body weight,
FBG, cholesterol, LDL and TG according to earlier research findings [299, 380].
Therefore, the increase in the placebo group measurements mentioned above was not
due to the corn starch consumption
Moreover, there was a significant difference in WC (P-value=0.019), HDL (Pvalue=0.003) and TG (P-value=0.05) between males and females in the response to
the intervention in the treatment groups. Males tend to have a higher BP, WC, FBG
and TG through the intervention period in all the treatment groups, while females had
an increased level of HDL when compared to males. These differences could be due
to the tendency for males in general to have a higher blood pressure than females [381].
A previous study emphasized that elevated WC in males is correlated with increased
BP in males than in females [382]. On the other hand, an earlier study concluded that
impaired fasting glucose incidence is more common in males than in females [383].
Another study indicated that adult females have better metabolism of blood glucose
than males, therefore better glyceamic control [384]. A systematic review discussed
gender differences and their role in cardiovascular diseases and found that higher
abdominal fat motivates increased synthesis of very low density cholesterol (VLDL)
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that leads to higher levels of triglycerides in males than females, which increases the
possibility of abnormalities in males lipid profile [385]. These previous studies in
agreement with our findings in terms of higher levels of fasting blood glucose in males
than in females. Together, all of these factors increase the possibility of higher
incidence of cardiovascular diseases in men than in women [385]. Therefore, a study
that examines the effect of the treatment groups for each gender separately is
recommended.
Previous studies investigated the effect of ginger, cinnamon and black seed powder on
CVD risk factors using different dosage. Dosage of these spices varied from 1 gram
per day to 3 grams per day [182, 198], while the duration varied from 6 weeks to 16
weeks [182, 192]. Mahluji et al. reported no significant effect of ginger powder on
FBG, TG, HDL and HbA1c when investigating the effect of 2 g/d of ginger for 12
weeks on blood glucose and lipid profile [182]. In contrast, Arablou et al. assessed the
effect of 1.6 g/day of ginger powder for 12 weeks on inflammatory markers, blood
glucose and lipid profile to find that ginger powder decreased FBG, HbA1c, TG, total
cholesterol and CRP significantly, while it had no significant effect on HDL and LDL
[386]. Moreover, Mozaffari and his colleagues proved that the consumption of 3 g/day
of ginger powder for 8 weeks exhibited a significant decrease in FBG and HbA1c,
while no significant effect was noted for weight and BMI [139]. Similarly, cinnamon
had a significant effect only on FBG when ingested in 3 g/day for 16 weeks, though,
no significant effect was reported in terms of HbA1c and lipid profile as Mang et al.
reported [136]. A study conducted by Vanschoonbeek et al. concluded that the
consumption of 1.5 g/day of cinnamon powder for 6 weeks had no significant effect
on FBG nor lipid profile [387]. Moreover, Akilen et al. reported a significant effect of
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cinnamon powder when consumed in 2 g/day for 12 weeks in HbA1c and blood
pressure. While WC, FBG, weight, BMI and lipid profile demonstrated no significant
difference [193]. On the other hand, black seed powder was proved to show a
significant effect on FBG, HbA1c, TG and HDL when consumed in 3 g/day for 12
weeks. However, it exhibited no significant effect on total cholesterol and HDL as
Hashmati et al. reported. In contrast, Qidwai et al. examined the effect of 1 g/day of
black seed powder for 6 weeks on blood glucose, lipid profile, WC and blood pressure
and concluded there was no significant effect of black seed powder on the previously
mentioned parameters [204]. Previous studies that administrated less than 12 weeks or
less than 2 grams of the spice powder in their intervention, recommended longer
interventional periods and a higher dose of the spice powders to exhibit a significant
effect of spice powders consumption on lipid profile, blood glucose, WC and body
composition (weight, PBF and BMI) [139, 193, 198, 386, 387].
In contrast, ginger, cinnamon and black seed powder have been found to have a reverse
health effects when consumed in large amounts, however, toxicity, irritation, diarrhea,
inflammation and damage can be caused due to misuse of these spices [388, 389].
Safety and tolerability of ginger, cinnamon and black seed was proved when consumed
in 3 g/day in previous studies [204, 390, 391].
Therefore, to increase the possibility of achieving significant findings in this current
study and to assure safety, 3 grams per day of the treatment for 12 weeks were
administered.
Moreover, due to hormonal and body composition differences between males and
females [392], different reaction to treatments was observed in the undertaken study
over time. Considering that males had higher WC, BP, TG and FBG measurements
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when compared to females, the duration or dose of the treatment could be modified for
each gender, as males and females have a different cut-off points (WC and HDL) [36].
Strengths and limitations of this study also should be noted. As strength points, this
study was done on human sample rather than animals and thus the results reflect the
effect on human directly, subjects were from both genders and different adult ages,
both dietary intake and physical activity level were taken into consideration to not be
changed during the study so as to show the effect of spices powder only, and body
composition was measured by (In body 720 and DEXA) to monitor body changes. As
for limitations, randomization of the participants into four groups was applied during
the screening phase which took into consideration the age and the diagnostic criteria
of the MetS only without the inclusion of all the measured parameters. Consequently,
significant differences in some of the parameters (that were not part of the screening)
at baseline were observed. Such differences were impossible to avoid between
treatment groups and placebo group after randomization at baseline.
Additionally, self-reporting of food intake and physical activity was considered as a
limitation. Some of participants were either under/overestimating their food intake and
physical activity levels, which were mainly due to difficulty in recalling these
information. Moreover, participants were not familiar with food portion sizes, which
took more time for explanations by the researcher in order to ensure correct record of
information in the food dairy record. The stability in body fat mass, percent body fat
and body weight with significant change in WC for ginger and black seed group,
maybe contributed to fat redistribution Therefore, exact explanation for WC reduction
was not accurate due to lack of fat redistribution measures.
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In conclusion, previous studies findings are in consistence with our recent study
results. This study indicates that consumption of three g/d of ginger, cinnamon and
black seed powders daily for 12 weeks, had a significant effect on improving WC,
body composition, blood glucose and lipid profile.
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Chapter 5: Summary and Recommendations
5.1 Summary
The number of deaths caused by non-communicable diseases (NCDs) is increasing
worldwide according to the World Health Organization (WHO). In 2015, 70% of
global deaths were caused by NCDs, where the majority were caused due to the
complications from the main four NCDs; namely cardiovascular diseases (CVDs),
cancers, diabetes and chronic lung diseases [1].
Of these four, the highest cause of death is CVDs. Of 40 million NCD deaths annually,
17.7 million (45%) are attributed to CVDs [1], with the main cause attributed to
obesity, type 2 diabetes, hypertension and high blood lipids [2-4].
Metabolic Syndrome (MetS) is a combination of medical illnesses that consists of,
high fasting blood glucose (FBG), high blood pressure, central obesity, elevated blood
triglycerides (TG), increased blood low density lipoprotein (LDL) and decreased blood
high density lipoprotein (HDL) [5]. The diagnostic criteria of MetS are controversial,
although all definitions agreed on three common characteristics namely, decreased
HDL, elevated blood pressure and increased insulin resistance [5-7]. MetS
management aims to reduce the risk of clinical factors that could lead to CVDs.
Changing lifestyle could help in treating and improving the quality of life of people at
risk of CVDs [8, 9].
The dietary factor includes improving the nutritional habits of an individual’s diet.
Reducing fat intake in the diet and managing the carbohydrate intake could improve
blood glucose, insulin sensitivity and blood lipids [10, 11]. On the other hand, herbal
therapy is broadly used in many countries as a treatment or as a preventive measure to
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manage cardiovascular diseases risk factors, including, blood glucose, blood pressure
and blood lipids [12-16].
In order to understand the positive effect of herbs and spices on people at risk for
CVDs, chemical analysis could help in breaking down the components of individual
spice and understand the nutritional value of each.
Moreover, spices such as Ginger (Zingiber officinale), Cinnamon (Cinnamomum),
black seed (Nigella sativa), fenugreek (Trigonella foenum graecum), cardamom
(Elettaria cardamomum), cloves (Eugenia aromaticum) and saffron (Crocus sativus)
were examined in prior studies that demonstrated a positive effect of spices on blood
glucose, body composition, lipid profile, inflammation markers, tumor necrosis and
the level of oxidation in blood and tissues. These positive effects were due to the
availability of active compounds and their higher content of vitamins and minerals
[17-23]. Therefore, the current research study chemically analyzed the above seven
spices to understand their effects on health and to explore the possibility of their usage
as supplements in the management of CVDs risk factors.
The effect of spice consumption (ginger, cinnamon and black seed) on blood glucose,
lipid profile, WC and body composition in people at risk for cardiovascular diseases
was investigated for a period of 12 weeks. The investigation concluded that
consumption of 3 grams per day of ginger, cinnamon and black seed powders daily for
12 weeks, had a significant effect on improving WC, body composition, blood glucose
and lipid profile.
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Summary of the key outcomes of the two studies of this dissertation is listed below:
1- Macronutrients and lipid composition analysis of ginger (Zingiber officinale),
cinnamon (Cinnamomum), black seed (Nigella sativa), fenugreek (Trigonella
foenum graecum), cardamom (Elettaria cardamomum), cloves (Eugenia
aromaticum) and saffron (Crocus sativuswere) was relatively consistent with
previous research. While micronutrient and sugar content of the spices were not in
agreement with the findings from previous published assessments.
2- When analyzing ginger powder for gingerols and shogaols, 6-shogaols had the
highest value followed by 6-gingerols and 8-gingerols 56.10, 30.21, 7.92 mg/100
g respectively.
3- Consumption of 3 g/day of ginger powder for 12 weeks for people at risk of CVD
has significantly reduced WC (P-value=0.000), FBG (P-value=0.012) and TG
levels (P-value=0.046).
4- Consumption of 3 g/day of cinnamon powder for 12 weeks for people at risk of
CVD has resulted in a significant decrease in WC (P-value < 0.001), BFM (Pvalue=0.001), body weight (P-value=0.011), BMI (P-value=0.001), PBF (Pvalue=0.027), HbA1c (P-value=0.003), FBG (P-value=0.048), LDL (Pvalue=0.004) and TG (P-value=0.046), and contributed to a significant elevation
in HDL blood levels (P-value=0.012).
5- Consumption of three g/day of black seed powder for 12 weeks for people at risk
of CVD has significantly reduce WC (P-value=0.000), HbA1c (P-value=0.009),
FBG (P-value=0.007) and TG levels (P-value=0.001).
6- There was a significant difference in WC (P-value=0.019), HDL (P-value=0.003)
and TG levels (P-value=0.05) of males and females in the response to the
intervention in the four different treatment groups.
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7- Males tend to have a higher BP, WC, FBG and TG through the intervention period,
while females had a more elevated level of HDL when compared to males.
8- The change of WC, FBG, HDL and TG levels over time (in the three phases of the
research: baseline, midpoint and endpoint) differs between males and females (Pvalue < 0.05).
5.2 Recommendations
After analyzing extensively seven commonly consumed spices, and after studying the
effect of three spices (ginger, cinnamon and black seed) on cardiovascular diseases
risk factors, the recommendations of this research are:
1- Spices extracts and oils could be widely used in nutritional supplements and for
treatments considering their decent source of valuable nutrients and active
compounds.
2- Longer-term interventional research studies are required to investigate the effect
of the spice on cardiovascular disease risk factors. Difference in some tested
parameters such as HbA1c and BP was remarkable but not significant, therefore,
longer duration of the intervention could demonstrate their efficiency in managing
cardiovascular diseases risk factors.
3- Future intervention studies are needed for examining the effect of fenugreek
powder, cardamom powder, clove powder and saffron powder on cardiovascular
diseases risk factors and investigating the effect of ginger, cinnamon and black
seed powder mixture on cardiovascular diseases risk factors is warranted.
4- To minimize participant dropout, administration of spices in capsule form would
be more efficient and practical, especially that it can eliminate the pungent taste of
some spices.
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5- Investigation of the effect of the treatment groups for each gender separately is
recommended, as males tend to have higher BP, WC, FBG and TG through the
intervention period in all the treatment groups and control group, while females
had a more elevated level of HDL when compared to males.
6- Investigating the effect of spices intake along with physical activity modifications
for an optimum results.
7- Monitoring of fat distribution and bowel distention is required for such
interventional study along with fat redistribution assessment to better understand
the effect of spice powder on WC reduction.
8- Physical activity health benefits awareness campaign is essential for the UAE
community, as participants of this study had a sedentary lifestyle.
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Appendices
Appendix 1: Screening Questionnaire Sheet

SCREANING QESTIONNAIRE SHEET
The Effect of Spices Powder on Blood Glycaemia, Blood
Lipidemia and Body Composition on Adults at Risk for Cardio
vascular Diseases: A controlled, randomized, single blind,
parallel-design study
Name

Weight (kg)
Height (m)
Gender (M/F)
Age (years)

Please tick yes / no in answer to
the following questions:
1.

Do you suffer from any heart
/ blood related conditions?

2.

Do you suffer from any
kidney-related conditions?

3.

Do you suffer from any
gastro-intestinal conditions?

4.

Do you suffer from any
metabolic conditions, e.g.
diabetes?

5.

Are you on any medication?

6.

Are you on any special diet
or suffer from any food
allergies?

No

Yes

If yes, please give details,
where appropriate:

226
7.

Are you currently trying to
lose weight by means of
dietary restriction and / or
exercise?

8.

Has your weight fluctuated
within the last 3 months by
more than 3 kg?

9.

Do you suffer from any other
medical condition not
covered here?

10.

Did you ever make yourself
sick after having eaten in
order to lose weight or not to
gain weight?

11.

Do you smoke?

12.

Female Participants – Are
you Pregnant?
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Appendix 2: Food Diary
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Appendix 3: International Physical Activity Questionnaire

231

232

Digitally signed by Shrieen
DN: cn=Shrieen, o=United Arab
Emirates University, ou=UAEU
Library Digitizatio,
email=shrieen@uaeu.ac.ae, c=AE
Date: 2020.02.11 09:18:48 +04'00'

